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Hyaluronic acid (HA) is a polysaccharide synthesized in the plasma membrane of 
cells and is associated with the host cell's extracellular matrix. Recent studies have 
established that HA plays an important role in cancer metastasis by interacting with 
cancer cell's CD44 receptor and serving as a chemoattractant for establishing metastatic 
foci. In first generation studies, HA oligosaccharides were found to show profound 
antimetastatic activity in a B 16F10 mouse melanoma model. Our goal was to develop 
mimetic compounds for the natural HA oligosaccharides that would be resistant to 
enzymatic degradation and serve as candidates for antimetastatic drugs in the treatment of 
cancer. Described in this dissertation is the synthesis of C-/0-linked and S-/0-linked HA 
tetrasaccharide mimetics and S-/0-linked HA hexasaccharide mimetics. The C-/0-linked 
HA tetrasaccharide was synthesized in collaboration with Dr. Zhong-Xu Ren via 
trichloroacetimidate glycosylation of two specifically protected C-disaccharides as 
building blocks, which were obtained by C-coupling reactions of a glycosyl tin derivative 
and a glycosyl pyridinylsulfone with an aldehyde, promoted by MeLi/BuLi and Smlz, 
respectively. The S-/0-linked HA tetrasaccharide was synthesized via 
trichloroacetimidate glycosylation of two strategically protected S-disaccharides, which 
were accomplished through base-mediated coupling of a thiol with two different triflates. 
Based on the chemistry developed in the synthesis of S-/0-linked HA tetrasaccharide 
mimetics, the synthesis of S-/0-linked hexasaccharide mimetics was accomplished via 
trichloroacetimidate glycosylation from a universal S-linked disaccharide unit that is 
lV 
strategically protected to be used as either a C-1 glycosyl donor or as a 3'-0H glycosyl 
acceptor. 
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1.1. Biological Background 
Hyaluronic acid (HA), a polysaccharide composed of a repeating disaccharide 
unit in which D-glucuronic acid is linked to the 3-position of N-acetyl-D-glucosamine, i.e., 
[,B-D-GlcNAc-(1➔4)-,8-D-GlcA-(1➔3)]0 , is synthesized in the plasma membrane and is 
associated with extracellular metrix (as shown in Figure 1). 1 Recent studies have 
established HA as an increasingly important bioactive polysaccharide that has potential 
important in medicine. As a result of its unique pyhsicochemical properties, HA has 
found use in drug delivery, as an antiadhesive, in opthamatic tissue replacement, and in 
osteoarthritis therapy application.2•4 However, the most significant roles are those it has 
been shown to play in cancer.5·7 
As we know, cancer as a disease is characterized by (1) uncontrolled cell growth, 
(2) a lack of cell differentiation, (3) invasion of other neighboring tissues, and (4) 
C02H _s~~ 
~.,_.,.~-O~o~O 
AcHN HO HO AcHN HO HO 
Figure 1. Hyaluronic Acid (HA). 
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metastasis-the ability to establish new foci at site remote from the primary neoplastic 
growth.8 Metastasis itself is a complex series of events that require the cell to (1) loosen 
its adhesion from its primary cell (tumor) neighbors, (2) migrate through tissues to reach 
a blood vessel, (3) cross the basal lamina and endothelium of the blood vessel to enter the 
general circulation, (4) adhere to the cell wall in a new tissue, (5) extravasate by crossing 
the basal lamina, and (6) migrate through the surrounding tissue to gain a colonization 
foothold. 9-12 These processes appear to be mediated by interactions between cell-adhesion 
molecules on the cancer cell and structural elements on the host cell. 13 The major 
participants in this cell-cell adhesion process have been identified. 14 Processes involving 
protein-protein interacting, 15 as well as sialic acid-E-selectin binding, 16 have been 
demonstrated. Recent studies discovered that HA plays an important role in stages (2) 
and/or (6) by interacting with the tumor cell's CD44 receptor (CD= "cluster of 
differentiation"). 
The interaction between HA and CD44 receptor is complex and is still not fully 
understood. Early evidence indicates that HA facilitates tumor-cell migration. HA is 
extruded into the extracellular space where it is hydrated and expands the intercellular 
space which facilitates cell movement along HA-enriched tracks in the expanded 
space. 17•18 Carcinomas are usually associated with the production of large quantities of 
HA that is located primarily at the interface of the tumor and the surrounding normal 
tissue, 19-21 and malignant tumors express high levels of HA-binding receptors.22•23 Several 
lines of evidence further implicate a CD44-HA interaction in cancer metastasis.24-29 
CD44 is a transmembrane glycoprotein that plays important roles in angiogenesis, 
2 
cellular adhesion and migration, hyaluronate degradation, lymphocyte activation, and 
macrophage aggregation. 30 Due to the mechanism of variable splicing during 
transportation, CD44 is actually expressed as a number of isoforms that can vary from 
one tissue to another. All CD44 isoforms appear to have the potential for binding to 
HA.31 
Based on these studies, a metastasis model is depicted in Figure 2: Migrating 
cancer cells release paracrine growth factors that induce host cells in adjacent stroma to 
produce increased amounts of extracellular HA. The cancer cells then make use of their 
CD44 receptors to bind to and migrate along the newly synthesized HA tracks into new 
tissues, spawning metastases. The interest in cancer-related CD44-HA interaction is 
broad and not limited to the particular scenario of the melanoma-lung focused upon by 
our biological model. A number of reports have provided further evidence that 
HA-CD44 binding is involved in several different types of neoplastic growths such as 
pancreatic,32 ovarian,33·34 breast,35 colon,36 prostate,37 and brain38·39 cancers. 
1.2. Biological Evaluation of HA Oligosaccharides as Metastasis Inhibitors 
Based on these studies, we proposed to use HA oligosaccharides as CD44 
"metastasis receptor" antagonists since, if HA polysaccharide strands are used as "tracks" 
for cancer cell migration, then small HA oligosaccharides should inhibit the binding of 
CD44 to the tracks, thus block metastasis (as shown in Figure 3). This therapeutic 
approach, if successful, would be refreshingly novel, as it would involve essentially cell-
surface phenomena and would not make use of cytotoxic agents that involve the cell 
3 
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Figure 3. Pharmacological Intervention in Metastasis. 
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cycle. One could envision a therapeutic approach that would involve either surgical 
removal or radiation therapy on the primary tumor, followed by treatment with a CD44 
antagonist that would, in cases of highly metastatic tumors, prevent metastasis. In cases 
of highly metastatic forms of cancer, a metastasis inhibitor could prolong life, especially 
in cases where the primary tumor is untreatable. Such an approach using non-HA type 
compounds as ligand-mimicking drugs to effectively block cancer-cell adhesion has been 
suggested for patients at high risk of metastasis.40-42 
To support our hypothesis, a set of experiments were carried out by our 
collaborator, Dr. Richard Cysyk and co-workers, as follows: 43 (1) HA was degraded with 
hyaluronate lyase (EC 4.2.2.1) from Streptomyces hyalurolyticus. (2) The resulting 
oligosaccharides were incubated with B 16F10 melanoma cells in vitro (105 cell count), 
and the mixture was then injected i.v. (tail vein) into mice. In the control set of 
experiments, the mice were injected with only B16F10 melanoma cells. (3) After ten 
days, the lungs of the mice of both groups were excised and examined for metastatic 
colonies. It was anticipated that a reduction in metastasis would be observed in the mice 
that received pretreated melanoma cells with HA oligosaccharides. To our amazement 
there was not only a reduction, but a near-total absence of metastatic colonies in the lungs 
of the mice receiving pretreated B16F10 melanoma cells with HA oligosaccharides. The 
experiment has been repeated with identical results using a verity of controls to ascertain 
that the result is genuine. B 16F10 cell viability in the HA-oligosaccharide-treated sample 
was checked, as well as various controls of column effluent, buffers, etc .. To identify 
possible toxic effects of the digest on the melanoma cells, experiments using double and 
6 
triple the amount of HA oligosaccharides (up to 3 mg/mL) were carried out, and no 
toxicity was found (as determined by cell viability assays). A similar experiment with HA 
itself (1 mg/mL) shows an antimetastastic effect; however, the fact that the purified 
oligosaccharides (free of HA) are active as metastasis inhibitors indicates that a relatively 
small molecule can function as an antimetastatic probe, which is essential to our research. 
Preliminary studies show activity setting in with the 8-mer. 
1.3. Design of Hydrolase-Resistant Mimetics of HA Oligosaccharides 
It is well known that HA is degraded in the local tissues where it is produced, as 
well as in the lymph and in the liver.44•45 Degradation may be initiated by the receptor-
mediated process whereby the CD44 receptor binds to HA, after which it is endocytosed, 
transferred to a lysozome, and degraded by acid hydrolases.46.47 In addition, degradation 
pathways via extracellular hyaluronidases are also suspected.48 In mammals, the 
degradation is accomplished by three enzymes: Hyaluronidase (EC 3.2.1.35), /3-D-
glucuronidase (EC 3.2.1.31), and 2-acetamido-2-deoxy-D-hexosaminidase (EC 
3.2.1.30).49 Hyaluronidase is an endo-glycosidase specific for the glycosidic bond /J-D-
GlcNAc-(1---+4)- /3-D-GlcA; while the /3-D-glucuronidase and 2-acetamido-2-deoxy-D-
hexosaminidase are exo-glycosidases that remove a GlcNAc or a GlcA residue from the 
nonreducing end of the polymer respectively. 
An oligosaccharide that would foil the degrading enzymes would ideally be one in 
which the glycosidic -0- linkages are replaced with -CHr. Such C-glycosylic 
compounds are known to conformationally mimic their O-glycoside counterparts and are 
7 
resistant to enzymatic cleavage.50 However, such compounds are difficult of synthesis, 
the degree of difficulty increasing with the number of sugar units in the target compound. 
To date, the largest C-oligosaccharide is but a C-trisaccharide; hence, a C-
oligosaccharide of four or more units for use as readily available probe or drug candidate 
is, at present, out of question. Therefore, rather than synthesizing an entirely C-linked 
oligosaccharide, we would design a "mixed" oligosaccharide, in which the vulnerable 
(1 ➔4 )-O-linkages will be replaced with C-linkage so that the oligosaccharides would be 
safe from enzymatic hydrolysis, while the (1➔3)-linkage would be a regular O-linkage, 
mainly to facilitate ready synthesis, as the chemistry of glycosides is the most well-
documented displine in carbohydrate chemistry.51 
In addition to the -CHrlinked oligosaccharides, -S-linked compounds, known as 
thioglycosides, could also be considered. Thioglycosides are well studied compounds 
because of their utility as C-1 activator groups in glycosylation reactions.52•53 
Thiooligosaccharides are considerably easier of synthesis than their C-linked 
counterparts.52 These are generally known to confer hydrolytic stability to the glycosidic 
linkage;54 however, to our knowledge no one has evaluated these types against 
hyaluronidases and related oligosaccharides. Candidate compounds are shown in Figure 4. 
The principal asset of this approach-"mixed" oligosaccharides-is their ready 
accessibility through a convergent "block synthesis" approach wherein multiple copies of 
a single C-linked (or S-linked) disaccharide are linked n times via normal glycosidation 
techniques to produce oligomers of specified length (of either 4, 6, or 8 residues, etc.). 




X= S, CH2. 
Figure 4. Mimetics of HA Oligosaccharides. 
GlcA-X-GlcNAc unit) was made, as this repeat unit removes any vulnerability to 
glucuronidase activity. 
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II. STATEMENT OF THE PROBLEM 
2.1. Objectives 
Our synthetic goals are as follows: 
1. Synthesis of C-/O-linked HA Tetrasaccharide Mimetics 
2. Synthesis of S-/O-linked HA Tetrasaccharide Mimetics 
3. Synthesis of Higher Order S-/O-linked HA Oligosaccharide Mimetics 
With respect to the synthesis of C-/O-linked HA oligosaccharide rnimetics, we would 
focus on the synthesis of a properly protected C-linked disaccharide that would serve as a 
building block of the synthesis of higher order C-/O-linked HA oligosaccharide mimetics. 
The disaccharide, once synthesized, will be handed over to my co-worker, Dr. Zhong-Xu 
Ren, for completion of the synthesis of C-/O-linked HA tetraaccharide mimetics. Since 
the chemistry of the synthesis of S-linked oligosaccharides is well documented compared 
to that of C-linked compounds, our efforts would mainly focus on the synthesis of S-/O-
linked HA tetrasaccharide mimetics which would (1) allow us to investigate the 
chemistry for the synthesis of higher order S-/O-linked HA oligosaccharide rnimetics, (2) 
provide us the material for NMR and molecule modeling studies, and (3) allow us to 
study the resistance to degradation by HA-degrading enzymes. With a small protecting 
group modification of the S-disaccharides for the S-/O-linked HA tetrasaccharide 
mimetics, we would adapt this chemistry to the synthesis of S-/O-linked HA 
hexasaccharide mimetics and beyond. 
10 
2.2. Research Plan-Retrosynthetic Analysis 
A retrosynthetic analysis for the synthesis of S-/0- and C-/0- "mixed" linked 
oligosaccharides is shown in Scheme 1. The oligosaccharides will be built up via 
Schmidt's trichloroacetimidate glycosylation from a versatile GlcNAc-X-GlcA unit that 
is strategically protected to be used as either a glycosyl acceptor (3'-0H free) or as a C-1 
glycosyl donor (1-0H free), activated as a trichloroacetimidate (as shown in Scheme 2). 
X-linked disaccharide trichloroacetimidate C reacts with disaccharide acceptor E to 
afford the tetrasaccharide, which after selective removal of R4 would serve as an acceptor 
D. This tetrasaccharide acceptor is resubjected to trichloroacetimidate C to afford 
hexasaccharide B. In theory, higher order oligosaccharides could be obtained by 
repeating the selective removal of R4 and glycosylation. Furthermore, the GlcA moiety is 
protected to allow selective 6-deprotection-oxidation to glucuronic acid (6-C02H group) 
at a late stage in the synthesis. This basic strategy will allow the glycosidic linker to be 
either-S- or -CHr. Some fine tuning of this general strategy-mainly the selection of 
optimum protecting groups for -S- vs. -CHr series of compounds-has been necessary 
once we began actual synthetic work. 
2.3. Synthesis of C-/0-linked HA Tetrasaccharide Mimetics 
In our group's previous work,55 Martin's method56•57 (as shown in Scheme 3), as 
well as an intramolecular radical coupling via the condensation of phenylseleno amino 
sugar and 4-C-methylene-fi-D-xylo-hexopyranosiduronic acid58·59 (as shown in Scheme 
11 
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Scheme 1. Retrosynthetic Analysis. 
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Scheme 3. Our Group's Previous Approach to C-linked Disaccharides. 
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4), was investigated, which gave no desired results. AC-linked HA disaccharide mimetic, 
albeit via Kessler's dianion method (as shown in Scheme 5),60-62 was successfully 
obtained.63 However, problems presented in the modification of protective groups (to free 
3'-0H) as several severe conditions were involved in the preparation of starting materials 
as well as in the coupling reaction. In Beau's recent studies,64•65 the synthesis of a-C-
glycosides via the coupling of 2-acetamido-3,4,6-tri-O-benzyl-1,2-dideoxy-1-
pyridinylsulfonyl-a-D-galactopyranose with aldehydes or ketones under the promotion of 
samarium diiodide was desicribed. We suspected that the ,B-2-pyridinyl sulfone would 
give predominantly ,8-C-glycosides. Furthermore, this method also raises the possibility 
of modifying the protective groups since the reaction conditions are relatively mild. 
However, their efforts to synthesize a 2-acetamido-1,2-dideoxy-1-pyridinylsulfonyl-,8-D-
glucopyranose resulted in a very low yield, while coupling reactions involving C-2-azido 
or C-2-benzylcarbamoyl functionality afforded no desired C-glycosides. To this end, no 
reactions involving 2-acetamido-4,6-0-benzylidene-3-0-tert-butyldimethylsilyl-1,2-
dideoxy-1-pyridinylsulfonyl-,B-D-glucopyranose (20) have been reported. Therefore, at 
this stage, our main efforts are devoted to (1) developing a route to the appropriately 
protected 2-acetamido-4,6-0-benzylidene-3-0-tert-butyldimethylsil yl-1,2-dideoxy- l-
pyridinylsulfonyl-,8-D-glucopyranose (20), (2) investigating the chemistry for the 
synthesis of ,8-C-linked disaccharides via the reaction of appropriately protected 2-
acetamido-4,6-0-benzylidene-3-0-tert-butyldimethylsilyl-1,2-dideoxy-1-
pyridinylsulfonyl-,8-D-glucopyranose (20) with appropriately protected aldehyde 21 




















































Scheme S. Our Group's Previous Approach to C-linked Disaccharides (cont'd). 
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obtained as a building block to synthesize C-/O-linked HA tetrasaccharide mimetics. 
A retrosynthetic analysis is shown in Scheme 6. Glycosyl donor, the sulfone 20, 
will be prepared from commercially available compound, 2-acetamido-2-deoxy-a-D-
glucose (22). According to our group's previous work,66 glycosyl acceptor, aldehyde 21, 
could be synthesized from commercially available D-galactose pentaacetate (23). Sulfone 
20 will be reacted with aldehyde 21 under the promotion of samarium diiodide (Smlz) to 
afford disaccharide 19. The protective groups' pattern in disaccharide 19 satisfies the 
requirements for the synthesis of higher order C-/O-linked HA oligosaccharide mimetics. 
Hence, p-methoxyphenyl (MP) group could be selectively unmasked with ammonium 
cerium(IV) nitrate (CAN) in the presence of all the other groups.67•68 A glycosyl donor 
could be obtained if the resulting disaccharide is activated as the trichloroacetimidate; 
while the O-tert-butyldimethylsilyl (O-TBDMS) could be deprotected with 
tetrabutylammonium fluoride (TBAF) to afford a glycosyl acceptor.69 Furthermore, the 
GlcA moiety is protected to allow selective 6-deprotection-oxidation to the glucuronic 
acid (6-C02H group) at a late stage in the synthesis. 
2.4. Synthesis of S-/O-linked HA Oligosaccharide Mimetics 
The requisite chemistry to the S-/O-linked HA oligosaccharide mimetics requires 
that four levels of differential protection be implemented: (1) selective manipulation of 
C-6 oxidation, (2) sulfur-atom introduction, (3) selective deprotection of the glycosyl 
acceptor, and (4) activation of the glycosyl donor site. In our group's previous work,66 a 
route based on chemistry developed by Driguez and co-workers70-72 in which a 1-
18 
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Scheme 6. Retrosynthetic Analysis of C-/O-linked HA Oligosaccharides. 
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n 
thiosugar (Gly-SH) displaces an axial 4-0-triflyl group of a protected galactose moiety 
was investigated. Unfortunately, the reaction that involved a complicated N-phthalimido 
derivative did not work, owing no doubt to complex stereochemical interactions between 
the reactants (as shown in Scheme 7). An alternative route, however, has been developed, 
albeit via the less common "reverse strategy" of reacting a 4-SH glycosyl acceptor with a 
suitably activated glycosyl donor, a trichloroacetirnidate. However, protective-group 
manipulations of intermediate 29 suffered from low yields and other problems (as shown 
in Scheme 8). With a small protective group modification, an alternative S-disaccharide 
was obtained. In this case, although the anomeric deprotection was successfully achieved, 
problems arose in deacetylation to give the free 3'-0H and activation of the disaccharide 
as the trichloroactirnidate (as shown in Scheme 9). 
Recent years saw several papers devoted to this topic. Yuan C. Lee and co-
workers73 reported the synthesis of S-linked tetrasaccharides via the condensation of 2-
acetamido-3,4,6-tri-0-acetyl-2-deoxy-l-thio-P-D-glucopyranose with triflates under the 
promotion of sodium hydride or cysteamine (as shown in Scheme 10). Similar reactions 
were also reported by France-Isabelle Auzanneau and co-workers (as shown in Scheme 
11). 74 This chemistry could be employed in our project with modification of the 
protective groups. In our group's previous work,63 an S-linked HA disaccharide mimetic 
has been successfully synthesized via the condensation of 2-acetamido-3,4,6-tri-0-acetyl-
2-deoxy-l-thio-P-D-glucopyranose with methyl 2,3-di-0-acetyl-6-0-tert-
butyldimetylsilyl-4-0-trifluoromethanesulfonyl-P-D-galactopyranoside in the presence of 
cesium carbonate(Cs2C03). However, as restrained by the protective groups, the 
20 
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Scheme 8. Our Group's Previous Approach to S-linked Disaccharides (cont'd). 
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Scheme 9. Our Group's Previous Approach to S-linked Disaccharides (cont'd). 
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Scheme 10. Lee and Co-workers' Approach to an S-linked Tetrasaccharide. 
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Scheme 11. Auzanneau and Co-workers' Approach to S-linked Disaccharides. 
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synthesis of higher order S-/0-linked HA oligosaccharide mimetics based on this 
disaccharide was not practical, and further efforts in the synthesis of higher order 
oligosaccharides failed (as shown in Scheme 12). 
2.4.1. Retrosynthetic Analysis for S-/O-linked HA Tetrasaccharide Mimetics 
Our immediate research goal was to synthesize S-/0-linked HA tetrasaccharide 
mimetics as it contains all the chemistry needed for the synthesis of higher order HA 
oligosaccharide mimetics, as well as provides us the material for NMR and molecular 
modeling studies, and for the study of the resistance to degradation by HA-degrading 
enzymes. If this is successful, efforts would be focused on the synthesis of higher order 
S-/0-linked HA oligosaccharide mimetics. A retrosynthetic analysis for the synthesis of 
S-/0-linked "mixed" tetrasaccharide 52 is shown in Scheme 13. The tetrasaccharide will 
be built up via Schmidt's trichloroacetimidate glycosylation. Two S-linked disaccharides 
building blocks, namely 56 and 57, are proposed. The protective groups are strategically 
set up to allow: (a) upon deallylation and activation of compound 56 as 
trichloroacetimidate, compound 54 would serve as donor. An acetyl group was used on 
C-2 of the GlcA component to facilitate the formation of the /J isomer in the coupling 
reaction; (b) after deacetylation and regioselective protection of compound 57, the 
resulting compound 55 would serve as an acceptor, which is made possible by using 
benzyl groups as protective groups on the GlcA component. Furthermore, the GlcA 
moiety is protected to allow selective 6-deprotection-oxidation to the glucuronic acid 
(6-C02H group) at a late stage in the synthesis. Further disconnections go to the 1,4-thiol 
26 
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Scheme 13. Retrosynthetic Analysis of S-/O-linked Tetrasaccharide Mimetics. 
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bonds. Three key monosaccharides, 35, 58, and 59 are thus proposed. 
2.4.2. Retrosynthetic Analysis for Higher Order S-/0-linked HA Oligosaccharide 
Mimetics 
To satisfy the need for the synthesis of higher order S-/0-linked HA 
oligosaccharide mimetics, the protective groups for a universal S-disaccharide must meet 
the following requirements: (1) the protective group for the anomeric position could be 
selectively unveiled to allow activation to glycosyl donor, for example, 
trichloroacetimidate; (2) the glycosyl acceptor site must be protected to allow selective 
unmasking; (3) the GlcA moiety is protected to allow selective 6-deprotection-oxidation 
to the glucuronic acid (6-C02H group) at a late stage in the synthesis; and (4) all 
hydroxyl groups not involved in glycosylations must be permanently protected until final 
deprotection. Furthermore, an ester protective group should be considered for the C-2 
position of the GlcA residue to facilitate the formation of the /3 isomer in the 
glycosylation reaction. Based on these requirements, two universal S-disaccharide 
building blocks were targeted. Methodology described by Yuan C. Lee and coworkers73 
will be employed in the formation of both disaccharides. In disaccharide 60, benzoyl 
groups were chosen to protect the C-2 and C-3 positions of the GlcA residue since, 
according to Vince Pozsgay,75 acetyl groups could be selectively unmasked in the 
presence of benzoyl groups. This gave us the possibility to synthesize acceptor 63 from 
disaccharide 60 by selective deacetylation and subsequent 4-,6-protection (as shown 1n 
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Scheme 14. Design of a Universal S-linked Disaccharide Building Block (Plan A). 
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on the GlcNAc residue. A levulinoyl group will be installed to protect the C-3 position 
since it could be selectively unveiled in the presence of acetyl groups. 76 In addition. all 
the protective groups could be unmasked with sodium methoxide or lithium hydroxide in 
the final deprotection. Although this GlcNAc residue is slightly different from the thiol 
35 we proposed above, the chemistry involved would be totally different (as shown in 
Scheme 15). 
2.5. Significance 
The chemistry described in this dissertation is novel and refreshing. With respect 
to synthesis of C-/O-linked HA tetrasaccharide mimetics, very few examples exist in the 
literature. Although a C-linked disaccharide mimetic related to HA has been successfully 
obtained by our previous group member, this chemistry is limited in that it cannot be 
employed in the synthesis of higher order C-/O-linked HA oligosaccharide mimetics as 
manipulation of protective groups is impossible due to the severe reaction conditions 
employed. Additionally, generation of the requisite ,B stereochemistry is also a big issue. 
Compared to the synthesis of C-/O-linked compounds, synthesis of S-/O-linked HA 
oligosaccharide mimetics seems to be less complex, as this chemistry is well documented 
in the literature. However, sulfur might present problems in this particular case, since 
most oxidizing agents that oxidize hydroxyl groups to carboxylic acids also oxidize sulfur. 
Installation of the carboxylic acid group before coupling narrows down the coupling 
possibilities due to electronic effects. In addition, sulfur restrains the choice of protective 
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Scheme 15. Design of a Universal S-linked Disaccharide Building Block (Plan B). 
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III. RESULTS AND DISCUSSION 
3. 1. Synthesis of C-/O-linked HA Tetrasaccharide Mimetics 
As predicted in section 2.3, the Smlz-promoted coupling reaction gave the desired 
disaccharides. However, condensation of the glycosyl donor and acceptor derived from 
disaccharide 19 gave predominantly the a tetrasaccharide. In order to facilitate the 
formation of the /3 tetrasaccharide, an acetyl group was required to be installed on C-2 of 
the glycosyl donor. While modification of protective groups of disaccharide 19 has 
proved to be time-consuming, as the synthesis of this disaccharide has already taken so 
many steps, an alternative glycosyl donor, trichloroacetimidate 91, was synthesized 
according to the dianion method reported by Horst Kessler and co-workers. The synthesis 
of C-/O-linked HA tetrasaccharide mimetics has been accomplished by my co-worker, Dr. 
Zhong-Xu Ren, via condensation of trichloroacetimidate 91 and acceptor 84, as detailed 
below. 
3.1.1. Synthesis of Glycosyl Acceptor 84 
3.1.1.1. Synthesis of GlcA Component 21 
The synthesis of aldehyde 21 followed the 8-step procedure described in Kenneth 
Price's dissertation66 as shown in Scheme 16. Hence, treatment of commercially available 
D-galactose pentaacetate 23 with p-methoxyphenol in dichloromethane (CH2Ch) in the 
presence of trimethylsilyl trifluromethanesulfonate (TMSOTf) at O °C for 3 h afforded 
















































Scheme 16. Synthesis of GlcA Component 21. 
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74 
constant of Im. H2 = 10.8 Hz.77 Deacetylation of 68 with sodium methoxide (NaOMe) in 
1:5 dichloromethane (CH2Clz) and methanol gave the corresponding tetraol 69 in nearly 
quantitative yield. Regioselective bis-protection of the 4-OH and 6-OH positions with a 
p-methoxybenzylidene group was accomplished via treatment of tetraol 69 with 
anisaldehyde dimethyl acetal (ADMA) in the presence of a catalytic amount of p-
toluenesulfonic acid (TsOH) in dry acetonitrile to afford diol 70 as a precipitate in 84% 
yield.78 The resulting diol 70 was then treated with sodium hydride (NaH) at O °C for 10 
min, followed by addition of benzyl bromide (BnBr) in N,N-dimethylforrnamide (DMF), 
to give compound 71 in 95% yield. Regioselective reductive cleavage of the benzylidene 
ring of compound 71 was achieved via treatment with sodium cyanoborohydride 
(NaBH3CN) and trifluroacetic acid (TFA) in the presence of 4 A MS in N,N-
dimethylformamide (DMF) at r. t. for 10 h to render the 4-OH isomer 72 in 74% yield as 
the major product, along with the 6-OH isomer as a byproduct (21 %).79 Treatment of 
compound 72 with trifluoromethanesulfonic anhydride (Tf2O) in pyridine at O °C 
overnight gave the corresponding triflate 73 in nearly quantitative yield. Exposure of 
triflate 73 to tetrabutylammonium cyanide (Bu4NCN) in tetrahydrofuran (THF) afforded 
the SN2 substitution product 74 in 60% yield. The main byproduct was presumably the 
E2 elimination product, which is slightly less polar than the substitution product on TLC. 
Reduction of compound 74 with diisobutylaluminum hydride (DIBAI-H) in 
tetrahydrofuran (THF) at -78 °C, followed by treatment with 1.0 N phosphoric acid 
(H3PO4) at O °C, afforded aldehyde 21 in 71 % yield. 66·80·81 
35 
3.1.1.2. Synthesis of GlcNAc Component 20 
The synthesis of GlcNAc component 20 was carried out as shown in Scheme 17. 
Hence, treatment of commercially available 2-acetamido-2-deoxy-a-D-glucose (22) with 
acetyl chloride afforded 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-a-D-glucopyranosyl 
chloride (75). 82 Exposure of chloride 75 to K2C03 and 2-mercaptopyridine in dry acetone 
at r. t. gave the desired pyridinyl sulfide 76. Only the /J isomer was isolated in this 
reaction, as confirmed by 1HNMR spectroscopy with a coupling constant of JHI, HZ= 10.5 
Hz.83 In order to manipulate the protective groups, sulfide 76 was treated with sodium 
methoxide (NaOMe) in 1:5 dichloromethane (CH2Ch) and methanol to afford trio! 77. 
Then, a benzylidene ring was installed to mask the 4- and 6-positions via treatment with 
benzaldehyde and zinc chloride (ZnCh) at r. t. for 10 h.84·85 A combination of 
benzaldehyde dimetyl acetal and p-toluenesulfonic acid (TsOH), which works in most 
cases, gave complicated results, due no doubt to the fact that p-toluenesulfonic acid 
(TsOH) reacts with the pyridinyl residue. Treatment of compound 78 with tert-
butyldimethylsilyl chloride (TBDMSCI) in the presence of imidazole in N,N-
dimethylformamide (DMF) at r. t. overnight gave compound 79,69 which was readily 
converted to the corresponding sulfone 20 in good yield (79%) via treatment with m-
chloroperoxybenzoic acid (m-CPBA) and sodium carbonate (Na2C03) in 
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Scheme 17. Synthesis of GlcNAc Component 20. 
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3.1.1.3. Samarium Diiodide Promoted Coupling Reaction 
With aldehyde 20 and sulfone 21 in hand, the stage was set for the synthesis of C-
disaccharides. The coupling reaction was carried out under the promotion of samarium 
diiodide (Smlz) in tetrahydrofuran (THF) at r. t. as planned. In this reaction, two chiral 
centers were involved, which would give four possible isomers. Actually, only one a 
isomer 80c and two ,B isomers (80a and 80b) were isolated. As a radical or anion 
intermediate was involved in this reaction, the selectivity of this reaction was predicted to 
be relatively poor; however, to our surprise, we found that the two ,B isomers were 
obtained as major products (as shown in Scheme 18). All the three disaccharides were 
easily identified by positive-ion mode ESIMS spectra (as shown in Figure 5-7). However, 
it is it extremely difficult to fully characterize these disaccharides as the signal of H-1' in 
the lD and 2D (gCOSY, HSQC) NMR spectra was obscured by several other signals (for 
spectra, refer to Appendix II). 
Fortunately, the absolute structure of disaccharide 80a was ascertained via X-ray 
crystallography as shown in Figure 8 and Figure 9 (for crystal data, refer to Appendix I). 
Crystals suitable for X-ray crystallography were obtained by slow diffusion of hexanes 
into a saturated solution of compound 80a in ethyl acetate (EtOAc ). Disaccharide 80b 
was also shown to have the ,B linkage as, after deoxygenation, it gave the same 
disaccharide as that of 80a (as described below), while disaccharide 80c was assigned as 
the a anomer as the deoxygenated derivative of 80c is different from that of 80a and 80b. 
Conversion of the a isomer 80c to the /J isomers (80a and 80b) was achieved by my co-
worker, Dr. Zhong-Xu Ren, via oxidation of compound 80c to the corresponding a 
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Scheme 18. Samarium Diiodide Promoted Coupling Reaction. 
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Figure 5. Positive-Ion Mode ESIMS of 80a. 
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Figure 6. Positive-Ion Mode ESIMS of 80b. 
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Figure 7. Positive-Ion Mode ESIMS of 80c. 
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Figure 8. ORTEP of /J Epimer 80a. 
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ketone 81 with pyridinium chlorochromate (PCC) in dichloromethane (CH2Cl2), 
isomerization of the resulting a ketone 81 to the ,B ketone 82 with sodium methoxide 
(NaOMe) in methanol, and subsequent reduction of the ,B ketone 82 to 80a and 80b with 
sodium borohydride (NaB!4) in ethanol (EtOH) (as shown in Scheme 19). Removal of 
the hydroxyl moiety was achieved according to Barton and McCombie.87·88 Thus 
treatment of 80a or 80b with sodium hydride (NaH) in the presence of imidazole in 
tetrahydrofuran (THF), followed by addition of carbon disulfide (CS2) and then methyl 
iodide (Mel) after 40 min, afforded 83a or 83b in 54% or 52% yield, respectively. 
Exposure of 83a or 83b to tri-n-butyltin hydride (n-Bu3SnH) and azoisobutyronitrile 
(AIBN) in refluxing toluene afforded the desired disaccharide 19 in 91 % yield, which 
after removal of the tert-butyldimethylsilyl (O-TBDMS) group with tetrabutylammonium 
fluoride (TBAF) in tetrahydrofuran (THF), gave acceptor 84 in 93% yield (as shown in 
Scheme 20). 
Acceptor 84 has been handed over to co-worker, Dr. Zhong-Xu Ren, for 
completion of the synthesis of C-/O-linked HA tetrasaccharide mimetics as follows. 
3.1.2. Synthesis of Trichloroacetimidate 91 
C-disaccharides 85a and 85b were prepared according to the method reported by 
Horst Kessler and co-workers as shown in Scheme 21.60-62 Hence, deprotonation of 
compound 10 in tetrhydrofuran (THF) was achieved with methyllithium (MeLi) at -78 
°C, followed by treatment with butyllithium (BuLi) at -60 °C, which provided a dianion 
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Scheme 19. Conversion of 80c to 80a and 80b. 
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Scheme 21. Synthesis of Trichloroacetimidate 91. 
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aldehyde 21 in situ to give disaccharides 85a and 85b in 31 % and 28% yield respectively. 
Only the two desired /J isomers 85a and 85b were isolated in this reaction, as confirmed 
by 1D and 2D NMR spectra (gCOSY, HSQC). Treatment of 85a or 85b with sodium 
hydride (NaH) in the presence of imidazole in dry tetrahydrofuran (THF), followed by 
addition of carbon disulfide (CS2), and then methyl iodide (Mel) after 40 min, afforded 
xanthogenate 86a or 86b in 81 % or 80% yield, respectively, which upon treatment with 
tri-n-butyltin hydride (n-Bu3SnH) in the presence of azoisobutyronitrile (AIBN) in 
refluxing toluene, gave the desired deoxygenated derivative 87 in 66% yield. In order to 
facilitate the formation of the P-Cl ➔3)-linked tetrasaccharide using trichloroacetimidate 
glycosylation, the protective groups on disaccharide 87 were modified as follows. 
Removal of the p-methoxybenzyl (PMB) group was achieved via treatment of 
disaccharide 87 with 2,3-dichloro-5,6-dicyano-1,4 benzoquinone (DDQ) in 15:1 
dichloromethane (CH2Clz) and water at r. t. for 1.5 h to afford disaccharide 88 in 95% 
yield,89 which upon levulinoylation with levulinic acid and 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide (EDCI) in dichloromethane (CH2C}z) in the presence of a catalytic 
amount of 4-dimethylaminopyridine (DMAP),90 afforded disaccharide 89 in nearly 
quantitative yield. Treatment of disaccharide 89 with Pearlman's catalyst, Pd(OH)z/C, in 
a hydrogen (H2) atmosphere at r. t. for 3 days, followed by acetylation with acetic 
anhydride (Ac20) in pyridine at r. t. overnight, gave compound 90 in 80% yield. Removal 
of the p-methoxyphenyl (MP) group on the anomeric carbon with ammonium cerium(IV) 
nitrate (CAN) in 4: 1 acetonitrile and water (84% yield, with an a, /J anomeric ratio of 
6: 1), followed by treatment of the resulting disaccharide with trichloroacetonitrile 
49 
(CChCN) in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in 
dichloromethane (CH2Cl2) at r. t. for 1 h, gave the desired trichloroacetimidate 91 in 79% 
yield, , with an a, ,B anomeric ratio of 2.4: 1.91 
3.1.3. Synthesis of C-/O-linked HA Tetrasaccharide Mimetics 
Condensation of trichloroacetimidate 91 and acceptor 84 was achieved via 
treatment with a catalytic amount of trimethylsilyl trifluoromethanesulfonate (TMSOTf) 
in dichloromethane (CH2Ch) at -15 °C for 2 h to afford the protected tetrasaccharide 92 
in 56% yield.92 Removal of the levulinoyl (Lev) group with hydrazine in the presence of 
acetic acid (AcOH) in pyridine at r. t., followed by removal of p-methoxybenzyl (PMB) 
group with 2,3-dichloro-5,6-dicyano-l,4-benzoquinone (DDQ) in 15:1 dichloromethane 
(CH2Ch) and water at r. t., afforded diol 93 in 41 % yield. Oxidation of the resulting diol 
93 to the corresponding carboxylic acid 94 was achieved in 57% yield via treatment with 
2,2,6,6-tetramethyl-l-piperidinyloxy (TEMPO) and aq NaOCl in the presence of a 
catalytic amount of sodium bromide (NaBr).93 Finally, debenzylation with Pearlman's 
catalyst, Pd(OH)z/C, in a hydrogen (H2) atmosphere in ethyl acetate (EtOAc) and 
methanol (MeOH) for 3 days, followed by deacetylation with lithium hydroxide (LiOH) 
in 1 :2 tetrahydrofuran (THF) and water at r. t. for 10 h, furnished the target 
tetrasaccharide 95 in 72% yield (as shown in Scheme 22). 
3.2. Synthesis of S-/O-linked HA Tetrasaccharide Mimetics 
Although the introduction and presence of sulfur functionality presented problems 
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Scheme 22. Synthesis of C-/O-linked HA Tetrasaccharide Mimetics. 
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in oxidation and debenzylation as predicted in section 2.5, the synthesis of S-/0-linked 
HA tetrasaccharide mimetics went exactly as planed as detailed below. 
3.2.1. Synthesis of Trichloroacetimidate 54 
Triflate 58 required for the synthesis of S-disaccharide 56 was prepared by 
following a 7-step procedure beginning with commercially available compound, 0-
galactose (96) as shown in Scheme 23. Hence, treatment of compound 96 with acetic 
anhydride (Ac20) in the presence of perchloric acid (HC104), followed by addition of red 
phosphorus (P) and bromine (Br2), afforded glycosyl bromide 97. Glycosylation with 
allyl alcohol was achieved in chloroform (CHCh) under the promotion of mercuric 
bromide (HgBr2) and mercuric oxide (HgO) in the presence of calcium sulfate anhydride 
(CaS04) to give compound 98 in nearly quantitative yield.94 After deacetylation with 
sodium methoxide (NaOMe) in 1:5 dichloromethane (CH2C}z) and methanol (MeOH), 
the resulting tetraol 99 was treated with anisaldehyde dimethyl acetal (ADMA) in the 
presence of a catalytic amount of p-toluenesulfonic acid (TsOH) in dry acetonitrile 
(CH3CN) at r. t. for 2 h to give regioselectively protected compound 100 with the 4- and 
6-positions protected with a p-methoxybenzylidene group, which precipitated out in 88% 
yield. Acetylation of diol 100 was achieved via treatment with acetic anhydride (Ac20) in 
pyridine at r. t. to give compound 101 in 91 % yield. Regioselective reductive cleavage of 
the benzylidene ring to a free 4-0H and a 6-0-p-methoxybenzyl (PMB) ether (compound 
102) was effected with sodium cyanoborohydride (NaBH3CN) and trifluoroacetic acid 










































a byproduct.95 Upon activation of the hydroxyl group as the triflate derivative with triflic 
anhydride (Tf2O) in pyridine at 0 °C overnight, triflate 58 was synthesized in nearly 
quantitative yield. 
Synthesis of thiol 35 proceeded from commercially available compound, 2-
acetiamido-2-deoxy-D-glucose (22) as shown in Scheme 24, According to Horton and 
Wolfrom,96 following treatment of compound 22 with acetyl chloride (AcCl) at r. t. 
overnight, the glycosyl chloride 75 thus obtained was exposed to thiourea in refluxing 
acetone to give pseduthiourea derivative 103 as a precipitate, which was readily 
converted to thiol 35 in nearly quantitative yield via treatment with sodium sulfite 
(Na2SO3) in 5: 1 water and acetone at r. t. for 2 h.97 
Base-promoted coupling of thiol 35 and triflate 58 was carried out in N,N-
dimethylformamide (DMF) at O °C via treatment of thiol 35 with sodium hydride (NaH) 
for 10 min, followed by addition of triflate 58, to give the desired S-linked disaccharide 
56 in 51 % yield. However, this reaction suffered from low yield due to the fact that 
sodium hydride (NaH) is a strong base, which partially deprotected the acetyl groups in 
the coupling reaction. In order to improve the yield of disaccharide 56, an alternative 
route, has been developed, albeit via the less common "reverse strategy" of reacting a 
4-SH glycosyl acceptor with a suitably activated glycosyl donor, namely, glycosyl 
chloride 75, as shown in Scheme 25. Hence, treatment of triflate 58 with potassium 
thioacetate (KSAc) in N,N-dimethylformamide (DMF) at O °C afforded thioacetate 104 in 
76% yield.98 Subsequent S-deacetylation of thioacetate 104 with cysteamine in the 
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Scheme 25. Synthesis of S-linked Disaccharide 56. 
56 
(DMF) at r. t. furnished thiol 105 in 94% yield. Exposure of thiol 105 to a relatively 
weaker base, potassium carbonate (K2CO3), in N,N-dimethylformamide (DMF) at 0 °C 
for 10 min, followed by addition of 2-3 equivalents of glycosyl chloride 75, gave the 
same S-linked disaccharide in 86% yield. Only the desired /3 anomer was observed in this 
reaction, as confirmed by ID and 2D (gCOSY, HSQC) NMR spectroscopy with a 
coupling constant of lHt, H2 = 10.8 Hz (for spectra, refer to Appendix II). Conversion of 
56 to 106 was achieved in 95% yield, with an a, /3 anomeric ratio of 1 :2, via a two-step 
process involving isomerization of the allyl group with hydrogen (H2) pre-activated (l ,5-
cyclooctadiene )bis(methyldiphenylphosphine )iridium(!) hexafl uorophosphate in 
terahydrofuran (THF), followed by cleavage of the resulting propenyl ether with iodine 
(Ii) and sodium bicarbonate (NaHCO3) in tetrahydrofuran (THF) and water.99 Treatment 
of disaccharide 106 with trichloroacetonitrile (CCIJCN) in the presence of l ,8-
diazabicyclo[5 .4.0]undec-7-ene (DBU) in dichloromethane (CH2Cli) gave 
trichloroacetimidate 54 in 86% yield, with an a, /3 anomeric ratio of 6: 1, as shown in 
Scheme 26. 
3.2.2. Synthesis of Acceptor 55 
The synthesis of acceptor 55 began with diol 100 (for synthesis of diol 100, refer 
back to Scheme 23) as shown in Scheme 27. Hence, diol 100 was treated with sodium 
hydride (NaH) in N,N-dimethylformamide (DMF) at O °C for 10 min and then reacted 
with benzyl bromide (BnBr) to give compound 107 in 93% yield, which upon 
regioselective reductive cleavage with sodium cyanoborohydride (NaBH3CN) and 
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trifloroacetic acid (TFA) in the presence of 4 A MS in N,N-dimethylformamide (DMF) 
afforded the 4-OH isomer 108 as the major product in 65% yield, along with a trace of 
the 6-OH isomer as a byproduct. Activation of alcohol 108 to triflate 59 was achieved in 
nearly quantitative yield via treatment with triflic anhydride (Tf2O) in the presence of 
pyridine in dichloromethane (CH2Clz), The resulting triflate 59 was exposed to pretreated 
thiol 35 with sodium hydride (NaH) in N,N-dimethylformamide (DMF) at O °C to afford 
the desired S-disaccharide 57 in 75% yield. The S-(1➔4) linkage was confirmed to be /J 
by ID and 2D (gCOSY, HSQC) NMR spectroscopy, with a coupling constant of JHI, HZ= 
10.2 Hz (for spectra, refer to Appendix II). Deacetylation of compound 57 with sodium 
methoxide (NaOMe) in 1:5 dichloromethane (CH2Cl2) and methanol, followed by 4,6-
regioselective protection of the resulting trio! with benzaldehyde dimethyl acetal in the 
presence of a catalytic amount of p-toluenesulfonic acid (TsOH) in acetonitrile (CH3CN) 
at r. t., rendered acceptor 55 as a precipitate in 93% yield. 
3.2.3. Synthesis of S-/O-linked HA Tetrasaccharide Mimetics 
As acceptor 55 is barely soluble in dichloromethane (CH2C}z), reverse addition 
was employed in the condensation of trichloroacetimidate 54 and acceptor 55 as shown in 
Scheme 28. Hence, acceptor 55 was suspended in dichloromethane (CH2Cl2) at -15 °C 
under the protection of nitrogen (N2) and treated with a catalytic amount of trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) for 20 min, and then a solution of 
trichloroacetimidate 54 in dichloromethane (CH2Clz) was added dropwise, to give 
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Scheme 28. Synthesis of S-/O-Iinked HA Tetrasaccharide Mimetics. 
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(gCOSY, HSQC, TOCSY, HMBC) NMR spectroscopy with a coupling constant of JH 1. 
82 = 6.6 Hz (for spectra, refer to Appendix II). Removal of the p-methoxybenzyl (PMB) 
groups with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in 15:1 dichloromethane 
(CH2Ch) and water at r. t. gave dial 109 in 60% yield. As predicted, sulfur presented 
problems in the following oxidation and debenzylation reactions. TEMPO (2,2,6,6-
tetramethyl-1-piperidinyloxy) reagent, a very efficient reagent to oxidize primary 
hydroxyl groups to carboxylic acids in most cases, did not afford the desired carboxylic 
acid here, while a combination of the Swem oxidation of primary hydroxyl groups to the 
aldehyde and oxidation of the resulting aldehyde to carboxylic acid with sodium chlorate 
(NaC1O2) also failed. Finally, to our amazement, we found that oxidation of dial 109 with 
pyridinium dichromate (PDC) in N,N-dimethylformamide (DMF) could afford us the 
desired tetrasaccharide 110 in 79% yield. It is well known that a benzylidene ring and 
benzyl groups can be unveiled with Pd/C or Pd(OH)i/C in a hydrogen (H2) atomsphere. 
However, in this particular case, all attempts with different combinations of catalysts and 
solvents gave negative results. Finally, we found that under very strong conditions, i.e., 
an excess of Pd/C in 80% acetic acid under a pressure of 50 psi of hydrogen (H2), we 
could push the reaction to give the desired tetrasaccharide with both benzylidene ring and 
benzyl groups removed in 31 % yield. 100 Deacetylation of the resulting tetrasaccharide 
with sodium methoxide (NaOMe) in 1:5 dichloromethane (CH2Ch) and methanol 
provided the target S-/O-linked HA tetrasaccharide mimetic 52 in nearly quantitative 
yield. Tetrasaccharide 52 was characterized extensively via 1D and 2D (gCOSY, HSQC, 
TOCSY, HMBC, etc.) NMR spectroscopy (for spectra, refer to Appendix II). Negative-
62 
ion mode ESI mass spectroscopy as shown in Figure 10 confirms the molecular 
composition as shown by 848.9 [M - Hr, 870.9 [M - 2H + Nar, 886.9 [M - 2H + Kr. 
3.3. Synthesis of Higher Order S-/O-linked HA Oligosaccharide Mimetics 
Based on the success of the synthesis of S-/O-linked HA tetrasaccharide mimetics, 
significant advances were achieved toward the synthesis of higher order S-/O-linked HA 
oligosaccharide mimetics. However, although universal 5-linked disaccharide building 
blocks 60 and 64 seemed to be promising, unforeseen problems forced us to revise our 
strategies. In particular, the introduction and presence of the sulfur functionality 
restrained our choice of protective groups and reagents. The ways in which steric and/or 
electronic effects of protective groups, as well as a longer chain, affect the stability and/or 
reactivity of glycosyl donors and acceptors is not predictable. However, to our 
gratification, the synthesis of S-/O-linked HA hexasaccharide mimetics has been 
accomplished via plan B as detailed below. This strategy should allow us to get rapid 
access to eight-mer and beyond. 
3.3.1. Efforts to Higher Order S-/O-linked HA Oligosaccharide Mimetics via Plan A 
In order to cut down on the number of the steps required for the synthesis of 
higher order S-/O-linked HA oligosaccharide mimetics, disaccharide 60 as shown in 
Figure 11 was first targeted as a universal building block. As we described above, the 
ally! group could be selectively deprotected via the two-step process involving 
isomerization and oxidation, and the disaccharide would also serve as a donor if activated 
63 
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Figure 10. Negative-Ion Mode ESIMS of Tetrasaccharide 52. 
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Figure 11. Design of Universal Disaccharide Building Block 60 (Plan A). 
as the trichloroacetimidate. According to Pozsgay,75 acetyl groups could be selectively 
unmasked in the presence of benzoyl groups via treatment with tetrafluoroboric acid 
(HBF4). This gave us the possibility of generating acceptor 63 from disaccharide 60 by 
selective deacetylation and 4,6-protection. 
3.3.1.1. Synthesis of Universal S-linked Disaccharide Building Block 60 
The synthesis of triflate 61 began with diol 100 (for synthesis of diol 100, refer 
back to Scheme 23) as shown in Scheme 29. Hence, dial 100 was stirred with benzoyl 
chloride (BzCl) in pyridine at r. t. overnight to afford compound 111 in 89% yield, which 
upon regioselective reductive cleavage of the benzylidene ring to a free hydroxyl group 
and p-methoxybenzyl (PMB) ether with sodium cyanoborohydride (NaBH3CN) and 
trifluoroacetic acid (TFA) in the presence of 4 A MS in N.N-dimethylformamide (DMF) 
afforded the desired 4-OH isomer 112 in 80% yield, along with a trace of the 6-OH 
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Scheme 29. Synthesis of Trichloroacetimidate 62. 
66 
presence of pyridine in dichloromethane (CH2Clz) at 0 °C overnight gave triflate 61 in 
nearly quantitative yield. Base-mediated coupling of triflate 61 and pretreated thiol 35 
(for synthesis of 35, refer back to Scheme 24) with sodium hydride (NaH) at O °C 
afforded the desired /J disaccharide 60 in 53% yield. Compound 60 was converted to 113, 
with an a, fJ anomeric ratio of 1 :2, in 95% yield via the two-step process involving 
isomerization of the allyl group with hydrogen (H2) pre-activated (1,5-
cyclooctadiene )bis(meth yldi phen ylphosphine )iridi um(I) hexafl uorophosphate in 
terahydrofuran (THF) for 3 days, followed by cleavage of the resulting propenyl ether 
with iodine (h) and sodium bicarbonate (NaHCO3) in tetrahydrofuran (THF) and water at 
0 °C. Unlike that of compound 54, isomerization of compound 60 required reflux, due 
probably to the deactivating effect of benzoyl group at C-2. Treatment of disaccharide 
113 with trichloroacetonitrile (CChCN) in the presence of 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) in dichloromethane (CH2C}z) at r. t. for 1 h gave the desired 
trichloroacetimidate 62, with an a, fJ anomeric ratio of 6: 1, in 86% yield. 
3.3.1.2. Attempted Synthesis of S-/0-linked HA Tetrasaccharide Mimetic 118 
Although trichloroacetimidate 62 was successfully synthesized, a problem arose 
in the synthesis of acceptor 63. Instead of the desired compound 117, deacetylation of 
disaccharide 60 with tetrafluoroboric acid (HBF4) in 1:5 dichloromethane (CH2C'2) and 
methanol gave predominantly compound 114 (71 % ), with only a small amount of the 
desired compound 117 (13%). However, an alternative acceptor 116 was obtained by 
following the procedure as shown in Scheme 30. Hence, conversion of compound 117 to 
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Scheme 30. Synthesis of Acceptors 63 and 116. 
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compound 114 was achieved via treatment with trifluoroacetic acid (TFA) in 
dichloromethane (CH2C}z). 101 Disaccharide 114 was treated with benzaldehyde dimethyl 
acetal in the presence of a catalytic amount of p-toluenesulfonic acid (TsOH) in dry 
acetonitrile to afford compound 115 as a precipitate in 72% yield. Selective protection of 
the primary alcohol with the tert-butyldiphenylsilyl (TBDPS) group via treatment with 
tert-butyldiphenylsilyl chloride (TBDPSCl) and triethylamine (TEA) in the presence of a 
catalytic amount of 4-dimethylaminopyridine (DMAP) in dichloromethane (CH2Ch) 
gave an alternative acceptor 116 in 91 % yield. 102·103 Although this unexpected problem 
caused a slight change in our strategy, the following revised plan A as shown in Scheme 
31 still seemed to be promising. Unfortunately, all attempts (different combinations of 
catalysts, solvents, and reaction temperatures) to condense trichloroacetimidate 62 with 
either acceptor 116 or acceptor 63 (obtained via treatment of 117 with benzaldehyde 
dimethyl acetal and p-toluenesulfonic acid (TsOH) in acetonitrile.) together failed, due no 
doubt to the deactivating effect of the C-2 benzoyl group of the trichloroacetimidate (as 
shown in Scheme 32). This strategy was thus discarded. 
3.3.2. Efforts to Higher Order S-/0-linked HA Oligosaccharide Mimetics via Plan B 
As a replacement of disaccharide 60, an alternative universal disaccharide 
building block 64 was projected as shown in Figure 12. The protective groups were 
strategically set up so that the levulinoyl group could be selectively deprotected in the 
presence of acetyl groups, and the resulting disaccharide would serve as a glycosyl 
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Scheme 31. Revised Plan A. 
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Scheme 32. Efforts to S-/O-linked HA Tetrasaccharide via Plan A. 
71 
64 
Figure 12. Design of Universal Disaccharide Building Block 64 (Plan B). 
deallylation and activation as trichloroacetimidate. In addition, all the protective groups 
could be unveiled with lithium hydroxide (LiOH) or sodium methoxide (NaOMe) in the 
final deprotection. 
3.3.2.1. Synthesis of S-linked Disaccharide Donor 66 and Acceptor 67 
The synthesis of thiol 65 proceeded with peudothiourea 103 (for synthesis of 
peudothiourea 103, refer back to Scheme 24) as shown in Scheme 33. Hence, treatment 
of peudothiourea 103 with ethyl disulfide in the presence of triethylamine (TEA) in 
methanol gave disulfide 121 in 68% yield. 104• 105 In order to manipulate the protective 
groups, compound 121 was first treated with sodium methoxide (NaOMe) in 1 :5 
dichloromethane (CH2Clz) and methanol (MeOH) to unmask the acetyl groups. The 
resulting triol 122 was then stirred with anisaldehyde dimethyl acetal (ADMA) in the 
presence of a catalytic amount of p-toluenesulfonic acid (TsOH) in acetonitrile at r. t. for 
about 2 h, and acetal exchange occurred, resulting in the formation of a precipitate of 
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Scheme 33. Synthesis of Thiol 65. 
123 in 86% yield. Treatment of compound with levulinic acid and 1-(3-
dimethylaminopropyl)-3-ethylcarbdiimide hydrochloride (EDCI) in the presence of a 
catalytic amount of 4-dimethyaminopyridine (DMAP) in dichloromethane (CH2C'2) 
afforded compound 124 in 80% yield. In order to make the final deprotection easier, the 
benzylidine ring was replaced with acetyl groups as follows. Compound 124 was treated 
with tetrafluoroboric acid in methanol at r. t. for 1 h to give diol 125, and then the 
resulting diol 125 was acetylated with acetic anhydride in the presence of pyridine to 
afford compound 126 in 84% yield. Treatment of disulfide 126 with dithiothreitol (DTT) 
in the presence of triethylamine (TEA) in tetrahydrofuran (THF) and methanol (MeOH) 
afforded the desired thiol 65 in 80% yield. 104 Base-promoted SN2 coupling of thiol 65 and 
triflate 58 was achieved via treatment with cesium carbonate (Cs2CO3) in N,N-
dimethylformamide (DMF) at O °C for 2 h to provide the desired disaccharide 64 in 88% 
yield. Only the /J isomer was observed in this reaction, as confirmed by ID and 2D NMR 
spectroscopy with a coupling constant of lHi, HZ= 10.8 Hz (for spectra, refer to Appendix 
II). Deallylation of disaccharide 64 by following the two-step process involving 
isomerization of the ally! group with hydrogen (H2) pre-activated (1,5-
cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate in 
terahydrofuran (THF) for 3 days, followed by cleavage of the resulting propenyl ether 
with iodine (12) and sodium bicarbonate (NaHCO3) in tetrahydrofuran (THF) and water at 
0 °C afforded disaccharide 127, with an a, p anomeric ratio of 1 :2, in 92% yield. 
Treatment of disaccharide 127 with trichloroacetonitrile in the presence of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in dichloromethane (CH2Clz) at r. t. for 1 h 
74 
rendered the desired trichloroacetimidate 66, with an a, fl anomeric ratio of 8: 1, in 82% 
yield. Treatment of disaccharide 64 with hydrazine in the presence of acetic acid (AcOH) 
in pyridine furnished acceptor 67 in 89% yield (as shown in Scheme 34). 
3.3.2.2. Synthesis of Higher Order S-/O-linked HA Oligosaccharide Mimetics 
Condensation of trichloroacetimidate 66 with acceptor 67 in the presence of a 
catalytic amount of trimethylsilyl trifluoromethanesulfonate (TMSOTf) in 
dichloromethane (CH2Cl2) at -15 °C gave the desired tetrasaccharide 128 in very poor 
yield ( <20% ). However, we found that by simply changing the solvent from 
dichloromethane (CH2Clz) to 1,2-dichloroethane (ClCH2CH2Cl), the yield of 
tetrasaccharide 128 could be improved up to 69%. The ( 1 ➔ 3 )-linkage of tetrasaccharide 
128 was comfirmed to be /Jby 1D and 2D (gCOSY, HSQC, TOCSY, HMBC, etc) NMR 
spectroscopy, with a coupling constant of IHI, HZ= 7.8 Hz (for spectra, refer to Appendix 
II). Deprotection of tetrasaccharide 128 with hydrazine in the presence of acetic acid in 
pyridine provided tetrasaccharide acceptor 129 in 88% yield. However, when acceptor 
129 was resubjected to trichloroacetimidate 66 and a catalytic amount of trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) in 1,2-dichloroethane at -15 °C, only a small 
amount of hexasaccharide 130 was obtained (<10%), due probably to the deactivating 
effect of the prolonged acceptor chain. To our amazement, however, we found that the 
yield of hexasaccharide 130 could be improved to 46% by employing a reverse addition 
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Scheme 34. Synthesis of Glycosyl Donor 66 and Acceptor 67. 
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with a catalytic amount of trimethylsilyl trifluoromethanesulfonate (TMSOTf) at -15 °C 
for about 10 min, followed by addition of 1.5 equivalents of trichloroacetimidate 66. 
After 1 h, another 1.5 equivalents of trichloroacetimidate 66 were added, followed by 
addition of another catalytic amount of trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) (as shown Scheme 35). The newly formed (1➔3)-linkage of hexasaccharide 
130 was comfirmed to be also /Jby ID and 2D (gCOSY, HSQC, HMBC, TOSCY, etc) 
NMR spectroscopy, with a coupling constant of 181 , HZ= 8.4 Hz (for spectra, refer to 
Appendix II). Treatment of hexasaccharide 130 with 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) in 15: 1 dichloromethane (CH2C}z) and water at r. t. for 2 h gave 
hexasacchraride 131 in 83% yield. Oxidation of hexasaccharide 131 to carboxylic acid 
132 was achieved in 69% yield via treatment with pyridinium dichromate (PDC) in N.N-
dimethylformamide (DMF) at r. t. for 3 days. Finally, deprotection of carboxylic acid 132 
with lithium hydroxide (LiOH) in 1:2 tetrahydrofuran (THF) and water gave the desired 
S-/O-linked HA hexasaccharide mimetic 133 in 80% yield (as shown in Scheme 36). 
Hexasaccharide 133 was characterized extensively via ID and 2D (gCOSY, HSQC, 
TOCSY, HMBC, etc.) NMR spectroscopy (for spectra, refer to Appendix II). Negative-
ion mode MALDIMS as shown in Figure 13 confirms the molecular composition as 
shown by 1242.3100 [M - Hr, 1264.2767 [M - 2H + Nar, 1280.2525 [M - 2H + Kr, 
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Figure 13. Negative-Ion Model MALDIMS Spectrum of Hexasaccharide 133. 
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IV. CONCLUSIONS 
With respect to the objectives set forth in section 2.1, a C-linked disaccharide 
acceptor was successfully synthesized via SmI2-promoted coupling reaction of a properly 
protected sulfone and a properly protected aldehyde. The synthesis of C-/O-linked HA 
tetrasaccharide mimetics has been accomplished by my co-worker, Dr. Zhong-Xu Ren, 
by using this disaccharide as a building block. As for objective No. 2, the synthesis of S-
/O-linked HA tetrasaccharide mimetics was accomplished. Target compounds were 
obtained through trichloroacetimidate glycosylation of two strategically protected S-
disaccharides as building blocks, both of which were obtained via base-mediated 
coupling of a thiol donor and two properly protected triflates, respectively. 
Based on the chemistry developed in the synthesis of S-/O-linked HA 
tetrasaccharide mimetics, the synthesis of S-/O-linked hexasaccharide mimetics was 
accomplished via trichloroacetimidate glycosylation from a universal S-linked 
disaccharide unit that is strategically protected to be used as either a C-1 glycosyl donor 
(activated as trichloroacetimidate) or as a glycosyl acceptor (3'-OH free). This strategy 
should allow us to get rapid access to eight-mer and beyond. 
All the C-/O-linked and S-/O-linked HA oligosaccharide mimetics prepared 
herein will provide useful information for the synthesis and characterization of higher 
order HA oligosaccharide mimetics and related compounds. The "block strategy' 
employed here, i.e., of linking of S- or C-linked disaccharides by normal O-linkages, is a 
novel and practical approach to such oligosaccharide analogs. To date, nothing has been 
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documented in the literature using the idea of blockwise "mixed" oligosaccharide 
synthesis. These compounds might also find use as probes in the NMR spectral and 
molecular studies, as well as to serve as hyaluronidase inhibitors. In addition, their 
potential as antimetastatic agents will be evaluated. 
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V. EXPERIMENTAL SECTION 
General methods.-1H (250 :MHz, 300 :MHz, and 600 :MHz) and 13C (62.5 :MHz, 75 MHz, 
and 150 :MHz) NMR spectra were recorded at 25 °C with a Bruker AC 250, a Varian 
Mecury 300, or a Varian !nova 600 instrument, respectively. Chemical shifts are given in 
ppm relative to an internal standard of tetramethylsilane (TMS) for 1H, and relative to the 
signal for CDC13 (8 77.0) or DMSO-d6 (8 39.5) for 13C, unless otherwise stated. Apparent, 
first-order multiplicities are indicated by s, singlet; d, doublet; dd, doublet of doublets; t, 
triplet; dt, doublet of triplets; q, quartet, and m, multiplet. All assignments of 
disaccharides, tetrasaccharides and hexasaccharides were confirmed with the aid of two-
dimensional experiments (gCOSY, HSQC, HMBC and TOCSY), which were recorded 
with a Varian !nova 600. Column chromatography was performed on 60 A (63-200 µm, 
termed "coarse") silica gel (Sorbent Technologies) and fractions were monitored by TLC 
on Silica Gel 60 F254 (0.2-mm aluminum-backed plates, E. Merck) by detection with 254 
nm UV light and then spray-heat development using a p-anisaldehyde-sulfuric acid 
reagent. Melting points were measured with a Thomas-Hoover Capillary melting point 
apparatus. Optical rotations were performed with a Perkin-Elmer 241 polarimeter (1-dm 
cell) at 20 °C. ESI mass spectra analyses were obtained on a Micromass VG Quattro II 
electrospray instrument. MALDI mass spectra analyses were obtained on a Voyager-DE 
PRO BioSpectrometry Workstation. Elemental analyses were furnished by Atlantic 
Microlab, Inc. of Atlanta, GA. All solvents were dried and distilled by standard methods 
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unless otherwise stated. The (1,5-cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) 
hexafluorophosphate catalyst was purchased from Aldrich Chemical Co. 
p-Methoxyphenyl 2,3,4,6-tetra-O-acetyl-,B-D-galactopyranoside (68). To a solution of 
compound 23 (18.34 g, 47.2 mmol) andp-methoxylphenol (8.80 g, 70.97 mmol, 1.5 
equiv) in dry CH2Ch (250 mL) was TMSOTf (2 mL) added at O °C. The reaction was 
stirred at 0 °C for 2 h, and then it was quenched with tirethylamine (TEA). The mixture 
was washed with aq NaHCO3 and water, respectively and extracted with CH2Cl2. The 
organic phase was dried with anhyd Na2SO4 and then evaporated to dryness. The residue 
was submitted to coarse silica gel column chromatography (4:1 to 3:1 hexanes-EtOAc) to 
give compound 68 as a white amorphous solid (18.94 g, 41.90 mmol, 89%). The data 
match those reported in the literature.77 
p-Methoxyphenyl ,8-D-galactopyranoside (69). To a solution of compound 68 (20.5 g, 
45.4 mmol) in dry CH2Ch (50 mL) and dry MeOH (250 mL) was added NaOMe (25% in 
MeOH, 0.25 mL). The reaction was stirred at r. t. for 1 h, after which time the reaction 
was quenched with Dowex 50 x 2-100 (Ir form). The suspension was filtered and 
evaporated to afford tetraol 69 as a white amorphous solid (12.69 g, 44.0 mmol, 97% ), 
which was used in the next step without characterization. TLC (9: 1 CH2Clz-MeOH): Rr 
0.1; mp 158-160 °C; [a]o -35.7° (c 1.1, H2O). 
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p-Methoxyphenyl 4,6-0-p-methoxybenzylidene-,8-D-galactopyranoside (70). To a 
suspension of tetraol 69 (11.00 g, 38.5 mmol) in dry CH3CN (250 mL) were added 
anisaldehyde dimethyl acetal (ADMA, 69.0 mL, 0.40 mol) and p-toluenesulfonic acid 
(0.75 g, 3.9 mmol, 0.1 equiv). The solution was stirred at r. t. for about 4 h, after this time 
the reaction was quenched with triethylamine (TEA). The suspension was filtered and the 
solid was washed with EtOAc and MeOH sequentially to afford compound 70 as a white 
amorphous solid (13.07 g, 32.2 mmol, 84%). TLC (9:1 CH2Ch-MeOH): Rc0.5; mp 224-
226 °C; [a]0 -74.9° (c 1.0, DMSO); 1H NMR (250 MHz, DMSO-d6): 8 7.37 (d, 2 H, 
ArH), 7.01 (d, 2 H, ArH), 6.91 (d, 2 H, ArH), 6.86 (d, 2 H, ArH), 5.51 (s, 1 H, 
CH3OPhCH), 5.26 (d, 1 H, H-2), 5.02 (d, 1 H, H-3), 4.83 (d, 1 H, H-1, lH1. H2 = 6.5 Hz), 
4.10 (s, 1 H, H-4), 4.02 (s, 2 H, H-6), 3.74 (s, 3 H, OCH3), 3.70 (s, 3 H, OCH3), 3.67 (s, 1 
H, H-5), 3.58 (m, 1 H, OH); 13C NMR (62.5 MHz, DMSO-d6): 8 159.4, 154.3, 151.3, 
131.0, 127.5, 117.6, 114.4, 113.2, 101.5, 99.7, 75.8, 71.7, 69.7, 68.4, 66.0, 55.3, 55.1; 
ESIMS (positive-ion mode): m/z 404.7 [M + Ir], 426.7 [M + Na]+, 442.6 [M +Kt.Anal. 
Calcd for C21 H24O8 (404.72): C, 62.37; H, 5.98. Found: C, 62.30; H, 5.99. The data 
match those reported in Kenneth Price's dissertation.66 
p-Methoxyphenyl 2,3-di-0-benzyl-4,6-0-p-methoxybenzylidene-,B-D-
galactopyranoside (71). To a solution of diol 70 (7.35 g, 18.1 mmol) in dry DMF (40 
mL) was added NaH (60% in mineral oil, 2.17 g, 54.3 mmol) at O °C. The reaction was 
stirred at O °C for 10 min, and then BnBr (8.49 mL, 72.4 mmol) was added dropwise. The 
reaction was allowed to stir and warm tor. t. over 10 h, after which time it was quenched 
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with water and extracted with CH2Cl2. The organic phase was dried with anhyd Na2SO4 
and then concentrated to dryness. The residue was submitted to coarse silica gel column 
chromatography (3: 1 to 2: 1 hexanes-EtOAc) to give compound 71 as a white amorphous 
solid (10.0 g, 17.1 mmol, 95%). TLC (1:1 hexanes-EtOAc): Rf 0.5; mp 167-169 °C; 
[a]o-6.3° (c 1.0, CHC13); 1H NMR (250 MHz, CDCI)): 8 7.49 (d, 2 H, ArH), 7.40-7.25 
(m, 10 H, ArH), 7.06 (d, 2 H, ArH), 6.90 (d, 2 H, ArH), 6.80 (d, 2 H, ArH), 5.47 (s, 1 H, 
CH3OPhCH), 5.00 (d, 1 H, H-1, ltt1• ttz = 10.7 Hz), 4.86 (m, 2 H, H-2, H-3), 4.78 (s, 2 H, 
ArCH2O), 4.31 (d, 1 H, ArCH2O), 4.15-3.99 (m, 3 H, H-6, H-4, ArCH2O), 3.81 (s, 3 H, 
OCH3), 3.77 (s, 3 H, OCH3), 3.61 (dd, 1 H, H-5), 3.39 (s, 1 H, H-6); 13C NMR (62.5 
MHz, CDCh): 8 160.0, 155.2, 151.6, 138.6, 138.3, 130.4, 128.3, 128.2, 128.0, 127.8, 
127.7, 127.5, 118.9, 114.4, 113.4, 103.1, 101.2, 79.1, 78.1, 75.4, 73.6, 71.9, 69.0, 66.4. 
55.6, 55.2; ESIMS (positive-ion mode): m/z 585.2 [M +Hr, 607.2 [M + NaJ+, 623.2 lM 
+Kt.Anal. Calcd for C35H36Os (584.67): C, 71.90; H, 6.21. Found: C, 71.84; H, 6.30. 
The data match those reported in Kenneth Price's dissertation.66 
p-Methoxyphenyl 2,3-di-0-benzyl-6-0-p-methoxybenzyl-/J-D-galactopyranoside (72). 
A suspension of compound 71 (0.90 g, 1.54 rnmol), NaBH3CN (0.39 g, 6.16 mmol) and 4 
A MS (0.41 g) in dry DMF (20 mL) was stirred at O °C for 15 min, and then a solution of 
trifluoroacetic acid (TFA) (0.95 mL, 12.3 mmol) in dry DMF (3 mL) was added dropwise. 
The reaction was allowed to stir and warm tor. t. over 10 h, after which time the mixture 
was filtered through a Celite bed, washed with satd NaHCO3, and extracted with CH2Clz. 
The organic phase was dried with anhyd Na2SO4 and then concentrated to dryness. The 
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residue was submitted to coarse silica gel column chromatography (4: 1 to 3.5: 1 hexanes-
EtOAc) to give compound 72 as colorless crystals (0.67 g, 1.14 mmol, 74%). TLC (2:1 
hexanes-EtOAc): Rr 0.5; mp 93-95 °C; [a] 0 -6.2° (c 1.0, CHCh); 1H NMR (250 MHz, 
CDCh): 8 7.38-7.22 (m, 12 H, ArH), 7.03 (d, 2 H, ArH), 6.85 (d, 2 H, ArH), 6.80 (d, 2 H, 
ArH), 5.01 (d, 1 H, ArCH2O), 4.84 (d, 1 H, H-1, ltt1, Hz= 7.5 Hz), 4.81 (d, 1 H, ArCH2O), 
4.74 (s, 2 H, ArCH2O), 4.50 (s, 2 H, ArCH20), 4.05 (d, 1 H, H-6), 3.91 (t, 1 H, H-4), 3.80 
(s, 3 H, OCH3), 3.74 (s, 3 H, OCH3), 3.63 (t, 1 H, H-3), 3.56 (dd, 1 H, H-5), 2.56 (s, l H, 
OH); 13C NMR (62.5 MHz, CDCIJ): 8 159.3, 155.2, 151.5, 138.4, 137.8, 130.1, 129.4, 
128.5, 128.3, 128.1, 127.9, 127.8, 127.7, 118.6, 114.5, 113.8, 102.9, 80.6, 78.7, 75.3, 73.5, 
73.4, 72.5, 68.9, 66.8, 55.6, 55.2; ESIMS (positive-ion mode): m/z 609.3 [M + Na]+, 
625.2 [M +Kt.Anal. Calcd for C3sH3s08 (586.69): C, 71.65; H, 6.53. Found: C, 71.54; 
H, 6.60. The data match those reported in Kenneth Price's dissertation.66 
p-Methoxyphenyl 2,3-di-0-benzyl-6-0-p-methoxybenzyl-4-0-
trifluoromethanesulfonyl-P-D-galactopyranoside (73). To a solution of compound 72 
(10.0 g, 17.06 mmol) in dry CH2Cl2 (80 mL) and pyridine (3.5 mL, 43.3 mmol) was 
added triflic anhydride (3.5 mL, 21.3 mmol) dropwise at O 0 C. The reaction was stirred at 
0 °C for 10 h, after which time it was concentrated and passed through a short plug of 
coarse silica gel (3: 1 hexanes-EtOAc) to give triflate 73 as an unstable, pale-yellow 




glucopyranoside (74). To a solution of triflate 73 (12.26 g, 17.06 mmol) in dry THF (40 
mL) was added tetrabutylammonium cyanide (50 mL, 0.44 Min THF, 1.2 equiv) 
dropwise at -45 °C. The solution was allowed to stir and warm to r. t. over 4 h, at which 
time TLC (3: 1 hexanes-EtOAc) showed complete consumption of starting material and 
formation of two main spots. The reaction was concentrated to dryness, and the residue 
was subjected to coarse silica gel column chromatography (7:1 to 5.5:1 hexanes-EtOAc) 
to afford compound 74 as a yellow syrup (6.40 g, 10.75 mmol, 63%). TLC (3:1 hexanes-
EtOAc): Rr 0.4; [a]o -19.1 ° (c 1.0, CHCh); 1H NMR (250 :MIIz, CDCh): 8 7.34-7.20 (m, 
12 H, ArH), 6.99 (d, 2 H, ArH), 6.83 (d, 2 H, ArH), 6.79 (d, 2 H, ArH), 5.01 (d, 1 H, 
ArCH2O), 4.87 (s, 2 H, ArCH2O), 4.85 (d, 1 H, H-1, lHI, HZ= 7.5 Hz), 4.78 (d, 1 H, 
ArCH2O), 4.47 (dd, 2 H, ArCH2O), 3.71 (s, 3 H, OCH3), 3.69 (s, 3 H, OCH3), 3.78-3.64 
(m, 4 H, H-2, H-5, H-6), 3.55 (t, 1 H, H-3), 2.98 (t, 1 H, H-4); 13C NMR (62.5 MHz, 
CDCh): 8 158.4, 154.6, 150.2, 136.9, 136.4, 128.7, 128.4, 127.5, 127.4, 127.2, 127.1, 
127.0, 117.6, 116.6, 113.7, 112.9, 101.9, 80.5, 78.4, 74.9, 74.2, 72.5, 71.4, 68.2, 54.6, 
54.3, 35.0; ESIMS (positive-ion mode): m/z 618.2 [M + Na]+, 634.2 [M +Kt.Anal. 
Calcd for C36H31NO7 (595.70): C, 72.59; H, 6.26; N, 2.35. Found: C, 72.59; H, 6.45; N, 
2.24. The data match those reported in Kenneth Price's dissertation.66 
p-Methoxyphenyl 2,3-di-0-benzyl-4-deoxy-4-C-formyl-6-0-p-methoxybenzyl-/J-D-
glucopyranoside (21). To a solution of compound 74 (1.06 g, 1.78 mmol) in dry THF 
(25 mL) was added DIBAI-H (7.11 mL, 1.5 Min toluene, 6 equiv) at -78 °C. The 
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reaction was allowed to stir and warm tor. t. over 10 h, after which time it was quenched 
with EtOAc, and the solution was stirred with 1.0 N H3PO4 (10 mL) for another 30 min at 
0 °C. The mixture was then neutralized with satd NaHCO3, filtered though a Celite bed, 
and extracted with CH2Cl2• The organic phase was dried with anhyd Na2SO4 and then 
concentrated to dryness. The residue was submitted to a short plug of coarse silica gel 
(3.5: 1 hexanes-EtOAc) to give compound 21 as a pale-yellow syrup (0.76 g, 1.26 mmol, 
71 %). TLC (3: 1 hexanes-EtOAc): Rr 0.3; [a]o -31.7° (c 0.5, CH1C'2); 1H NMR (250 
MHz, CDC13): 8 9.65 (d, 1 H, CHO), 7.33-7.16 (m, 12 H, ArH), 6.99 (d, 2 H, ArH), 6.83 
(d, 2 H, ArH), 6.80 (d, 2 H, ArH), 5.05 (d, 1 H, ArCH2O), 4.84 (m, 3 H, ArCH2O, H-1, 
IHI. tt2 = 10.0 Hz), 4.56 (d, 1 H, ArCH2O), 4.40 (dd, 2 H, ArCH2O), 4.00 (t, 1 H, H-3), 
3.74 (s, 3 H, OCH3), 3.72 (s, 3 H, OCH3), 3.81-3.67 (m, 2 H, H-5, H-3), 3.58 (m, 2 H, H-
6), 3.01 (t, 1 H, H-4); 13C NMR (62.5 MHz, CDC'3): 8 200.1, 159.4, 155.5, 151.4, 138.3, 
138.0, 129.8, 129.5, 128.5, 128.5, 128.3, 128.1, 127.9, 118.5, 114.7, 113.9, 102.8, 82.6, 
78.8, 75.2, 75.1, 73.2, 72.1, 70.3, 57.3, 55.7, 55.3; ESIMS (positive-ion mode): mlz 621.1 
[M + Na]+, 637.2 [M +Kt.Anal. Calcd for C36H38O8 (598.70): C, 72.22; H, 6.40. Found: 
C, 72.44; H, 6.28. The data match those reported in Kenneth Price's dissertation.66 
2-Pyridinyl 2-acetamido-2-deoxy-1-thio-P-D-glucopyranoside (77). To a solution of 
compound 76 (20.0 g, 45.5 mmol) in MeOH (150 mL) and CH2C'2 (30 mL) was added 
NaOMe (25% in MeOH, 1.0 mL). The reaction was stirred at r. t. for 1 h, after which 
time 1 mL of satd N~Cl solution was added, and the solvent was evaporated to afford 
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compound 77 (13.6 g, 43.2 mmol, 95%) as a white amorphous solid that was used in the 
next step without characterization. mp 154-156 °C; [a] 0 +9.5° (c 1.0, DMSO). 
2-Pyridinyl 2-acetamido-4,6-0-benzylidene-2-deoxy-1-thio-,B-D-glucopyranoside (78). 
Compound 77 (16.0 g, 51.0 mmol) was stirred with dry ZnCh (14 g, 0.10 mol) in 
benzaldehyde (100 mL) at r. t. for 16 h, after which time the reaction was quenched with 
water (250 mL). The suspension was filtered, and the solid was washed with MeOH and 
EtOAc sequentially to afford compound 78 as a white amorphous solid (16.3 g, 40.5 
mmol, 80%). TLC (10:1 CHCh-MeOH): Rr0.4; mp 164-166 °C; [a] 0 +4.6° (c 0.5, 
DMSO); 1H NMR (250 MHz, DMSO-d6): 8 8.43-7.12 (m, 4 H, ArH), 7.47-7.32 (m, 5 H, 
ArH), 5.62 (s, 1 H, PhCH), 5.54 (d, 1 H, H-1, ltt 1,tt2 = 10.5 Hz), 5.46 (d, 1 H, NH), 4.19-
4.17 (m, 1 H, H-6), 3.85 (dd, 1 H, H-2), 3.74-3.63 (m, 2 H, H-3, H-4), 3.59-3.48 (m. 2 H. 
H-6, H-5), 3.16 (d, 1 H, OH), 1.80 (s, 3 H, CH3CO); 13C NMR (62.5 MHz, DMSO-d6): 
169.2, 157.2, 149.4, 137.7, 137.2, 128.9, 128.0, 126.4, 122.0, 120.5, 100.7, 83.3, 81.0, 
71.7, 70.2, 67.6, 54.0, 23.0; ESIMS (positive-ion mode): m/z 403.1 [M + H]+, 425.1 [M + 
Na]+, 441.1 [M +Kt.Anal. Calcd for C20H22N2OsS·0.l6CH2Ch (416.06): C, 58.20; H, 
5.41; N, 6.73. Found: C, 58.19; H, 5.56; N, 6.50. (The CH2Cl2 of solvation was 
confirmed by NMR spectroscopy.) 
2-Pyridinyl 2-acetamido-4,6-0-benzylidene-3-0-tert-bu tyldimethylsilyl-2-deoxy-1-
thio-,B-D-glucopyranoside (79). To a solution of compound 78 (16.30 g, 40.54 mmol) 
and imidazole (6.25g, 96.0 mmol) in dry DMF was added tert-butyldimethylsilyl chloride 
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(10.43 g, 69.0 mmol) at O °C. The reaction was allowed to stir and warm tor. t. over 15 h, 
after which time it was quenched with water, washed with satd NaHCO3, and extracted 
with CH2C}z. The organic phase was dried with anhyd Na2SO4 and then evaporated to 
dryness. The residue was submitted to coarse silica gel column chromatography (2.5: 1 to 
1: 1 hexanes-EtOAc) to yield compound 79 as a pale-yellow solid (16.3 g, 31.6 mmol, 
78%). TLC (1:2 hexanes-EtOAc): Rr0.5; mp 210-212 °C; [a] 0 +4.3° (c 1.0, CH2Clz); 
1H NMR (250 MHz, CDCh): 8 8.44-7.03 (m, 4 H, ArH), 7.55-7.34 (m, 5 H, ArH), 5.98 
(d, 1 H, NH), 5.85 (d, 1 H, H-1, lHi. Hz= 10.6 Hz), 5.51 (s, 1 H, PhCH), 4.31 (dd, 1 H, H-
6), 4.20-3.96 (m, 2 H, H-2, H-3), 3.82-3.48 (m, 3 H, H-6, H-5, H-4), 1.91 (s, 3 H, 
CH3CO), 0.82 (s, 9 H, C(CH3)3), 0.05 (s, 3 H, SiCH3), -0.02 (s, 3 H, SiCH3); 13C NMR 
(62.5 MHz, CDCh): 8 170.1, 156.6, 149.4, 137.2, 136.6, 129.0, 128.1, 126.3, 123.5, 
120.6, 101.8, 83.2, 82.1, 74.0, 70.8, 68.7, 56.2, 25.6, 23.5, 18.1, -4.1, -5.0; ESIMS 
(positive-ion mode): m/z 517.2 [M + H]+, 539.2 [M + Na]+, 555.2 [M +Kt.Anal. Calcd 
for C26H36N2O5SSi (516.74): C, 60.43; H, 7.02; N, 5.42. Found: C, 60.41; H, 6.83; N, 
5.36. 
2-Acetamido-4,6-O-benzylidene-3-O-tert-bu tyldimethy lsily I-1,2-dideoxy-1-
pyridinylsulfonyl-P-D-glucopyranose (20). To a stirred solution of compound 79 ( 16.3 
g, 31.6 mmol) in CH2Cl2 (200 mL) was added m-CPBA (50-60%, 33.0 g) at O 0 C. The 
reaction was allowed to stir and warm to r. t. over 1.5 h, after which time the reaction 
mixture was diluted with CH2Cl2, washed consecutively with satd Na2S2O3, satd Na2CO3 
and brine, and extracted with CH2Clz. The organic phase was dried with anhyd Na2SO4 
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and then concentrated to dryness. The residue was submitted to silica gel column 
chromatography (1:1 hexanes-EtOAc) to give compound 20 as a white amorphous solid 
(13.9 g, 25.4 mmol, 79%). TLC (1:2 hexanes-EtOAc): Rr0.4; mp 162-164 °C; [a]o-
34.80 (c 1.0, CH2Cl2); 1H NMR (250 MHz, CDCh): o 8.85 (d, 1 H, ArH), 8.16 (d, l H, 
ArH), 8.02 (t, 1 H, ArH), 7.62 (t, 1 H, ArH), 7.50-7.39 (m, 5 H, ArH), 6.84 (d, 1 H, NH), 
5.81 (d, 1 H, H-1, ltt1, tt2 = 10.3 Hz), 4.72-4.61 (m, 1 H, H-6), 4.12-4.02 (m, 2 H, H-2, 
H-3), 3.69-3.48 (m, 3 H, H-6, H-5, H-4), 2.06 (s, 3 H, CH3CO), 0.09 (s, 9 H, C(CH3)3), 
0.06 (s, 3 H, SiCH3), -0.01 (s, 3 H, SiCH3); 13C NMR (62.5 MHz, CDCh): o 171.0, 
155.1, 150.2, 137.8, 136.8, 128.9, 127.9, 127.6, 126.1, 124.2, 101.7, 86.1, 81.6, 71.0, 70.1, 
67.9, 53.5, 25.6, 23.5, 17.9, -4.4, -5.1; ESTh1S (positive-ion mode): m/z 549.0 [M + H]+, 
571.0 [M + Na]+, 587.0 [M +Kt.Anal. Calcd for C26H36N2O7SSi (548.74): C, 56.91; H, 
6.61; N, 5.11. Found: C, 56.72; H, 6.60; N, 4.96. 
Samarium diiodide-promoted coupling reaction-Preparation of 80a, 80b, and 80c. 
To a stirred solution of sulfone 20 (2.90 g, 5.3 mmol) and aldehyde 21 (2.50 g, 4.2 mmol) 
in THF (50 mL) was added a solution of Smlz in dry THF (0.1 M, 150 mL, 15 mmol) at 
20 °C under N2. The reaction was stirred at r. t. for 1 h, after which time it was quenched 
with satd ~Cl and extracted with CH2Cl2. The organic phase was dried with anhyd 
Na2SO4, and then evaporated to dryness. The residue was submitted to coarse silica gel 
column chromatography (3:1 to 1:1 hexanes-EtOAc) to afford 80a (845 mg, 0.84 mmol, 
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methoxybenzyl-4a-carba-/J-D-glucopyranoside (80a). TLC (2: 1 hexanes-EtOAc): Rr 
0.4; mp 176-178 °C; [a]o -41.2° (c 0.5, CH2C}z); 1H NMR (600 MHz, CDCl 3): 8 
7.51-7.19 (m, 17 H, ArH), 7.07 (d, 2 H, ArH), 6.84 (d, 2 H, ArH), 6.75 (d, 2 H, ArH), 
5.44 (s, 1 H, PhCH), 5.07 (d, 1 H, ArCH2O), 4.99 (d, 1 H, ArCH2O), 4.99 (d, 1 H, NH), 
4.91 (d, 1 H, H-1 1, IHI, H2 = 7.2 Hz), 4.80 (d, 1 H, ArCH2O), 4.59 (d, 1 H, ArCH2O), 4.45 
(dd, 2 H, ArCH2O), 4.21 (dd, 1 H, H-611), 4.02 (s, 1 H, CH-OH), 3.97 (dd, 1 H, H-61), 
3.91-3.83 (m, 2 H, H-51, H-i\ 3.80-3.76 (m, 3 H, H-i, H-31, CH-OH), 3.78 (s, 3 H, 
CH3O), 3.76 (s, 3 H, CH3O), 3.62-3.57 (m, 2 H, H-61, H-611), 3.43-3.36 (m, 2 H, H-411, 
H-1 n, IHi, Hz= 8.4 Hz), 3.29-3.21 (m, 2 H, H-3 11 , H-5n), 2.32-2.26 (m, 1 H, H-41), 1.76 (s, 
3 H, CH3CO), 0.77 (s, 9 H, C(CH3) 3), -0.05 (s, 3 H, SiCH3), -0.08 (s, 3 H, SiCH3); 13C 
NMR (62.5 MHz, CDCh): 8 171.2, 158.9, 155.0, 151.5, 138.8, 138.1, 137.1, 130.8, 129.8, 
129.0, 128.6, 128.4, 128.1, 127.8, 127.7, 126.2, 118.2, 114.5, 113.6, 102.7, 101.8, 83.1, 
82.0, 78.5, 78.4, 74.6, 74.2, 73.7, 73.5, 72.8, 71.4, 70.5, 68.6, 67.3, 55.5, 55.1, 53.5, 46.0, 
25.6, 23.2, 18.0, -4.0, -4.9; ESIMS (positive-ion mode): m/z 1028.4 [M + Na]+, 1044.5 
[M +Kt.Anal. Calcd for C57H71 NO 13Si (1006.28): C, 68.04; H, 7.11; N, 1.39. Found: C, 




methoxybenzyl-4a-carba-/J-D-glucopyranoside (80b ). TLC (1 :2 hexanes-EtOAc ): Rr 
0.5; mp 90-92 °C; [a] 0 -97.1 ° (c 0.5, CH2Ch); 1H NMR (600 MHz, CDCh): 8 
7.47-7.24 (m, 17 H, ArH), 7.04 (d, 2 H, ArH), 6.87 (d, 2 H, ArH), 6.79 (d, 2 H, ArH), 
5.40 (s, 1 H, PhCH), 5.09 (d, 1 H, ArCH2O), 5.03 (d, 1 H, ArCH2O), 4.99 (d, 1 H, NH), 
4.94 (d, 1 H, H-1 1, lm. H2 = 6.6 Hz), 4.77 (d, 1 H, ArCH2O), 4.65 (d, 1 H, ArCH2O), 4.50 
(d, 1 H, ArCH2O), 4.43 (d, 1 H, ArCH2O), 4.17 (dd, 1 H, H-61\ 3.88-3.74 (m, 5 H, H-5 1, 
H-3 11, H-i, CH-OH, H-31), 3.78 (s, 3 H, OCH3), 3.76 (s, 3 H, OCH3), 3.72 (dd, 1 H, H-61), 
3.61 (dd, 1 H, H-61), 3.58-3.52 (m, 2 H, H-611, H-1 11.Jm. H2 = 9.6 Hz), 3.48 (dd, 1 H, H-
211), 3.28 (t, 1 H, H-411), 3.26-3.21 (m, 1 H, H-511), 2.25-2.08 (m, 1 H, H-41), 1.89 (s, 3 H, 
CH3CO), 0.08 (s, 9 H, C(CH3) 3), -0.03 (s, 3 H, SiCH3), -0.07 (s, 3 H, SiCH3); 13C NMR 
(62.5 MHz, CDC13): 8 170.8, 159.3, 155.1, 151.4, 138.5, 138.0, 137.2, 130.0, 129.7, 
129.0, 128.7, 128.4, 128.1, 128.1, 127.8, 127.7, 126.3, 126.2, 114.5, 113.8, 102.8, 101.7, 
83.2, 82.2, 79.5, 78.7, 74.4, 73.1, 72.9, 71.5, 71.5, 69.6, 68.6, 56.9, 55.6, 55.2, 45.3, 25.7, 
23.5, 18.1, -4.1, -5.0; ESIMS (positive-ion mode): m/z 1006.4 [M + W], 1028.5 [M + 
Na]+, 1044.6 [M +Kt.Anal. Calcd for C57H71 NO 13Si (1006.28): C, 68.04; H, 7.11; N, 




methoxybenzyl-4a-carba-a-D-glucopyranoside (80c). TLC (2: l hexanes-EtOAc ): R1 
0.2; mp 96-98 °C; [a]o-2.9° (c 0.1, CH2C]i); 1H NMR (600 MHz, CDCl3): 8 7.47-7.26 
(m, 15 H, ArH), 7.21 (d, 2 H, ArH), 7.00 (d, 2 H, ArH), 6.84 (d, 2 H, ArH), 6.81 (d, 2 H, 
ArH), 6.10 (d, 1 H, NH), 5.44 (s, 1 H, PhCH), 5.11 (d, 1 H, ArCH2O), 5.05 (d, 1 H, 
ArCH2O), 4.93 (d, 1 H, H-1 1, Im, tt2 = 7.2 Hz), 4.75 (d, 1 H, ArCH2O), 4.74 (d, 1 H, 
ArCH2O), 4.46 (d, 1 H, ArCH2O), 4.35 (d, 1 H, ArCH2O), 4.27 (m, 1 H, H-i1) 4.12 (dd, 
1 H, H-611), 4.02 (m, 1 H, H-41'), 3.95 (m, 2 H, H-31, H-3 11), 3.84-3.71 (m, 4 H, H-61, H-5 1, 
H-1 11, CH-OH), 3.78 (s, 3 H, CH3O), 3.78 (s, 3 H, CH3O), 3.68 (t, 1 H, H-2'), 3.65-3.61 
(m, 1 H, H-6\ 3.56 (t, 1 H, H-611), 3.50-3.40 (m, 1 H, H-5 11), 2.05-1.98 (m, 1 H, H-41), 
1.86 (s, 3 H, CH3CO), 0.75 (s, 9 H, C(CH3) 3), -0.08 (s, 3 H, SiCH3), -0.13 (s, 3 H, 
SiCH3); 13C NMR (62.5 MHz, CDCh): 8 169.7, 159.1, 155.1, 150.9, 137.5, 137.3, 137.1, 
129.6, 129.0, 128.8, 128.6, 128.3, 128.1, 128.1, 128.0, 127.7, 127.7, 126.1, 118.2, 114.4, 
113.5, 102.5, 101.6, 83.0, 82.7, 80.0, 75.2, 74.3, 73.5, 73.2, 71.9, 71.4, 71.3, 69.1, 67.6, 
65.4, 55.6, 55.2, 54.5, 48.3, 25.7, 23.4, 18.0, -4.0, -4.9; ESIMS (positive-ion mode): mlz 
1006.2 [M + H]+, 1023.2 [M + NRit, 1028.2 [M + Na]+, 1044.2 [M +Kt.Anal. Calcd 
for C57H71 NO 13Si (1006.28): C, 68.04; H, 7.11; N, 1.39. Found: C, 67.79; H, 7.03; N, 
1.47. 
p-Methoxypheny I C-(2-acetamido-4,6-O-benzy lidene-3-O-tert-buty ldimethy lsilyl-2-
deoxy-/3-D-glucopyranosyl)-(l ➔4a )-( 4aR)-2,3-di-O-benzy l-4a-O-
methy lthiothiocarbonyl-6-O-p-methoxybenzyl-4a-carba-/3-D-glucopyranoside (83a). 
To a solution of compound 80a (1.90 g, 1.68 mmol) and imidazole (10 mg, 0.15 mmol) 
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in dry THF (15 mL) was added NaH (60% in mineral oil, 135 mg, 3.38 mmol). The 
reaction was stirred for 30 min, after which time CS2 (1.74 mL, 3.78 mmol) was added, 
and then Mel (0.42 mL, 6.72 mmol) was added after another 40 min. The mixture was 
stirred for 40 min, after which time it was quenched with wet CH2Cl2 (20 mL), poured 
into water (50 mL), and extracted with CH2Clz. The organic phase was dried with anhyd 
Na2SO4 and then evaporated to dryness. The residue was submitted to coarse silica gel 
column chromatography (3: 1 to 2: 1 hexanes-EtOAc) to yield compound 83a as a white 
amorphous solid (1.01 g, 0.91 mmol, 54%). TLC (2:1 hexanes-EtOAc): Rr 0.5; mp 
85-87 °C; [a]o-4.3° (c 0.1, CH2C}z); 1H NMR (600 MHz, CDCh): o 7.46-7.23 (m, 17 
H, ArH), 7.06 (d, 2 H, ArH), 6.85 (d, 2 H, ArH), 6.74 (d, 2 H, ArH), 6.33 (m, 1 H, 
CHOC=S), 5.44 (s, 1 H, PhCH), 5.09 (d, 1 H, ArCH2O), 5.08 (d, 1 H, ArCH2O), 4.86 (d, 
1 H, H-1 1, JHI,tt2 = 7.8 Hz), 4.75 (d, 1 H, ArCH2O), 4.67 (d, 1 H, ArCH2O), 4.51 (d, 1 H, 
ArCH2O), 4.42 (d, 1 H, ArCH2O), 4.23 (dd, 1 H, H-611) 4.00-3.95 (m, 2 H, H-61, H-5 1), 
3.80-3.74 (m, 1 H, H-i), 3.77 (s, 3 H, OCH3), 3.73 (s, 3 H, OCH3), 3.66-3.32 (m, 8 H. 
H 31 H 611 H 61 H 311 H II II H 511 II ? I ? 55 ' 3 H - , - , - , - , -2 , H-1 , - , H-4 ), 2.72-2.5_ (m, 1 H, H-4 ), -· (s, . 
SCH3), 1.49 (s, 3 H, CH3CO), 0.77 (s, 9 H, C(CH3)3), -0.08 (s, 3 H, SiCH3), -0.09 (s, 3 
H, SiCH3); 13C NMR (62.5 MHz, CDCh): o 216.3, 169.7, 158.9, 155.1, 151.5, 139.0, 
138.0, 137.1, 130.8, 129.0, 128.3, 128.0, 127.7, 127.4, 127.3, 126.3, 118.3, 114.4, 113.5, 
102.9, 101.9, 83.4, 82.3, 78.9, 75.5, 74.5, 74.3, 73.4, 72.9, 71.8, 71.0, 70.6, 68.5, 55.5, 
55.1, 54.5, 44.9, 25.6, 23.3, 19.4, 18.0, -4.2, -5.1; ESIMS (positive-ion mode): m/z 
1096.4 [M + H]+, 1118.5 [M + Na]+, 1134.6 [M + Kt. Anal. Calcd for Cs9H73NO13S2Si 
(1096.45): C, 64.63; H, 6.71; N, 1.28. Found: C, 64.58; H, 6.71; N, 1.26. 
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p-Methoxyphenyl C-(2-acetamido-4,6-O-benzylidene-3-O-tert-butyldimethy lsily 1-2-
deoxy-/J-D-glucopyranosyl)-(1 ➔4a)-( 4aS)-2,3-di-O-benzyl-4a-O-
methylthiothiocarbonyl-6-O-p-methoxybenzyl-4a-carba-/J-D-glucopyranoside (83b). 
To a solution of compound 80b (1.90 g, 1.68 mmol) and imidazole (10 mg, 0.15 mmol) 
in dry THF (15 mL) was added NaH (60% in mineral oil, 135 mg, 3.38 mmol). The 
reaction was stirred for 30 min, after which time CS2 (1.74 mL, 3.78 mmol) was added, 
and then Mel (0.42 mL, 6.72 mmol) was added after another 40 min. The mixture was 
stirred for 40 min, after which time it was quenched with wet CH2C}z (20 mL), poured 
into water (50 mL), and extracted with CH2C}z. The organic phase was dried with anhyd 
Na2SO4 and then evaporated to dryness. The residue was submitted to coarse silica gel 
column chromatography (3:1 to 2:1 hexanes-EtOAc) to yield compound 83b as a white 
amorphous solid (0.94 g, 0.85 mmol, 50%). TLC (2:1 hexanes-EtOAc): Rr0.45; mp 
80-82 °C; [a] 0 -9.0° (c 0.5, CH2C}z); 1H NMR (600 MHz, CDCh): 8 7.46-7.23 (m, 17 
H, ArH), 7.11 (d, 2 H, ArH), 6.85 (d, 2 H, ArH), 6.75 (d, 2 H, ArH), 6.42 (m, 1 H, 
CHOC=S), 5.37 (s, 1 H, PhCH), 5.32 (d, 1 H, ArCH20), 5.05 (d, 1 H, ArCH2O), 5.00 (d, 
1 H, NH), 4.93 (d, 1 H, H-1 1, Im, Hz= 7.2 Hz), 4.78 (dd, 2 H, ArCH2O), 4.58 (t, 1 H, H-
411), 4.48 (dd, 2 H, ArCH2O), 4.43 (d, 1 H, H-1 11, lH1,H2 = 10.8 Hz), 4.14 (d, 1 H, H-61\ 
4.02 (d, 1 H, H-61), 3.77 (s, 3 H, CH30), 3.76 (s, 3 H, CH3O), 3.79-3.73 (m, 3 H, H-3 11 , 
H-i1, H-3\ 3.49-3.43 (m, 4 H, H-5 1, H-1 11 , H-6 11 , H-61), 3.19 (t, 1 H, H-5 11 ), 2.73 (m. I H. 
H-i11), 2.55 (s, 3 H, SCH3), 2.21 (t, 1 H, H-41), 1.33 (s, 3 H, CH3CO), 0.79 (s, 9H, 
C(CH3)3), -0.11 (s, 3H, SiCH3), -0.14 (s, 3H, SiCH3); 13C NMR (62.5 MHz, CDCl3): 
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8 216.7, 170.2, 159.1, 155.0, 151.5, 138.8, 137.8, 137.2, 130.6, 129.2, 129.1, 128.9, 128.3, 
128.2, 128.0, 127.8, 126.3, 126.2, 118.0, 114.5, 113.7, 102.7, 101.8, 83.1, 82.5, 80.4, 79.1, 
76.8, 75.0, 74.3, 73.9, 73.0, 72.3, 69.7, 68.9, 68.3, 56.9, 55.5, 55.1, 42.2, 25.6, 23.4, 19.0, 
18.1, -4.3, -5.1; ESIMS (positive-ion mode): mlz 1118.1 [M + Na]+, 1134.1 [M + Kt. 
Anal. Calcd for Cs9H73NO13S2Si (1096.45): C, 64.63; H, 6.71; N, 1.28. Found: C, 64.39; 
H, 6.86; N, 1.22. 
p-Methoxyphenyl C-(2-acetamido-4,6-0-benzylidene-3-0-tert-butyldimethylsilyl-2-
deoxy-/3-D-glucopyranosyl)-(l ➔4a)-2,3-di-0-benzyl-6-0-p-methoxybenzyl-4a-carba­
/3-D-glucopyranoside (19). To a refluxing solution of tri-n-butyltin hydride (1.33 mL, 5.0 
mrnol) in dry toluene (10 mL) was added a solution of compound 83a or 83b (1.00 g, 
0.91 mrnol) and AIBN (11 mg) in dry toluene (10 mL) dropwise. The reaction was stirred 
for 30 min, and then the reaction mixture was extracted with CH2C}z. The organic phase 
was dried with anhyd Na2SO4 and concentrated to dryness. The residue was submitted to 
coarse silica gel column chromatography (2: 1 hexanes-EtOAc) to yield compound 19 as 
a white amorphous solid (820 mg, 0.83 mmol, 91 %). TLC (2: 1 hexanes-EtOAc): Rr 0.3; 
mp 67-69 °C; [a]o-21.3° (c 0.5, CH2Clz); 1H NMR (600 MHz, CDCI)): 8 7.47-7.25 (m, 
20 H, ArH), 7.04 (d, 2 H, ArH), 6.89 (d, 2 H, ArH), 6.80 (d, 2 H, ArH), 5.44 (s, 1 H, 
PhCH), 5.08 (d, 1 H, ArCH2O), 5.02 (d, 1 H, ArCH2O), 4.84 (d, 1 H, H-1 1, JHI,H2 = 7.8 
Hz), 4.79 (d, 1 H, ArCH2O), 4.60 (d, 1 H, ArCH2O), 4.57 (d, 1 H, NH), 4.51 (d, 1 H, 
ArCH2O), 4.44 (d, 1 H, ArCH2O), 4.19 (dd, 1 H, H-611), 3.79 (s, 3 H, OCH3), 3.77 (s, 3 H, 
QC 6, 1 " , 611 H 211 H 31) H3), 3.74-3.68 (m, 3 H, H- , H-2, H-3 ), 3.60-3.50 (m, 4 H, H-6, H- , - , - , 
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3.50-3.44 (m, 2 H, H-51, H-411 ), 3.34-3.28 (m, 1 H, H-1 11 , lHi. H2 = 8.4 Hz), 3.25-3.20 (m. 
II I 1 H, H-5 ), 2.12-2.05 (m, 1 H, H-4 ), 1.73 (m, 1 H, CH2), 1.67 (s, 3 H, CH3CO), 1.61 (Liu. 
1 H, CH2), 0.77 (s, 9 H, C(CH3)3), -0.03 (s, 3 H, SiCH3), -0.08 (s, 3 H, SiCH3); 13C 
NMR (62.5 MHz, CDCh): 8 169.5, 159.1, 155.1, 151.5, 139.1, 138.1, 137.1, 130.2, 129.5, 
128.9, 128.4, 128.3, 128.1, 128.0, 127.5, 126.2, 118.3, 114.4, 113.7, 103.0, 101.7, 83.2, 
82.4, 80.7, 75.8, 74.5, 73.8, 73.3, 73.0, 70.0, 68.7, 57.0, 55.4, 55.1, 39.8, 28.8, 25.5, 23.3, 
17.9, -4.1, -5.1; ESIMS (positive-ion mode): m/z 1012.4 [M + Na]+, 1028.5 [M + Kt. 
Anal. Calcd for Cs7H71NO12Si (990.28): C, 69.13; H, 7.23; N, 1.41. Found: C, 68.57; H, 
7.28; N, 1.34. 
p-Methoxyphenyl C-(2-acetamido-4,6-0-benzylidene-2-deoxy-/J-D-glucopyranosyl )-
(1 ➔4a)-2,3-di-O-benzyl-6-0-p-methoxybenzyl-4a-carba-/J-D-glucopyranoside (84). 
To a solution of compound 19 (1.22 g, 1.23 mmol) in dry THF (20 mL) was added 
Bu4NF (1.35 mL, 1.0 Min THF, 1.1 equiv). The reaction was stirred at r. t. for 1.5 h, 
after which time it was quenched with water, and the mixture was extracted with CH2C'2. 
The organic phase was dried with anhyd Na2SO4 and evaporated to dryness. The residue 
was submitted to coarse silica gel column chromatography (50:1 CH2Clz-MeOH) to give 
compound 84 as a white amorphous solid (1.00 g, 1.14 mmol, 93%). TLC (10:1 
CH2Clz-MeOH): Rf0.5; mp 234-236 °C; [a]o-36.7° (c 0.5, CH2Ciz); 1H NMR (600 
MHz, CDCh): 8 7.53-7.24 (m, 15 H, ArH), 7.21 (d, 2 H, ArH), 7.04 (d, 2 H, ArH), 6.82 
(dd, 4 H, ArH), 6.67 (d, 1 H, NH), 5.52 (s, 1 H, PhCH), 5.16 (d, 1 H, ArCH20), 5.11 (d, l 
H, ArCH2O), 4.90 (d, 1 H, H-1 1, JH 1, HZ= 7.8 Hz), 4.89 (d, 1 H, ArCH2O), 4.60 (d, 1 H, 
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ArCH2O), 4.48 (s, 2 H, ArCH2O), 4.29-4.24 (m, 1 H, H-6'), 4.16-4.13 (dd, 1 H, H-611), 
3.90-3.87 (m, 1 H, H-5'), 3.79 (s, 3 H, OCH3), 3.78 (s, 3 H, OCH3), 3.70-3.67 (m, 2 H, 
H-21, H-3 11), 3.64-3.60 (m, 1 H, H-61), 3.54 (dd, 1 H, H-31), 3.47-3.34 (m, 5 H, H-6 11 , H-
511, H-1 11, H-211, H-41'), 2.04-1.98 (m, 1 H, H-4'), 1.81-1.76 (m, 1 H, CH2), 1.57 (s, 3 H, 
COCH3), 1.39-1.36 (m, 1 H, CH2); 13C NMR (62.5 MHz, CDCh): 8 171.4, 159.2, 155.3, 
151.3, 137.9, 137.2, 136.8, 129.8, 129.4, 129.3, 129.1, 129.0, 128.8, 128.5, 128.3, 128.2, 
127.9, 126.3, 118.4, 114.5, 113.7, 102.9, 101.7, 83.1, 83.0, 82.7, 76.8, 74.5, 74.0, 73.2, 
70.1, 69.1, 69.0, 64.8, 55.6, 55.2, 53.5, 41.6, 28.9, 22.5; ESIMS (positive-ion mode): m/z 
876.3 [M + H]+, 893.3 [M + ~t, 898.2 [M + Na]+, 914.3 [M +Kt.Anal. Calcd for 
Cs1Hs1NO12 (876.01): C, 69.93; H, 6.56; N, 1.60. Found: C, 69.86; H, 6.66; N, 1.67. 
Allyl 2,3,4,6-tetra-0-acetyl-,B-o-galactopyranoside (98). To a solution of glycosyl 
bromide 97 (45.0 g, 109.8mmol) and ally! alcohol (13.0 mL, 0.64 mol) in dry CHCl3 (150 
mL) were added HgBr2 (4.5 g, 12.5 mmol), HgO (24.0 g, 110 mmol), and CaSO4 (46.2 g, 
340 mmol) at O °C. The reaction was allowed to stir and warm to r. t. over 10 h, after 
which time it was filted, washed with aq NaBr, and extracted with CH2Ch. The organic 
phase was dried with anhyd Na2SO4 and then evaporated to dryness. The residue was 
submitted to coarse silica gel column chromatography (3:1 hexanes-EtOAc) to give pure 
98 as a colorless syrup (41.73 g, 107.6 mmol, 98%). TLC (1:1 hexanes-EtOAc): Rr 0.78. 
The data match those reported in the literature.94 
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Allyl p'-D-galactopyranoside (99). To a solution of compound 98 (30.0 g, 66.1 mmol) in 
dry CH2Clz (50 mL) and MeOH (250 mL) was added NaOMe (25% in MeOH, 0.25 mL). 
The reaction was stirred at r. t. for 1 h, after which time Dowex 50 x 2-100 (H+ fonn) was 
added to quench the reaction. The suspension was filtered and evaporated to afford tetraol 
99 as a white amorphous solid (18.2 g, 63.6 mmol, 96%) that was used in the next step 
without characterization. TLC (5: 1 CH2Clz-MeOH): Rr 0.55. 
Allyl 4,6-O-p-methoxybenzylidene-,B-D-galactopyranoside (100). To a solution of ally! 
,8-D-galactopyranoside (99) ( 17 .0 g, 77 .3 mmol) and p-toluenesulfonic acid monohydrate 
(TsOH) (0.5 g, 2.6 mmol) in dry acetonitrile (200 mL) was added anisaldehyde dimethyl 
acetal (ADMA) (22.55 mL, 115.9 mmol, 1.5 equiv). The solution was stirred at r. t. for 3 
h, after which time triethylamine (TEA) was added to quench the reaction, and the 
suspension was filtered. The solid was washed with EtOAc and MeOH sequentially to 
afford compound 100 as a white amorphous solid (23.0 g, 68.0 mmol, 88%). TLC (5:1 
CH2Clz-acetone): Rr 0.35; mp 183-184 °C; [a]o -23.5° (c 1.0, DMSO); 1H NMR (250 
MHz, DMSO-d6): 8 7.36 (d, 2 H, ArH), 6.91 (d, 2 H, ArH), 5.89 (m, 1 H, CH=CH2), 5.36 
(s, 1 H, CH3OPhCH), 5.34 (dd, 1 H, CH=CH2), 5.14 (dd, 1 H, CH=CH2), 5.03 (d, 1 H, 
H-2), 4.89 (d, 1 H, H-3), 4.25 (m, 1 H, OCH2CH=CH2), 4.23 (d, 1 H, H-1, IHI. H2 = 7.5 
Hz), 4.06 (m, 1 H, OCH2CH=CH2), 4.03 (m, 3 H, H-5, H-6), 3.74 (s, 3 H, OCH3), 3.43 (s, 
2 H, OH), 3.39 (s, 1 H, H-4); 13C NMR (62.5 MHz, DMSO-d6): 8 159.35, 134.91, 131.05, 
127.54, 116.48, 113.16, 102.42, 99.68, 75.92, 71.91, 70.00, 68.88, 68.52, 65.90, 55.09: 
ESIMS (positive-ion mode): m/z 339.1 [M + H]+, 356.0 [M + NI-Li]\ 361.1 [M + Na]+, 
101 
377.1 [M +Kt.Anal. Calcd for C17H22O1 (338.36): C, 60.35; H, 6.55. Found: C, 60.20; 
H,6.65. 
Allyl 2,3-di-O-acetyl-4,6-0-p-methoxybenzylidene-p'-D-galactopyranoside (101). To a 
solution of allyl 4,6-O-p-methoxybenzylidene-,8-D-galactopyranoside (100) (5.0 g, 14.8 
mmol) in dry pyridine (6.0 mL, 74.2 mmol) was added Ac2O (5.0 mL, 45.3 mmol). The 
reaction was stirred at r. t. for 10 h, after which time it was quenched with water, and the 
solution was sequentially washed with aq NaHCO3 and 1 M HCI and then extracted with 
CH2Clz. The organic phase was dried with anhyd Na2SO4 and evaporated to dryness. The 
residue was crystallized from EtOAc and hexanes to give pure 101 as colorless crystals 
(5.68 g, 13.5 mmol, 91%). TLC (2:1 hexanes-EtOAc): Rf0.41; mp 156-157 °C; [a] 0 
+51.8° (c 1.0, CHC13); 1H NMR (250 MHz, CDCh): 8 7.44 (d, 2 H, ArH), 6.89 (d, 2 H, 
ArH), 5.85 (m, 1 H, CH=CH2), 5.45 (s, 1 H, CH3OPhCH), 5.38 (dd, 1 H, CH=CH2), 5.27 
(dd, 1 H, CH=CH2), 5.17 (d, 1 H, H-2), 4.96 (d, 1 H, H-3), 4.54 (d, 1 H, H-1, lH1. H2 = 7.5 
Hz), 4.39 (m, 1 H, OCH2CH=CH2), 4.34 (dd, 2 H, H-6), 4.12 (m, 1 H, OCH2CH=CH2), 
4.04 (d, 1 H, H-5), 3.80 (s, 3 H, OCH3), 3.48 (s, 1 H, H-4), 2.07 (s, 3 H, CH3CO), 2.06 (s, 
3 H, CH3CO); 13C NMR (62.5 MHz, CDCh): 8 170.46, 169.13, 159.94, 133.65, 130.01, 
127.54, 116.86, 113.31, 100.74, 99.73, 73.22, 71.80, 69.17, 68.63, 68.48, 66.13, 55.08, 
20.64; ESIMS (positive-ion mode): m/z 439.9 [M + ~t, 444.9 [M + Na]+, 460.8 [M 
+Kt.Anal. Calcd for C21H26O9 (422.43): C, 59.71; H, 6.20. Found: C, 59.68; H, 6.21. 
102 
Allyl 2,3-di-O-acetyl-6-O-p-methoxybenzyl-,6-D-galactopyranoside (102). To a 
mixture of ally! 2,3-di-O-acetyl-4,6-O-p-methoxybenzylidene-,6-D-galactopyranos1de 
(101) (4.26 g, 10.1 mmol), NaBH3CN (2.54 g, 40.4 mmol), and 4A MS (2.0 g) in dry 
DivfF (30 mL) was added trifluoroacetic acid (TFA) (5.78 mL, 80.8 mmol) dropwise at 0 
°C. The reaction was then allowed to stir and warm tor. t. over 10 h, after which time it 
was filtered through a Celite bed. The mixture was neutralized with satd NaHCO3 and 
extracted with CH2C]z. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (3: 1 hexanes-EtOAc) to give pure 102 as a colorless syrup (3.90 g, 9.2 
I mmol, 91 % ). TLC (1: 1 hexanes-EtOAc): Rr 0.32; [a] 0 -5.3° (c 1.0, CHCl3); H NMR 
(250 MHz, CDCl3): 8 7.24 (d, 2 H, ArH), 6.86 (d, 2 H, ArH), 5.85 (m, l H, CH=CH2). 
5.29 (dd, 1 H, H-2), 5.23 (dd, 1 H, CH=CH2), 5.15 (dd, 1 H, CH=CH2), 4.92 (d, l H, H-
3), 4.88 (d, 1 H, H-1, lH1. H2 = 9.4 Hz), 4.86 (s, 2 H, ArCH2O), 4.32 (dd, 1 H, 
OCH2CH=CH2), 4.07 (m, 2 H, OCH2CH=CH2,H-6), 3.77 (s, 3 H, OCH3), 3.71 (m, 3 H, 
H-6, H-5, H-4), 3.12 (s, 1 H, OH), 2.06 (s, 3 H, CH3CO), 2.03 (s, 3 H, CH3CO); 13C 
NMR (62.5 MHz, CDCh): 8 170.13, 169.36, 159.02, 133.52, 129.61, 129.16, 116.85, 
113.63, 99.90, 73.35, 73.06, 69.37, 69.20, 68.57, 67.54, 55.00, 20.57; ESIMS (positive-
ion mode): m/z 442.2 [M + ~]+, 446.9 [M + Nat, 462.9 [M +Kt.Anal. Calcd for 
C21H2sO9 (424.44): C, 59.43; H, 6.65. Found: C, 59.03; H, 6.77. 
Allyl 2,3-di-O-acetyl-6-O-p-methoxybenzyl-4-O-trifluoromethanesulfonyl-/J-D-
galactopyranoside (58). To a solution of ally! 2,3-di-O-acetyl-6-O-p-methoxybenzyl-/3-
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D-galactopyranoside (102) (4.25 g, 10.0 mmol) and dry pyridine (2.64 mL, 32.0 mmol) in 
dry CH2Cl2 was added triflic anhydride (2.73 mL, 16.0 mmol) dropwise at O °C. The 
reaction was stirred at O °C for 10 h, after which time it was concentrated to dryness. The 
residue was passed though a short plug of silica gel (2.5: 1 hexanes-EtOAc) to give pure 
58 as an unstable, pale-yellow syrup (5.28 g, 9.5 mmol, 95%) that was used in the next 
step without characterization. TLC (2: 1 hexanes-EtOAc): Rr 0.49. 
Ally I S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-( 1 ➔4 )-2,3-di-
0-acetyl-6-0-p-methoxybenzyl-4-thio-/J-D-glucopyranoside (56). To a 100-mL flask 
containing 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-l-thio-,B-D-glucopyranose (35) (705 
mg, 1.94 mmol, 1.2 equiv) and NaH (60% in mineral oil, 93 mg, 2.33 mmol, 1.2 equiv) 
under N2 was added dry DMF (20 mL) at O °C. The mixture was stirred for 10 min, and 
then a solution of triflate 58 (900 mg, 1.62 mmol) in dry DMF (10 mL) was added. The 
reaction was allowed to stir at O °C for 4 h, after which time it was quenched with water 
and extracted with CH2Cl2. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (1:2 hexanes-EtOAc) to afford compound 56 as a white amorphous 
solid (635 mg, 0.83 mmol, 51 %). TLC (1:3 hexanes-EtOAc): Rr 0.38; mp 68-69 °C; 
[a] 0 -34.2° (c 1.0, CHCh); 1H NMR (600 l\1Hz, CDC13): 8 7.26 (d, 2 H, ArH), 6.90 (d, 2 
H, ArH), 5.82 (m, 1 H, CH=CH2), 5.52 (d, 1 H, NH), 5.23 (dd, 1 H, CH=CH2), 5.16 (dd, 
1 H, CH=CH2), 5.10 (dd, 1 H, H-3\ 4.98 (t, 1 H, H-zl), 4.95 (m, 2 H, H-3 11 , H-411), 4.65 
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II (d, 1 H, H-1 , ltt 1, tt2 = 10.8 Hz), 4.56 (d, 1 H, ArCH2O), 4.43 (d, l H, ArCH2O), 4.41 (d, 
1 H, H-1 1, ltt 1, tt2 = 8.4 Hz), 4.31 (m, l H, OCH2CH=CH2), 4.06 (m, 4 H, H-i1, H-6 11 , 
OCH2CH=CH2), 3.94 (dd, 1 H, H-61), 3.81 (m, 1 H, H-61), 3.79 (s, 3 H, OCH3), 3.67 (dd, 
1 H, H-5 1), 3.55 (m, 1 H, H-5 11), 3.01 (t, 1 H, H-41), 2.04 (s, 3 H, CH3CO), 2.03 (s, 3 H, 
CH3CO), 2.01 (s, 3 H, CH3CO), 2.00 (s, 3 H, CH3CO), 1.98 (s, 3 H, CH3CO), 1.85 (s, 3 
H, CH3CO); 13C NMR (62.5 MHz, CDCh): 8 171.05, 170.50, 170.04, 169.41, 169.06, 
169.01, 159.09, 133.40, 129.94, 129.28, 116.85, 113.63, 99.41, 82.19, 75.48, 75.27, 74.03, 
73.07, 72.30, 70.54, 69.27, 68.52, 68.23, 62.38, 55.02, 52.19, 45.79, 22.71, 20.65, 20.35; 
ESIMS (positive-ion mode): m/z 770.1 [M + H]+, 787.1 [M + ~]+, 792.0 [M + Na]+, 
808.0 [M +Kt.Anal. Calcd for C3sf47NO16S (769.83): C, 54.61; H, 6.15; N, 1.82. 
Found: C, 54.33; H, 6.15; N, 1.85. 
Allyl 2,3-di-O-acetyl-4-S-acetyl-6-0-p-methoxybenzyl-4-thio-/J-D-galactopyranoside 
(104). To a solution of triflate 58 (1.27g, 2.28 mmol) in dry DMF (10 mL) was added 
potassium thioacetate (520 mg, 4.56 mmol, 2 equiv) at O °C. The reaction was stirred at 0 
°C for another 1 h, after which time it was diluted with EtOAc, washed with water, and 
extracted with EtOAc. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (3: 1 hexanes-EtOAc) to give pure 104 as a white amorphous solid 
(0.84g, 1.73 mmol, 76%). TLC (2:1 hexanes-EtOAc): Rf0.31; mp 102-103 °C; [a]o-
23.60 (c 0.5, CHCh); 1H NMR (250 MHz, CDCh): 8 7.25 (d, 2 H, ArH), 6.87 (d, 2 H, 
ArH), 5.84 (m, 1 H, CH=CH2), 5.23 (m, 3 H, H-2, CH=CH2), 4.97 (d, 1 H, H-3), 4.54 (d, 
1 H, H-1, IHI, tt2 = 8.03 Hz), 4.47 (s, 2 H, ArCH2O), 4.34 (dd, 1 H, OCH2CH=CH2), 4.10 
(dd, 2 H, OCH2CH=CH2, H-6), 3.73 (m, 1 H, H-6), 3.72 (s, 3 H, OCH3), 3.67 (m, 2 H, H-
6, H-5), 3.57 (t, 1 H, H-4), 2.28 (s, 3 H, CH3CO), 2.03 (s, 3 H, CH3CO), 2.01 (s, 3 H, 
CH3CO); 13C NMR (62.5 MHz, CDCh): 8 192.91, 169.85, 169.16, 159.00, 133.38, 
129.83, 129.10, 117.03, 113.49, 99.14, 74.12, 72.93, 72.60, 71.20, 69.45, 69.14, 54.99, 
44.52, 30.45, 20.44, 20.33; ESIMS (positive-ion mode): m/z 500.0 [M + NJLi]+, 504.9 
[M + Na]+, 520.8 [M +Kt.Anal. Calcd for C23H30O9S (482.16): C, 57.25; H, 6.27. 
Found: C, 57.51; H, 6.39. 
Allyl 2,3-di-O-acetyl-6-O-p-methoxybenzyl-4-thio-,8-D-galactopyranoside (105). To a 
solution of cysteamine (431 mg, 3.80 mmol, 4 equiv) and 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) (284 µL, 1.90 mmol, 2 equiv) in dry DMF (10 mL) was added ally! 2,3-di-
O-acetyl-4-S-acetyl-6-O-p-methoxybenzyl-4-thio-,8-D-galactopyranoside (104) (420 mg, 
0.95 mmol) at O °C. The reaction was stirred at O °C for 1 h, after which time it was 
diluted with EtOAc, washed with water, and extracted with EtOAc. The organic phase 
was dried with anhyd Na2SO4 and then evaporated to dryness. The residue was submitted 
to coarse silica gel column chromatography (3:1 to 2:1 hexanes-EtOAc) to give pure 105 
as a colorless syrup (393 mg, 0.89 mmol, 94% ). TLC (2: 1 hexanes-EtOAc ): Rr 0.30; [ a]D 
- 52.4° (c 0.5, CHCh); 1H NMR (250 MHz, CDC13): 8 7.28 (d, 2 H, ArH), 6.89 (d, 2 H, 
ArH), 5.85 (m, 1 H, CH=CH2), 5.21 (m, 2 H, CH=CH2), 4.94 (m, 2 H, H-2, H-3), 4.60 (d, 
1 H, ArCH2O), 4.51 (d, 1 H, H-1, Itt1, tt2 = 6.55 Hz), 4.47 (d, 1 H, ArCH2O), 4.31 (dd, 1 
H, OCH2CH=CH2), 4.09 (dd, 1 H, OCH2CH=CH2), 3.84 (m, 2 H, H-6), 3.80 (s, 3 H, 
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OCH3), 3.45 (m, 1 H, H-5), 3.06 (dd, 1 H, H-4), 2.09 (s, 3 H, CH3CO), 2.04 (s, 3 H, 
CH3CO), 1.40 (d, 1 H, SH); 13C NMR (62.5 MHz, CDCIJ): 8 170.28, 169.37, 159.18, 
133.50, 129.92, 129.28, 117.14, 113.69, 99.47, 77.57, 75.27, 73.10, 72.48, 69.56, 68.87. 
55.13, 40.30, 20.58; ESIMS (positive-ion mode): m/z 458.2 [M + NHi]\ 463.2 [M + 
Na]+, 479.2 [M +Kt.Anal. Calcd for C23H30O9S (440.15): C, 57.26; H, 6.41. Found: C, 
57 .50; H, 6.54. 
Ally I S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/3-D-glucopyranosyl)-(l ➔4 )-2,3-di-
O-acetyl-6-O-p-methoxybenzyl-4-thio-/3-D-glucopyranoside (56) (Route 2). To a 
solution of ally! 2,3-di-O-acetyl-6-O-p-methoxybenzyl-4-thio-/3-D-galactopyranoside 
(105) (393 mg, 0.89 mmol) in dry DMF (10 rnL) was added K2CO3 (185 mg, 1.31 mmol) 
at O °C. The mixture was stirred for 10 min, and then a solution of 2-acetamido-3,4,6-tri-
O-acetyl-2-deoxy-a-D-glucopyranosyl chloride (75) (975 mg, 2.67 mmol, 3 equiv) in dry 
Dl\1F (10 rnL) was added. The reaction was stirred for 2 hat O °C, after which time it was 
quenched with water and extracted with EtOAc. The organic phase was dried with anhyd 
Na2SO4 and then evaporated to dryness. The residue was submitted to coarse silica gel 
column chromatography (1:2 hexanes-EtOAc) to afford compound 56 as white 
amorphous solid (593 mg, 0.77 mmol, 86%). The data of this compound match those of 
the compound synthesized using NaH as the promoter. 
S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/J-D-gluco pyranosy 1)-( 1 ➔4 )-2,3-di-O-
acetyl-6-O-p-methoxybenzyl-4-thio- a, ,8-D-glucopyranose (106). ( 1,5-
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cyclooctadiene )bis(methyldiphenylphosphine )iridium(!) hexafluorophosphate ( 100 mg) 
was suspended in dry tetrahydrofuran (THF) (5 mL) at r. t. and treated with H2 for 15 min 
until the solids had completely dissolved and the red color had completely changed to a 
pale tan color. Then the solution was evacuated, purged with N2 and added to a 50-mL 
flask containing compound 56 (1.5 g, 1.95 mmol) under N2. The reaction was stirred at r. 
t. for 3 days, after which time it was cooled down to O °C and a solution of NaHCO3 
(620.5 mg, 7.38 mmol) in water (15 mL) and Ii (1.48 g, 5.85 mmol) were added. The 
reaction was stirred at O °C for another 20 min, then it was diluted with water and CH2Cl 2. 
Solid sodium thiosulfate was added until the iodine color completely disappeared. The 
mixture was extracted with CH2Ch, and the organic phase was dried with anhyd Na2SO4 
and then evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (60: 1 CH2Ch-MeOH) to afford compound 106, with an a, /3 anomeric 
ratio of 1:2, as a white amorphous solid (1.351 g, 1.85 mmol, 95%). TLC (10:1 
CHCb-MeOH): Rr 0.53; [a]0 -5.2° (c 1.0, CHCb); 1H NMR (600 MHz, CDCl3): 8 7.27 
(d, 2 H, /3-ArH), 7.25 (d, 1 H, a-ArH), 6.91 (d, 2 H, /3-ArH), 6.89 (d, 1 H, a-ArH), 5.72 
(d, 0.5 H, a-NH), 5.53 (m, 1.5 H, /3-NH, a-H-3\ 5.49 (t, 0.5 H, a-H-1 1, JH1, H2 = 3.0 Hz, 
lH1. oH = 3.6 Hz), 5.16 (dd, 1 H, /J-H-31), 5.02 (dd, 1.5 H, ,8-H-411 , a-H-4 11 ), 4.99 (m, 0.5 H, 
a-H-2\ 4.85 (t, 1 H, /3-H-zi), 4.78 (d, 0.5 H, a-H-1 11 , lHi, H2 = 10.8 Hz), 4.69 (d, 1 H, /3-
H-l 11, IHI, H2 =10.2 Hz), 4.58 (dd, 1 H, /3-H-l 1, lH1, H2 = 9 Hz, JH1, oH = 8.4 Hz,), 4.57 (d, 1 
H, /3- ArCH2O), 4.54 (d, 0.5 H, a-ArCH2O), 4.45 (d, 1.5 H, a-ArCH2O, /3-ArCH2O), 
4.16-4.05 (m, 4.5 H, /J-H-211, a-H-zi1, /J-H-3 11 , a-H-3 11 , /J-H-6 11 , a-H-6 11), 3.98 (m, 1.5 H, 
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/J-H-61, a-H-61), 3.82 (s, 4.5 H, a-CH3O, /J-CH3O), 3.81-3.73 (m, 3 H, ,B-H-61, a-H-61, /J-
H-51, a-H-51), 3.63 (m, 0.5 H, a-H-511), 3.60 (m, 1 H, /J-H-5 11), 3.11 (t, 1 H, /J-H-41), 3.09 
(t, 0.5 H, a-H-41), 2.10 (s, 3 H, /J-CH3CO), 2.09 (s, 1.5 H, a-CH3CO), 2.08 (s, 3 H, /J-
CH3CO), 2.04 (s, 3 H, /J-CH3CO), 2.03 (s, 3 H, a-CH3CO), 2.02 (s, 1.5 H, a-CH1CO). 
2.01 (s, 3 H, /J-CH3CO), 1.91 (s, 1.5 H, a-CH3CO), 1.88 (s, 3 H, ,B-CH3CO), l.6 I (s, l.5 
H, a-CH3CO), 1.60 (s, 3 H, /J-CH3CO); 13C NMR (62.5 MHz, CDCh): 8 171.34, 171.22, 
170.76, 170.68, 170.58, 170.40, 169.98, 169.83, 169.76, 169.26, 159.27, 159.15, 129.83, 
129.73, 129.49, 113.82, 113.70, 95.10, 89.95, 82.02, 81.89, 76.99, 76.48, 75.32, 74.38, 
74.12, 73.31, 72.45, 70.01, 69.66, 68.64, 68.14, 67.40, 62.42, 62.26, 60.32, 55.19, 52.10, 
45.75, 22.81, 20.67, 20.51; ESIMS (positive-ion mode): m/z 730.1 [M + H]+, 752.0 [M + 
Na]+, 768.1 [M +Kt.Anal. Calcd for C32HnNO 16S (729.76): C, 52.67; H, 5.94; N, 1.92. 
Found: C, 52.43; H, 6.01; N, 1.93. 
S-(2-Acetamido-3,4,6-tri-0-acetyl-2-deoxy-,B-D-glucop yranosy I)-( 1 ➔4 )-2,3-d i-O-
acetyl-6-0-p-methoxybenzyl-4-thio-a, ,8-D-glucopyranosyl trichloroacetimidate (54). 
To a mixture of compound 106 (103 mg, 0.14 mmol) and trichloroacetonitrile (0.14 rnL, 
14 mmol, 10 equiv) in dry CH2Cl2 (2 rnL) was added 1,5-diazabicyclo[5.4.0]undec-5-ene 
(DBU) (1 drop). The reaction was stirred at r. t. for 40 min, after which time it was 
concentrated to dryness and submitted to coarse silica gel column chromatography (1:2.5 
hexanes-EtOAc) to afford compound 54, with an a, ,B anomeric ratio of 6: 1, as an 
unstable colorless foam (104 mg, 0.12 mmol, 86%). TLC (1:3 hexanes-EtOAc): Rf0.43 
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(a anomer); [a]o +19.0° (c 1.0, CHCh, a anomer); 1H NMR (600 MHz, CDC13, a 
anomer): 8 8.63 (s, 1 H, C=NH), 7.26 (d, 2 H, ArH), 6.90 (d, 2 H, ArH), 6.61 (d, l H, H-
11, ltt1, H2 = 3.6 Hz), 5.70 (d, 1 H, NH), 5.55 (dd, 1 H, H-31), 5.11 (dd, 1 H, H-2'), 5.00 (m, 
2 H, H-3 11, H-41'), 4.70 (d, 1 H, H-1 11, ltt1.H2 = 10.8 Hz), 4.54 (d, 1 H, ArCH2O), 4.46 (d, 
1 H, ArCH2O), 4.31 (d, 1 H, H-51), 4.18 (m, 1 H, H-i11), 4.11 (d, 1 H, H-61), 4.05 (m, 2 H, 
H-611), 3.82 (s, 3 H, OCH3), 3.67 (dd, 1 H, H-6'), 3.53 (m, 1 H, H-5 11), 3.25 (t, 1 H, H-41), 
2.09 (s, 3 H, CH3CO), 2.05 (s, 3 H, CH3CO), 2.02 (s, 3 H, CH3CO), 2.01 (s, 3 H, 
CH3CO), 1.98 (s, 3 H, CH3CO), 1.91 (s, 3 H, CH3CO); 13C NMR (62.5 :MHz, CDCI3, a 
anomer): 8 171.28, 170.80, 170.22, 169.68, 169.53, 169.17, 160.73, 159.30, 129.86, 
129.52, 113.80, 94.12, 82.02, 75.51, 74.40, 73.45, 71.09, 68.16, 66.03, 67.00, 62.32, 
55.22, 51.93, 45.07, 22.92, 20.96, 20.55; ESil\1S (positive-ion mode): m/z 890.l [M + 
~t. 895.0 [M + Na]+, 911.0 [M +Kt.Anal. Calcd for C34HnChN2O16S (874.14): C, 
46.72; H, 4.96; N, 3.20. Found: C, 46.86; H, 5.02; N, 3.07. 
Allyl 2,3-di-O-benzyl-4,6-O-p-methoxybenzylidene-/J-D-galactopyranoside (107). To 
a solution of allyl 4,6-O-p-methoxybenzylidene-,B-D-galactopyranoside (100) (6.50 g, 
19.20 mmol) in dry DMF was added NaH (60% in mineral oil, 2.3 g, 57.5 mmol) at O °C. 
After stirring for 10 min, BnBr (5.5 mL, 46.3 mmol) was added dropwise. The reaction 
was allowed to stir and warm tor. t. over 10 h, after which time it was quenched with 
water and extracted with CH2Ch. The organic phase was dried with anhyd Na2SO4 and 
then concentrated to dryness. The residue was submitted to coarse silica gel column 
chromatography (2:1 hexanes-EtOAc) to give pure 107 as a white amorphous solid (9.2 
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g, 17.76 mmol, 93%). TLC (2:1 hexanes-EtOAc): Rr0.71; mp 125-126 °C; [a] 0 +29.3° 
(c 1.0, CHCh); 1H NMR (250 MHz, CDCh): 8 7.49-7.24 (m, 12 H, ArH), 6.87 (d, 2 H, 
ArH), 5.91 (m, 1 H, CH=CH2), 5.44 (s, 1 H, CH3OPhCH), 5.33 (dd, 1 H, CH=CH2), 5.18 
(dd, 1 H, CH=CH2), 4.94 (d, 1 H, ArCH2O), 4.77 (d, 1 H, ArCH2O), 4.75 (m, 2 H, H-2, 
H-3), 4.46 (m, 1 H, OCH2CH=CH2), 4.43 (d, 1 H, H-1, ltt1, ttz = 7.5 Hz), 4.28 (d, 1 H, 
ArCH2O), 4.13 (m, 1 H, OCH2CH=CH2), 4.09 (m, 1 H, H-6), 3.98 (d, 1 H, ArCH2O), 
3.87 (t, 1 H, H-5), 3.79 (s, 3 H, OCH3), 3.54 (dd, 1 H, H-6), 3.28 (s, 1 H, H-4); 13C NMR 
(62.5 MHz, CDCh): 8 160.00, 138.84, 138.45, 134.22, 130.49, 128.43, 128.25, 128.19, 
128.04, 127.89, 127.76, 127.66, 127.55, 127.44, 117.05, 113.42, 102.63, 101.17, 79.21, 
78.43, 75.24, 73.90, 71.92, 70.10, 69.12, 66.35, 55.23; ESIMS (positive-ion mode): m/z 
519.1 [M + H]+, 541.1 [M + Nat, 557.0 [M +Kt.Anal. Calcd for C3 1H34O7 (518.61): 
C, 71.80; H, 6.61. Found: C, 71.65; H, 6.62. 
Allyl 2,3-di-O-benzyl-6-O-p-methoxybenzyl-jJ-D-galactopyranoside (108). To a 
mixture of allyl 2,3-di-O-benzyl-4,6-O-p-methoxybenzylidene-jJ-D-galactopyranoside 
(107) (6.07 g, 11.73 mmol), NaBH3CN (2.95 g, 46.92 mmol), and 4A MS (2.0 g) in dry 
DMF (30 mL) was added trifluoroacetic acid (TFA) (6.71 mL, 94.64 mmol) dropwise at 
0 °C. The reaction was allowed to stir and warm to r. t. over 10 h, after which time it was 
filtered through a Celite bed. The mixture was neutralized with satd NaHCO3 and 
extracted with CH2Clz. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (3: 1 hexanes-EtOAc) to give pure 108 as a colorless syrup (3.89 g, 7.66 
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mmol, 65%). TLC (2:1 hexanes-EtOAc): Rr0.70; [a]o +7.6° (c 0.5, CHCIJ); 1H NMR 
(250 MHz, CDCh): 8 7.35-7.24 (m, 12 H, ArH), 6.87 (d, 2 H, ArH), 5.94 (m, 1 H, 
CH=CH2), 5.33 (dd, 1 H, CH=CH2), 5.18 (dd, 1 H, CH=CH2), 4.92 (d, 1 H, ArCH2O), 
4.72 (d, 1 H, ArCH2O), 4.71 (s, 2 H, ArCH20), 4.50 (s, 2 H, ArCH2O), 4.43 (m, 1 H, 
OCH2CH=CH2), 4.40 (d, 1 H, H-1, JH1,H2 = 7.5 Hz), 4.12 (m, 1 H, OCH2CH=CH2), 4.00 
(d, 1 H, H-4), 3.79 (s, 3 H, OCH3), 3.76-3.64 (m, 3 H, H-2, H-3, H-6), 3.55-3.45 (m, 2 H, 
H-5, H-6), 2.40 (s, 1 H, OH); 13C NMR (62.5 MHz, CDCh): 8 159.21, 138.50, 137.83, 
134.01, 129.99, 129.31, 128.33, 128.17, 128.04, 127.71, 127.49, 116.99, 113.73, 102.63, 
80.51, 78.88, 75.11, 73.24, 73.09, 72.29, 70.00, 68.76, 66.78, 55.15; ESIMS (positive-ion 
mode): m/z 521.1 [M + H]+, 538.1 [M + N~]+, 543.1 [M + Na]+, 559.1 [M + K]+, 1063.l 
[2M + Nat. Anal. Calcd for C31H36O1 (520.62): C, 71.52; H, 6.97. Found: C, 71.46; H, 
6.99. 
Allyl 2,3-di-O-benzyl-6-O-p-methoxybenzyl-4-O-trifluoromethanesulfonyl-/3-D-
galactopyranoside (59). To a solution of allyl 2,3-di-O-benzyl-6-O-p-methoxybenzyl-/3-
D-galactopyranoside (108) (3.89 g, 7.66 mmol) and dry pyridine (1.45 mL, 17.58 mmol) 
in dry CH2Cl2 (20 mL) was added triflic anhydride (1.50 mL, 8.79 mmol) dropwise at 0 
°C. The reaction was stirred at O °C for 10 h, after which time it was concentrated to 
dryness and passed though a short plug of coarse silica gel (2.5: 1 hexanes-EtOAc) to 
give pure 59 as an unstable, pale-yellow syrup (4.69 g, 92%) that was used in the next 
step without characterization. TLC (2: 1 hexanes-EtOAc): Rr 0.75. 
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Allyl S-(2-acetamido-3,4,6-tri-0-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-2,3-di-
0-benzyl-6-0-p-methoxybenzyl-4-thio-p'-D-glucopyranoside (57). To a 100-rnL flask 
containing 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-,8-D-glucopyranose (35) (3 .33 
g, 9.17 mmol, 1.2 equiv) and NaH (60% in mineral oil, 0.44 g, 11.0 mmol, 1.2 equiv) was 
added dry DMF (20 rnL) at O °C under N2. The mixture was stirred for 10 min, and then a 
solution of triflate 59 (4.99 g, 7.66 mmol) in dry DMF (10 mL) was added. The reaction 
was stirred at O °C for 4 h, after which time it was quenched with water and extracted 
with CH2Ch. The organic phase was dried with anhyd Na2SO4 and then evaporated to 
dryness. The residue was submitted to coarse silica gel column chromatography (1 :2 
hexanes-EtOAc) to afford compound 57 as a white amorphous solid (4.95 g, 5.72 mmol, 
75%). TLC (1:2 hexanes-EtOAc): Rr0.40; mp 197-198 °C; [a]o +33.2° (c 1.0, CHCl3); 
1H NMR (600 MHz, CDCh): o 7.38 (d, 2 H, ArH), 7.33-7.25 (m, 10 H, ArH), 6.92 (d, 2 
H, ArH), 5.97 (m, 1 H, CH=CH2), 5.35 (dd, 1 H, CH=CH2), 5.21 (dd, 1 H, CH=CH2), 
5.08 (m, 2 H, H-3 11 , NH), 4.94 (m, 3 H, H-411 , ArCH2O), 4.83 (d, I H, ArCH~O). 4.76 (u. 
1 H, H-1 11 , ltt 1. tt2 = 10.2 Hz), 4.71 (d, 1 H, ArCH2O), 4.63 (d, 1 H, ArCH2O), 4.47 (d, l 
H, ArCH2O), 4.43 (m, 1 H, OCH2CH=CH2), 4.40 (d, 1 H, H-1 1, ltt 1. tt2 = 7.8 Hz), 4.15 (m, 
1 H, OCH2CH=CH2), 4.10 (dd, 1 H, H-61), 3.92 (m, 1 H, H-61), 3.89 (m, 1 H, H-611), 3.84 
(d, 1 H, H-611), 3.81 (s, 3 H, OCH3), 3.76 (dd, 1 H, H-i\ 3.49 (m, 2 H, H-i, H-3\ 3.40 
(m, 2 H, H-51, H-5 11), 2.97 (t, 1 H, H-41), 2.01 (s, 3 H, CH3CO), 2.00 (s, 3 H, CH3CO), 
1.99 (s, 3 H, CH3CO), 1.65 (s, 3 H, CH3CO); 13C NMR (62.5 MHz, CDCh): o 170.43, 
169.89, 169.28, 159.27, 138.65, 138.14, 133.95, 130.19, 129.49, 128.24, 128.13, 127.61, 
127.56, 127.31, 117.15, 113.85, 102.47, 82.92, 82.77, 80.69, 77.00, 76.49, 76.24, 75.31, 
113 
74.85, 74.76, 73.20, 73.09, 70.03, 69.48, 68.33, 62.12, 55.15, 54.14, 46.46, 22.89, 20.55; 
ESIMS (positive-ion mode): m/z 866.1 [M + H]+, 883.1 [M + N~]+, 888.0 [M + Na]+, 
904.0 [M +Kt.Anal. Calcd for C4sHssNO14S (865.99): C, 62.41; H, 6.40; N, 1.62. 
Found: C, 62.25; H, 6.41; N, 1.59. 
Allyl S-(2-acetamido-4,6-0-benzylidene-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-2,3-di-
0-benzyl-6-0-p-methoxybenzyl-4-thio-,B-D-glucopyranoside (55). To a solution of 
compound 57 (6.0 g, 6.94 mmol) in dry CH2Clz (10 mL) and MeOH (50 mL) was added 
NaOMe (25% in MeOH, 0.2 mL). The reaction was allowed to stir at r. t. for 2 h, after 
which time it was neutralized with Dowex 50 x 2-100 (Ir form), filtered, and 
concentrated to dryness to afford the triol as a w_hite amorphous solid. To a suspension of 
the triol thus obtained in dry acetonitrile (100 mL) was added p-toluenesulfonic acid 
monohydrate (0.1 g) and benzaldehyde dimethyl acetal (1.56 mL, 10.4 mmol, 1.5 equiv). 
The solution was stirred at r. t. for 3 h, after which time it was quenched with 
triethylamine (TEA). The suspension was filtered, and the solid was washed with EtOAc 
and MeOH sequentially to afford acceptor 55 as a white amorphous solid (5.33 g, 6.45 
mmol, 93%). TLC (10:1 CHCh-MeOH): Rt0.51; mp 213-214 °C; [a]o-25.1° (c 1.0, 
DMSO); 1H NMR (600 MHz, CDCh): 8 7.47-7.25 (m, 17 H, ArH), 6.92 (d, 2 H, ArH), 
5.95 (m, 2 H, NH, CH=CH2), 5.47 (s, 1 H, PhCH), 5.35 (dd, 1 H, CH=CH2), 5.22 (dd, 1 
H, CH=CH2), 4.94 (d, 1 H, ArCH2O), 4.89 (s, 2 H, ArCH2O), 4.72 (d, 1 H, ArCH2O), 
4.59 (d, 1 H, H-1 n, JH1. H2 = 10.2 Hz), 4.51 (d, 1 H, ArCH2O), 4.42 (dd, 1 H, 
OCH2CH=CH2), 4.39 (d, 1 H, H-1 1, IHI, HZ= 7.8 Hz), 4.16 (dd, 1 H, OCH2CH=CH2), 
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4.06 (dd, 1 H, H-61), 4.03 (dd, 1 H, H-6 11), 3.84 (d, 1 H, H-61), 3.77 (s, 3 H, OCH3), 3.63 
(m, 2 H, H-211 , H-3 11), 3.54 (t, 1 H, H-611), 3.49 (t, 1 H, H-i), 3.45 (m, 2 H, H-411, H-5 1), 
3.40 (t, 1 H, H-31), 3.17 (m, 1 H, H-5 11), 3.00 (t, 1 H, H-41), 1.81 (s, 3 H, CH3CO); 13C 
NMR (62.5 MHz, DMSO-d6): 8 169.01, 158.63, 139.00, 138.64, 137.76, 134.70, 130.60. 
128.79, 128.14, 128.02, 127.96, 127.66, 127.39, 126.40, 116.31, 113.59, 101.57, 100.72, 
83.32, 82.89, 81.04, 80.07, 75.04, 74.55, 73.87, 71.83, 71.49, 69.48, 69.09, 55.33, 54.99, 
46.76, 22.98; ESIMS (positive-ion mode): m/z 828.2 [M + H]+, 850.2 [M + Na]+, 866.1 
[M +Kt.Anal. Calcd for C46Hs3NO 11 S (828.00): C, 66.73; H, 6.45; N, 1.69. Found: C, 
66.48; H, 6.47; N, 1.68. 
Ally I S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/3-D-glucopyranosyl)-(l ➔4 )-(2,3-di-
0-acetyl-6-0-p-methoxybenzyl-4-thio-/3-D-glucopyranosyl)-(l ➔3)-S-(2-acetamido-
4,6-0-benzy lidene-2-deoxy-/J-D-glucopyranosyl)-( 1 ➔4 )-2,3-di-O-benzy 1-6-0-p-
methoxybenzyl-4-thio-/3-D-glucopyranoside (53). To a suspension of acceptor 55 
(708.7 mg, 0.86 mmol, 1. 1 equiv) and 4A MS (0.5 g) in dry CH2Clz was added TMSOTf 
(0.01 Min CH2Clz, 1.55 mL) at -15 °C under N2. The mixture was stirred for IO min, 
and then a solution of trichloroacetimidate 54 (670 mg, 0.78 mmol) in dry CH2Cl2 was 
added. The reaction was allowed to stir at -15 °C under N2 for another 2 h, after which 
time it was quenched with triethylamine (TEA), filtered, and then evaporated to dryness. 
The residue was submitted to coarse silica gel column chromatography (2: 1 
CH2Clz-EtOAc) to afford tetrasacchride 53 as a white amorphous solid (690 mg, 0.45 
mmol, 58%). TLC (10:1 CHClrMeOH): Rr0.55; mp 206-207 °C; [a]o-18° (c 0.1, 
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CHCh); 1H NMR (600 MHz, CDCl3): o 7.43-7.26 (m, 17 H, ArH), 7.22 (d, 2H, ArH), 
6.9l(dd, 4 H, ArH), 5.97 (m, 1 H, CH=CH2), 5.44 (d, 1 H, NH1v), 5.41 (s, 1 H, PhCH), 
5.35 (m, 2 H, CH=CH2, NH11), 5.21 (dd, 1 H, CH=CH2), 4.97 (m, 3 H, H-1 11, H-3 11 , H-
4IY), 4.93 (d, 1 H, ArCH2O), 4.87 (m, 4 H, H-2m, H-3IY, ArCH2O), 4.69 (d, 1 H, 
ArCH2O), 4.66 (d, 1 H, ArCH2O), 4.58 (d, 1 H, H-1 111, lH1. H2 = 6.6 Hz), 4.52 (d, 1 H, H-
1 IY, JHI, HZ= 10.8 Hz), 4.47 (d, 1 H, ArCH2O), 4.40 (m, 3 H, ArCH2O, H-11, JHI, HZ= 7.8 
Hz), 4.15 (m, 4 H, OCH2CH=CH2, H-611, H-211, H-311), 4.02 (m, 2 H, H-21v, H-61v), 3.84 
(m, 2 H, H-61, H-61v), 3.80 (s, 3 H, OCH3), 3.78 (s, 3 H, OCH3), 3.73 (m, 2 H, H-6 11 \ 
3.59 (t, 1 H, H-411), 3.48 (m, 5 H, H-611, H-zl, H-61, H-5m, H-5 1), 3.34 (t, 1 H, H-3 1), 3.28 
(m, 2 H, H-51v, H-5 11), 3.04 (t, 1 H, H-41), 2.89 (t, 1 H, H-4 111), 2.04 (s, 3 H, CH3CO), 2.02 
(s, 3 H, CH3CO), 2.01 (s, 3 H, CH3CO), 2.00 (s, 3 H, CH3CO), 1.89 (s, 3 H, CH3CO), 
1.84 (s, 3 H, CH3CO), 1.70 (s, 3 H, CH3CO); 13C NMR (62.5 MHz, CDCh): o 170.92, 
170.71, 170.49, 169.85, 169.49, 169.37, 169.07, 159.31, 159.03, 138.65, 138.20, 137.27, 
133.91, 130.28, 129.91, 129.82, 128.98, 128.18, 128.06, 127.56, 127.42, 127.16, 126.21, 
117.18, 113.80, 102.39, 101.30, 99.11, 83.47, 83.27, 82.88, 81.40, 79.33, 77.51, 76.49, 
75.49, 75.48, 75.18, 74.83, 74.03, 73.18, 73.09, 72.65, 71.19, 70.05, 69.97, 69.07, 68.44, 
67.85, 61.81, 55.80, 55.15, 52.37, 46.43, 46.10, 23.15, 22.81, 20.62, 20.45; ESIMS 
(positive-ion mode): m/z 1539.2 [M + Ht, 1556.3 [M + NH.it, 1561.2 [M + Na]+, 1577. l 
[M +Kt.Anal. Calcd for C78H94N2O26S2 (1539.72): C, 60.85; H, 6.15; N, 1.56. Found: C, 
60.63; H, 6.10; N, 1.76. 
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Ally I S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4 )-(2,3-di-
O-acetyl-4-thio-/J-D-glucopyranosyl)-(1 ➔3)-S-(2-acetamido-4,6-O-benzy lidene-2-
deoxy-/J-D-glucopyranosyl)-(1 ➔4 )-2,3-di-O-benzyl-4-thio-/J-D-glucopyranoside ( 109). 
To a solution of tetrasaccharide 53 (170 mg, 0.11 mmol) in CH2Clz (15 rnL) and H2O (1 
rnL) was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (74.9 mg, 0.33 mmol, 
3 equiv). The reaction was stirred at r. t. for 1 h, after which time the mixture was poured 
into a satd NaHCO3 solution and extracted with CH2Clz. The organic phase was dried 
with anhyd Na2SO4 and then evaporated to dryness. The residue was submitted to coarse 
silica gel column chromatography ( 40: 1 CH2Clz-MeOH) to afford compound 109 as a 
white amorphous solid (85 mg, 0.065 mmol, 60%). TLC (10:1 CHCh-MeOH): Rf0.48; 
mp 245-246 °C; [a]0 +5.4° (c 0.5, CHCI3); 1H NMR (600 MHz, DMSO-d6): 8 7.35-7.24 
(m, 15H, ArH), 5.92 (m, 1 H, CH=CH2), 5.63 (s, 1 H, PhCH), 5.31 (dd, 1 H, CH=CH2), 
5.15 (dd, 1 H, CH=CH2), 5.04 (m, 2 H, H-3m, H-4IY), 4.84 (d, 1 H, ArCH2O), 4.79 (m, 6 
H, H-1 11, H-i11, H-1 iv, ArCH2O, NH1v), 4.72 (d, 1 H, ArCH2O), 4.63 (m, 3 H, H-1 m, JH1. 
HZ= 9.6 Hz, H-3 1v, ArCH2O), 4.45 (d, 1 H, H-1 1, JH1. HZ= 7.8 Hz), 4.42 (br-s, l H, NH 11 ). 
4.34 (dd, 1 H, OCH2CH=CH2), 4.15 (dd, 1 H, H-6 11), 4.09 (dd, 1 H, OCH2CH=CH2), 
3.97 (m, 2 H, H-611 , H-61v), 3.80 (m, 2 H, H-6m, H-iv), 3.69 (m, 4 H, H-6 111 , H-61, H-3 11 , 
H-i1), 3.60 (m, 3 H, H-31, H-61v, H-5 111), 3.55 (m, 1 H, H-51), 3.38 (dd, 1 H, H-61), 3.25 
(m, 3 H, H-i, H-51v. H-5 11), 3.14 (t, 1 H, H-411), 2.95 (t, 1 H, H-411\ 2.69 (t, 1 H, H-41), 
2.00 (s, 3 H, CH3CO), 1.95 (s, 3 H, CH3CO), 1.92 (s, 3 H, CH3CO), 1.91 (s, 3 H, 
CH3CO), 1.89 (s, 3 H, CH3CO), 1.73 (s, 3 H, CH3CO), 1.57 (s, 3 H, CH3CO); 13C Niv1R 
(62.5 MHz, DMSO-d6): 8 170.76, 170.48, 170.40, 169.99, 169.89, 169.76, 169.43, 
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139.58, 139.32, 135.30, 130.18, 129.85, 128.84, 128.71, 128.34, 128.16, 128.02, 117.06, 
102.21, 100.81, 99.88, 84.79, 83.77, 83.59, 81.05, 80.67, 80.10, 79.66, 79.21, 77.14, 
76.88, 75.16, 74.96, 74.52, 74.08, 72.90, 72.35, 69.58, 69.19, 62.76, 62.25, 62.02, 61.19, 
53.05, 47.34, 45.85, 23.56, 23.26, 21.17, 21.12, 21.02; ESIMS (positive-ion mode): m/z 
1299.1 [M + H]+, 1316.0 [M + Nlii]\ 1321.0 [M + Na]+, 1337.0 [M +Kt.Anal. Calcd 
for C62H1sN2O24S2 (1299.43): C, 57.31; H, 6.05; N, 2.16. Found: C, 57.23; H, 6.02; N, 
2.25. 
Ally I S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/3-D-glucopyranosyl)-(l ➔4 )-(2,3-di-
O-acetyl-4-thio-/J-D-glucopyranosyluronic acid)-(1 ➔3)-S-(2-acetamido-4,6-O­
benzylidene-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4 )-2,3-di-O-benzy 1-4-thio-/J-D-
glucopyranosiduronic acid (110). To a solution of tetrasacchride 109 (200 mg, 0.154 
mmol) in dry DMF (2.0 mL) was added pyridinium dichromate (PDC) (1.16 g, 3.08 
mmol, 20 equiv). The reaction was allowed to stir at r. t. for 2 days, after which time it 
was concentrated to dryness. The residue was submitted to coarse silica gel column 
chromatography (20: 1: 1 CH2Cl2-MeOH-AcOH) to afford compound 110 as a white 
amorphous solid (162 mg, 0.122 mmol, 79%). TLC (12:1:1 CHCh-MeOH-AcOH): Rr 
0.39; mp 214-216 °C; [a] 0 -50.8° (c 0.25, DMSO); 1H NMR (600 MHz, 5:1 
CDCh-CD3OD): 8 7.48 (d, 2 H, ArH), 7.39-7.28 (m, 13 H, ArH), 5.93 (m, 1 H, 
CH=CH2), 5.50 (s, 1 H, PhCH), 5.34 (d, 1 H, CH=CH2), 5.22 (d, 1 H, CH=CH2), 5.15 (t, 
1 H, H-31v), 4.99 (t, I H, H-41v), 4.96 (dd, I H, H-3m), 4.93 (d, 2 H, ArCH2O), 4.90 (d, 2 
111 6 Ill H, ArCH2O), 4.89 (t, 1 H, H-2 ), 4.81 (d, 2 H, ArCH2O), 4.7 (d, 1 H, H-1 , lHI, Hz= 
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7.8 Hz), 4.71 (d, 1 H, H-1 11, lH1. H2 = 7.2 Hz), 4.69 (d, 2 H, ArCH2O, H-l 1v, JH 1, H2 = 11.4 
Hz), 4.49 (d, 1 H, H-11, lm,H2 = 7.8 Hz), 4.41 (dd, 1 H, OCH2CH=CH2), 4.23 (dd, 1 H, 
H-61v), 4.14 (dd, 1 H, OCH2CH=CH2), 4.10 (m, 2 H, H-61\ H-61v), 4.01 (m, 1 H, H-3 11), 
3.91 (d, 1 H, H-51), 3.90 (m, 2 H, H-21v, H-i'}, 3.88 (d, 1 H, H-5m), 3.70 (m, 1 H, H-51v), 
3.61 (m, 2 H, H-5 11, H-61'), 3.48 (t, 1 H, H-21), 3.40 (t, 1 H, H-31), 3.33 (m, 1 H, H-4 11 ), 
3.15 (t, 2 H, H-41, H-411'), 2.09 (s, 3 H, CH3CO), 2.03 (s, 3 H, CH3CO), 2.02 (s, 3 H, 
CH3CO), 2.01 (s, 6 H, CH3CO), 1.96 (s, 3 H, CH3CO), 1.89 (s, 3 H, CH3CO); 13C NMR 
(150 MHz, 5:1CDCh-CD30D):8173.98, 171.41, 170.95, 170.74, 170.60, 169.92, 
169.56, 169.28, 138.24, 137.90, 136.98, 133.39, 128.64, 128.14, 127.93, 127.49, 127.42, 
125.93, 117.42, 102.65, 100.63, 100.24, 86.51, 85.30, 82.40, 81.00, 78.80, 78.14, 76.40, 
75.90, 75.72, 75.19, 74.92, 73.34, 72.38, 71.14, 70.24, 70.16, 68.25, 61.96, 54.39, 52.80, 
48.10, 46.70, 22.50, 22.20, 20.26; ESIMS (negative-ion mode): m/z 662.3 [M- 2H]2-, 
1325.3 [M-Hr, 1347.3 [M-2H+ Nar, 1363.3 [M- 2H+ Kr. Anal. Calcd for 
C62H74N20 26S2 (1327.38): C, 56.10; H, 5.62; N, 2.11. Found: C, 55.87; H, 5.83; N, 2.01. 
n-Propyl S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-(1➔4)-(4-thio-/3-D­
glucopyranosyluronic acid)-(1 ➔3 )-S-(2-acetamido-2-deoxy-/J-D-glucopy ranosy I)-
0 ➔4)-4-thio-/J-D-glucopyranosiduronic acid (52). To a solution of compound 110 (40 
mg, 0.03 mmol) in AcOH (2 mL) and H20 (0.5 mL) was added Pd/C (10%, 100 mg). The 
reaction was stirred for 72 h in a H2 atmosphere (50 Psi), after which time the mixture 
was filtered though a pad of Celite, which was then washed with MeOH. [Caution. 
Extreme fire hazard.] The combined filtrates were concentrated to give a white 
119 
amorphous solid. TLC (5:1:1 CHCh-MeOH-AcOH): Rr0.12; ESIMS (negative-ion 
mode): mlz 529.2 [M- 2H]2-, 1059.1 [M- Hr, 1081.1 [M- 2H+ Nar, 1097.1 [M- 2H 
+Kr.The residue was redissolved in MeOH (2 mL) and treated with NaOMe (25% in 
MeOH, 2 drops) at r. t. for 2 h. After which time the reaction was neutralized with 
Dowex 50 x 2-100 (Ir form), filtered, and concentrated to dryness. The residue was 
purified by Diaion HP 20 column chromatography (20 cm) with water as an eluent to 
afford compound 52 as a white amorphous solid (8 mg, 0.009 mmol, 31 % ). TLC (2: 1: 1 
CHCh-MeOH-AcOH): Rr 0.25; 1H NMR (600 MHz, D2O): 8 4.58 (t, 2 H, H-1 n, H-1 rv, 
IHI, H2 = 9.6 Hz, 10.2 Hz), 4.43 (t, 2 H, H-1 1, H-1 m, IHI, H2 = 10.2 Hz, 8.4 Hz), 3.91-3.78 
II IV II 5IV 58 2 611 61V H II H IV 3 4 ( 4 2 , H-2 , H-5 , H- ), 3. (m, H, H- , H- ), 3.49 (t, 2 , H-4 , -4 ), . 1 m, 
II IV I III I III I III) 2 00 ( H, H-3 , H-3 , H-3 , H-3 ), 3.32 (m, 2 H, H-2 , H-2 ), 2.94 (t, 2 H, H-4 , H-4 , . s, 
OCH2CH2CH3); ESIMS (negative-ion mode): m/z 848.9 [M - Hr, 870.9 [M - 2H + Nar, 
886.9 [M - 2H + Kr. 
Allyl 2,3-di-0-benzoyl-4,6-0-p-methoxybenzylidene-/3-D-galactopyranoside (111). To 
a solution of allyl 4,6-O-p-methoxybenzylidene-/J-D-galactopyranoside (100) (3.70 g, 
10.9 mmol) in dry pyridine (6.0 mL, 74.2 mmol) was added benzoyl chloride (5 mL, 43.8 
mmol) at O °C. The reaction was allowed to stir and warm to r. t. over 10 h, after which 
time it was quenched with water and the solution was extracted with CH2Cl 2. The organic 
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phase was dried with anhyd Na2SO4 and then evaporated to dryness. The residue was 
submitted to coarse silica gel column chromatography (2:1 hexanes-EtOAc) to give 
compound 111 as a white amorphous solid (5.27 g, 9.65 mmol, 89%). TLC (1:1 
hexanes-EtOAc): Rr0.71; 1H NMR (250 MHz, CDCh): 8 7.98 (d, 4 H, ArH), 7.43 (m, 8 
H, ArH), 6.88 (d, 2 H, ArH), 5.85 (m, 2 H, H-2, CH=CH2), 5.50 (s, 1 H, CH3OPhCH), 
5.35 (dd, 1 H, H-3), 5.23 (dd, 1 H, CH=CH2), 5.11 (dd, 1 H, CH=CH2), 4.80 (d, 1 H, H-1, 
lH1, H2 = 8.1 Hz), 4.57 (dd, 1 H, OCH2CH=CH2), 4.39 (m, 2 H, H-6, OCH 2CH=CH 2). 
4.12 (m, 2 H, H-6, H-5), 3.80 (s, 3 H, OCH3), 3.66 (s, 1 H, H-4); 13C NMR (62.5 MHz, 
CDCh): 8 166.21, 165.21, 159.99, 133.71, 133.31, 132.99, 129.92, 129.67, 129.10, 
128.34, 128.26, 127.59, 117.40, 113.42, 100.83, 99.81, 76.49, 73.54, 72.81, 69.42, 69.04, 
66.87, 66.46, 55.24; ESIMS (positive-ion mode): m/z 564.2 [M + ~t. 569.1 [M + 
Na]+, 585.2 [M + Kt. 
Allyl 2,3-di-O-benzoyl-6-0-p-methoxybenzyl-,8-D-galactopyranoside (112). To a 
mixture of allyl 2,3-di-O-benzoyl-4,6-O-p-methoxybenzylidene-fi-D-galactopyranoside 
(111) (2.5 g, 4.58 mmol), NaBH3CN (1.42 g, 22.9 mmol), and 4A MS (2.0 g) in dry DMF 
(10 mL) was added trifluoroacetic acid (TFA) (3.28 mL, 45.8 mmol) dropwise at O 0 C. 
The reaction was allowed to stir and warm to r. t. over 10 h, after which time it was 
filtered through a Celite bed. The mixture was neutralized with a satd NaHCO3 solution 
and extracted with CH2Cl2. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (2: 1 hexanes-EtOAc) to give pure 112 as a colorless syrup (2.0 g, 3.65 
121 
mmol, 80%). TLC (1:1 hexanes-EtOAc): Rr0.68; 1H NMR (250 MHz, CDCl3): o 7.97 (d, 
4 H, ArH), 7.35 (m, 8 H, ArH), 6.88 (d, 2 H, ArH), 5.78 (m, 2 H, H-2, CH=CH2), 5.25 
(m, 2 H, CH=CH2), 5.10 (d, 1 H, H-3), 4.74 (d, 1 H, H-1, lH1. H2 = 8.0 Hz), 4.53 (s, 2 H, 
ArCH2O), 4.36 (m, 3 H, OCH2CH=CH2,H-6), 4.15 (dd, 1 H, OCH2CH=CH2), 3.79 (s, 3 
H, OCH3), 2.84 (s, 1 H, OH); 13C NMR (62.5 MHz, CDCl)): o 165.85, 165.28, 159.31, 
133.59, 133.25, 132.96, 129.79, 129.64, 129.40, 129.11, 128.34, 128.22, 117.36, 113.84, 
100.17, 76.48, 74.40, 73.36, 73.27, 69.689, 69.63, 68.87, 68.02, 55.20; ESIMS (positive-
ion mode): m/z 442.2 [M + NRd+, 446.9 [M + Na]+, 462.9 [M + K]+, 1115.2 [2M + 
Na]+, 1131.2 [2M + Kt. 
Allyl 2,3-di-O-benzoyl-4-O-trifluoromethanesulfonyl-6-O-p-methoxybenzyl-/J-D-
galactopyranoside (61). To a solution of ally! 2,3-di-O-benzoyl-6-O-p-methoxybenzyl-
/J-D-galactopyranoside (112) (2.0 g, 3.65 mmol) and dry pyridine ( 1.0 mL, 12.3 mmol) in 
dry CH2Ch was added triflic anhydride (0.75 mL, 4.4 mmol) dropwise at O 0 C. The 
reaction was stirred at O °C for 10 h, after which time it was concentrated to dryness and 
passed though a short plug of coarse silica gel (2:1 hexanes-EtOAc) to give pure 61 as an 
unstable, pale-yellow syrup (2.4 g, 3.53 mmol, 97%) that was used in the next step 
without characterization. TLC (2:1 hexanes-EtOAc): Rr0.65. 
Allyl S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-2,3-di­
O-benzoyl-6-O-p-methoxy benzyl-4-thio-/J-D-glucopyranoside (60). To a 100-mL flask 
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containing 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-1-thio-P-D-glucopyranose (35) (2.0 g, 
5.5 mmol, 1.2 equiv) and NaH (60% in mineral oil, 285 mg, 6.5 mmol, 1.2 equiv) under 
N2 was added dry DMF (20 mL) at O °C. The mixture was stirred for 10 min, and then a 
solution of triflate 61 (2.4 mg, 3.53 mmol) in dry DMF (10 mL) was added. The reaction 
was stirred at O °C for 4 h, after which time it was quenched with water and extracted 
with CH2Cb. The organic phase was dried with anhyd Na2SO4 and then evaporated to 
dryness. The residue was submitted to coarse silica gel column chromatography (1 :2 
hexanes-EtOAc) to afford compound 60 as a white amorphous solid (1.67 g, 1.87 mmol, 
53%). TLC (1:3 hexanes-EtOAc): Rr0.33; 1H NMR (600 MHz, CDCh): 8 7.94 (m, 4 H. 
ArH), 7.52 (m, 1 H, ArH), 7.38 (m, 5 H, ArH), 7.30 (d, 2 H, ArH), 6.91 (d, 2 H, ArH), 
5.76 (m, 1 H, CH=CH2), 5.59 (t, 1 H, H-3\ 5.46 (d, 1 H, NH), 5.45 (t, 1 H, H-2\ 5.20 
(dd, 1 H, CH=CH2), 5.08 (m, 2 H, H-3n, CH=CH2), 4.97 (t, 1 H, H-411), 4.91 (d, 1 H, H-
111, ltt1. H2 = 10.8 Hz), 4.64 (d, 1 H, H-1 1, lHJ, tt2 = 7.8 Hz), 4.59 (d, 1 H, ArCH2O), 4.51 (d, 
1 H, ArCH2O), 4.3 (m, 1 H, OCH2CH=CH2), 4.11 (m, 2 H, H-i1, OCH2CH=CH2), 4.04 
(ddd, 2 H, H-611, H-61), 3.90 (d, 1 H, H-6\ 3.87 (dd, 1 H, H-5\ 3.82 (s, 3 H, OCH3), 3.73 
(m, 1 H, H-51\ 3.29 (t, 1 H, H-41), 2.04 (s, 3 H, CH3CO), 2.03 (s, 3 H, CH3CO), 1.99 (s, 
3 H, CH3CO); 13C NMR (62.5 MHz, CDC13): 8 172.04, 166.08, 165.19, 137.14, 133.34, 
133.04, 129.77, 129.59, 129.28, 129.19, 128.87, 128.21, 127.97, 126.24, 117.29. 101.22. 
99.62, 85.88, 80.70, 76.48, 73.02, 72.44, 70.08, 69.84, 67.78, 61.44, 55.56, 47.43, 22.87. 
Ally I S-(2-acetamido-4,6-O-benzy lidene-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-2,3-di­
O-benzoyl-4-thio-/J-D-glucopyranoside (115). To a solution of compound 60 (500 mg, 
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0.56 mmol) in MeOH (20 mL) and CH2Ch(4 mL) was added HBF4 in Et20 (0.1 mL). 
The reaction was stirred at r. t. for 1 h. When TLC (5: 1 CHClrMeOH) showed complete 
consumption of the starting material and formation of a new spot, the reaction was 
quenched with triethylamine (TEA), and the solvents were evaporated. To a solution of 
the resulting residue in dry acetonitrile was added p-toluenesulfonic acid monohydrate 
(TsOH) (50 mg, 0.26 mmol) and benzaldehyde dimethyl acetal (0.13 mL, 0.84 mmol, 1.5 
equiv). The solution was stirred at r .t. for 3 h, after which time the reaction was 
quenched with TEA and then evaporated to dryness. The residue was submitted to coarse 
silica gel column chromatography (40:1 CH2Ch-MeOH) to afford compound 115 as 
colorless foam (296 mg, 0.40 mmol, 72%). TLC (10:1 CHCi)-MeOH): Rr0.32; 1H 
NMR (600 MHz, CDCh): 8 7.94 (m, 4 H, ArH), 7.51 (m, 2 H, ArH), 7.38 (m, 4 H, ArH), 
6.22 (d, 1 H, NH), 5.78 (m, 1 H, CH=CH2), 5.62 (dd, 1 H, H-3 1), 5.52 (s, 1 H, PhCH), 
5.44 (t, 1 H, H-i1), 5.23 (dd, 1 H, CH=CH2), 5.13 (d, 1 H, CH=CH2), 4.96 (d, 1 H, H-1 u, 
lH1, H2 = 10.2 Hz), 4.73 (d, 1 H, H-1 1, lH1, H2 = 7.8 Hz), 4.35 (m, 1 H, OCH2CH=CH2), 
4.15 (m, 1 H, OCH2CH=CH2), 4.09 (m, 2 H, H-6\ 4.02 (m, 1 H, H-61\ 3.84 (m, 2 H, H-
311, H-i11), 3.71 (m, 1 H, H-5\ 3.56 (m, 3 H, H-411, H-5 11, H-611), 3.25 (m, 1 H, H-41), 1.78 
(s, 3 H, CH3CO); 13C NMR (62.5 MHz, CDCh): 8 172.1, 166.3, 165.2, 137.1, 133.3, 
133.1, 129.8, 129.7, 129.2, 129.0, 128.3, 128.1, 126.3, 117.5, 101.4, 99.6, 85.4, 80.8, 76.3, 
73.4, 73.0, 72.3, 70.1, 69.9, 55.7, 47.3, 22.9; ESIMS (positive-ion mode): m/z 736.3 [M + 
H]+, 758.3 [M + Na]+, 774.1 [M + K]+, 1493.3 [2M + Na]+, 1509.3 [2M + Kt. 
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Ally I S-(2-acetamido-4,6-0-benzylidene-2-deoxy-/J-D-glucopyranosyl )-( 1 ➔4 )-2,3-di-
0-benzyl-6-0-tert-butyldiphenylsilyl-4-thio-/J-D-glucopyranoside (116). To a solution 
of compound 115 (180 mg, 0.25 mmol), triethylamine (0.034 mL, 1.1 equiv), and DMAP 
(1.2 mg, 0.04 equiv) in dry CH2Clz (10 mL) was added tert-butyldiphenylsilyl chloride 
(TBDPSCl) (0.14 mL, 0.52 mmol, 2.2 equiv). The reaction was stirred at r. t. for 18 h, 
and then it was quenched with water and extracted with CH2Cl2. The organic phase was 
dried with anhyd Na2SO4 and then evaporated to dryness. The residue was submitted to 
coarse silica gel column chromatography (1:2 hexanes-EtOAc) to afford compound 116 
as a colorless foam (205 mg, 0.18 mmol, 85%). 1H NMR (600 MHz, CDCl3): 8 7.99 (d, 
2 H, ArH), 7.94 (d, 2 H, ArH), 7.77 (dd, 4 H, ArH), 7.45 (m, 12 H, ArH), 6.02 (d, 1 H, 
NH), 5.82 (m, 1 H, CH=CH2), 5.63 (t, 1 H, H-31), 5.52 (s, 1 H, PhCH), 5.48 (t, 1 H, H-2\ 
5.22 (d, 1 H, CH=CH2), 5.13 (d, 1 H, CH=CH2), 5.00 (d, 1 H, H-1 11 , JH1. Hz= 10.2 Hz), 
4.70 (d, 1 H, H-1 1, JHI,Hz = 7.8 Hz), 4.36 (m, 1 H, OCH2CH=CH2), 4.21 (m, 2 H, H-61), 
4.15 (m, 1 H, OCH2CH=CH2), 3.92 (m, 1 H, H-i11), 3.82 (m, 1 H, H-3 11), 3.77 (m, 1 H, 
H-51), 3.55 (m, 3 H, H-4 11 , H-5 11, H-6 11), 3.34 (t, 1 H, H-41), 1.56 (s, 3 H, CH3CO), 1.09 (s, 
9 H, CH3CO); 13C NMR (62.5 MHz, CDCh): 8 171.57, 166.97, 165.00, 136.95, 135.65, 
135.47, 133.58, 133.45, 133.31, 132.95, 129.74, 129.61, 129.49, 129.19, 128.95, 128.55, 
128.31, 128.15, 128.04, 127.61, 127.51, 126.23, 117.10, 101.50, 99.14, 82.16, 80.82, 
76.51, 73.89, 73.00, 71.45, 69.78, 69.00, 68.10, 62.96, 55.14, 45.71, 26.66, 22.55, 19.15. 
2-Acetamido-3,4,6-tri-O-acetyl-1,2-dideoxy-1-ethyldithio-/J-D-glucopyranose ( 121 ). 
To a solution of pseudothiourea 103 (20.0 g, 45.5 mmol) in MeOH (100.0 mL) and 
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triethylamine (15.0 mL) was added ethyl disulfide (15.0 mL, 122 mmol). The reaction 
was stirred at r. t. for 3 h, after which time it was diluted CH2C}z, washed with water, and 
extracted with CH2Ch. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (70: 1 CH2Cl2-MeOH) to give compound 121 as a white amorphous 
solid (13.04 g, 30.8 mmol, 68%). TLC (10: 1 CH2C}z-MeOH): Rr 0.62; 1H NMR (300 
MHz, CDC13): 8 5.68 (d, 1 H, NH), 5.28 (t, 1 H, H-3), 5.08 (t, 1 H, H-4), 4.71 (d, 1 H, H-
1, lH1, HZ= 10.5 Hz), 4.18 (m, 3 H, H-2, H-6), 3.74 (m, 1 H, H-5), 2.80 (q, 2 H, 
SCH2CH3), 2.07 (s, 3 H, CH3CO), 2.04 (s, 3 H, CH3CO), 2.03 (s, 3 H, CH3CO), 1.94 (s, 
3 H, CH3CO), 1.30 (t, 3 H, SCH2CH3); 13C NMR (75 MHz, CDCh): 8 171.23, 170.86, 
169.62, 89.69, 76.22, 73.65, 68.52, 62.47, 52.99, 34.17, 23.54, 20.95, 20.88, 14.52. The 
data match those reported in the literature. 105 
2-Acetamido-1,2-dideoxy-1-ethyldithio-4,6-0-p-methoxybenzy lidene-/3-D-
glucopyranose (123). To a solution of 2-acetamido-3,4,6-tri-O-acetyl-1,2-dideoxy-l-
ethyldithio-/J-D-glucopyranose (121) (3.0 g, 7.1 mmol) in dry CH2Cl2 (5.0 mL) and 
MeOH (25.0 mL) was added NaOMe (25% in MeOH, 0.1 mL). The reaction was stirred 
at r. t. for 2 h, after which time it was neutralized with Dowex 50 x 2-100 (H+ form), 
filtered, and concentrated to afford trio! 122 as a white amorphous solid. To a suspension 
of trio! 122 and p-toluenesulfonic acid monohydrate (0.1 g, 0.53 mmol) in dry acetonitrile 
(100.0 mL) was added ADMA (1.70 mL, 9.86 mmol). The solution was stirred at r. t. for 
3 h, then the suspension was filtered and the solid was washed with EtOAc and MeOH 
126 
sequentially to afford compound 123 as a white amorphous solid (2.53 g, 6.45 mmol, 
86%). TLC (10:1 CHCh-MeOH): Rr0.49; mp 230-231 °C; [a] 0 -98.8° (c 1.0, DMSO); 
1H NMR (300 MHz, CDCh): 8 7.95 (d, 1 H, NH), 7.32 (d, 2 H, ArH), 6.89 (d, 2 H, ArH), 
5.53 (s, 1 H, CH3OPhCH), 5.40 (d, 1 H, H-4), 4.58 (d, 1 H, H-1, Im.Hz= 10.5 Hz), 4.16 
(dd, 1 H, H-6), 3.73 (s, 3 H, CH3O), 3.59 (m, 3 H, H-2, H-3, H-6), 3.39 (m, 1 H, H-5), 
2.73 (q, 2 H, SCH2CH3), 1.80 (s, 3 H, CH3CO), 1.20 (t, 3 H, SCH2CH3); 13C NMR (75 
MHz, CDCh): 8 169.14, 159.57, 130.04, 127.73, 113.34, 100.66, 90.92, 80.79, 71.49, 
70.32, 67.62, 55.15, 54.56, 32.82, 23.04, 14.24; ESIMS (positive-ion mode): m/z 416.1 
[M + H]+, 438.0 [M + Na]+, 454.0 [M +Kt.Anal. Calcd for C 1sH2sNO6S2 (415.11): C, 
52.03; H, 6.06; N, 3.37. Found: C, 51.80; H, 5.96; N, 3.28. 
2-Acetamido-1,2-dideoxy-1-ethyldithio-3-0-levulinoyl-4,6-0-p-methoxybenzylidene-
,B-D-glucopyranose (124). To a solution of 2-acetamido-1,2-dideoxy-l-ethyldithio-4,6-
O-p-methoxybenzylidene-JJ-D-glucopyranose (123) (5.0 g, 12.0 mmol) in dry CH2Cl2 (10 
mL) were added levulinic acid (2.08 g, 18 mmol, 1.5 equiv), EDCI (3 g), and an a 
catalytic amount of 4-dimethylaminopyridine (DMAP). The reaction was stirred at r. t. 
for 2 h, and then it was quenched with water and extracted with CH2Clz. The organic 
phase was dried with anhyd Na2SO4 and then evaporated to dryness. The residue was 
submitted to coarse silica gel column chromatography to give compound 124 as a while 
amorphous solid (4.93 g, 9.6 mmol, 80%). TLC (10:1 CHCh-MeOH): Rr0.56; mp 
222-223 °C; [a] 0 -130.4° (c 1.0, CHCh); 1H NMR (300 MHz, CDCh): 8 7.35 (d, 2 H, 
ArH), 6.86 (d, 2 H, ArH), 6.00 (d, 1 H, NH), 5.44 (s, 1 H, CH3OPhCH), 5.37 (t, 1 H, H-
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3), 4.73 (d, 1 H, H-1, JHI. Hz= 10.2 Hz), 4.26 (dd, 1 H, H-6), 4.18 (t, 1 H, H-2), 3.77 (s, 3 
H, CH3O), 3.68 (m, 2 H, H-4, H-6), 3.56 (m, 1 H, H-5), 2.74 (q, 2 H, SCH2CH3), 2.62 (m, 
2 H, COCH2), 2.52 (m, 2 H, COCH2), 2.14 (s, 3 H, CH3CO), 1.96 (s, 3 H, CH3CO), l.28 
(t, 3 H, SCH2CH3); 13C NMR (75 MHz, CDCh): 8 206.51, 172.91, 170.58, 160.02, 
140.48, 129.32, 127.47, 127.21, 113.51, 101.29, 89.65, 78.48, 72.86, 70.47, 68.39, 55.22, 
52.75, 37.89, 34.04, 29.68, 28.05, 23.20, 14.32; ESIMS (positive-ion mode): m/z 514.0 
[M + H]+, 536.0 [M + Na]+, 551.9 [M +Kt.Anal. Calcd for C23H31NOsS2 (513.15): C, 
53.78; H, 6.08; N, 2.73. Found: C, 53.83; H, 6.03; N, 2.69. 
2-Acetamido-4,6-di-0-acetyl-1,2-dideoxy-1-ethyldithio-3-0-Ievulinoyl-/3-D-
glucopyranose (126). To a solution of compound 124 (1.5 g, 2.9 mmol) in MeOH (30 
mL) and CH2Clz (6 mL) was added two drops of tetrafloroboric acid (HBF4). The 
reaction was stirred at r. t. for 2 h. When TLC showed complete consumption of the 
starting material and formation of a new spot, the reaction was quenched with 
triethylamine (TEA) and evaporated to dryness. The resulting diol was redissolved in dry 
pyridine (5.0 mL, 61.8 mmol) and treated with acetic anhydride (4.0 mL, 42.4 mmol) at r. 
t. for 10 h, after which time the reaction was quenched with water and diluted with 
CH2C}z. The solution was washed with a satd NaHCO3 solution and extracted with 
CH2C}z. The organic phase was dried with anhyd Na2SO4 and then evaporated to dryness. 
The residue was submitted to coarse silica gel column chromatography (10: 1 
CH2C}z-MeOH) to afford compound 126 as a white amorphous solid. ( 1.17 g, 2.44 mmol, 
84%). TLC (10:1 CHClrMeOH): Rr0.61; mp 155-156 °C; [a] 0 -80.6° (c 1.0, CHCl3); 
128 
1H NMR (300 MHz, CDC'3): 8 5.85 (d, 1 H, NH), 5.33 (t, 1 H, H-3), 5.06 (t, 1 H, H-4), 
4.81 (d, 1 H, H-1, ltt1. ttz = 9.9 Hz), 4.13 (m, 2 H, H-2, H-6), 3.73 (d, 1 H, H-6), 3.19 (m, 
1 H, H-5), 2.76 (m, 4 H, COCH2, SCH2CH3), 2.46 (m, 2 H, COCH2), 2.14 (s, 3 H, 
CH3CO), 2.04 (s, 6 H, CH3CO), 1.91 (s, 3 H, CH3CO), 1.28 (t, 3 H, SCH2CH3); 13C 
NMR (75 MHz, CDCh): 8 206.68, 172.47, 170.63, 170.55, 169.65, 88.75, 75.80, 73.27, 
67.94, 62.18, 52.87, 37.76, 33.85, 29.60, 28.00, 23.26, 20.71, 14.24; ESIMS (positive-ion 
mode): m/z 502.0 [M + Na]+, 517.9 [M +Kt.Anal. Calcd for C19H29NO9S2 (479.13): C, 
47.59; H, 6.10; N, 2.92. Found: C, 47.64; H, 5.99; N, 2.89. 
2-Acetamido-4,6-di-O-acetyl-2-deoxy-3-0-levulinoyl-1-thio-/J-D-glucopyranose ( 65). 
To a solution of compound 126 (200 mg, 0.42 mmol) in THF (4 mL), MeOH (0.6 mL), 
and triethylamine (TEA) (0.36 mL) was added DTT (50 mg, 0.32 mmol, 0.75 equiv). The 
reaction was stirred at r. t. for about 1 h, after which time the solvent was evaporated, and 
the residue was submitted to coarse silica gel column chromatography (65: 1 
CH2C}z-MeOH) to afford thiol 65 as a white amorphous solid. (140 mg, 0.33 mmol, 
80%). TLC (10:1 CHCb-MeOH): Rr0.48; mp 150-151 °C; [a]o-8.0° (c 0.5, CHCb); 
1H NMR (300 MHz, CDC13): 8 6.14 (d, 1 H, NH), 5.15 (t, 1 H, H-3), 5.07 (t, 1 H, H-4). 
4.67 (t, 1 H, H-1, JHI. tt2 = 9.3 Hz), 4.21 (dd, 1 H, H-6), 4.08 (dd, 1 H, H-6), 3.98 (t, 1 H, 
H-2), 3.68 (m, 1 H, H-5), 2.72 (q, 2 H, COCH2), 2.51 (d, 1 H, SH), 2.45 (m, 2 H, 
COCH2), 2.14 (s, 3 H, CH3CO), 2.07 (s, 3 H, CH3CO), 2.03 (s, 3 H, CH3CO), 1.96 (s. 3 
H, CH3CO); 13C NMR (75 MHz, CDC'3): 8 206.65, 172.71, 171.01, 170.79, 169.51. 
79.79, 75.96, 73.33, 67.80, 62.09, 56.84, 37.66, 29.56, 27.98, 23.22, 20.76, 20.62; ESIMS 
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(positive-ion mode): m/z 442.0 [M + Na]+, 458.0 [M +Kt.Anal. Calcd for C 17H25NO9S 
(419.13): C, 48.68; H, 6.01; N, 3.34. Found: C, 48.82; H, 5.93; N, 3.22. 
Allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-0-levulinoyl-/3-D-glucopyranosyl)-
(1➔4)-2,3-di-0-acetyl-6-0-p-methoxybenzyl-4-thio-/3-D-glucopyranoside (64). To a 
solution of 2-acetamido-4,6-di-O-acetyl-2-deox y-3-O-levulinoyl-1-thio-/J-D-
glucopyranose (65) (1.3 g, 2.87 mrnol) and Cs2CO3 (1.44 g, 4.42 mmol) in dry DMF (5.0 
mL) was added a solution of triflate 58 (3.3 g, 5.94 mrnol) in dry DMF (5.0 mL) at O °C. 
The reaction was stirred at O °C for 2 h, after which time it was quenched with water and 
extracted with CH2Clz. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (70: 1 CH2Clz-MeOH) to afford compound 64 as a colorless foam (2.1 g, 
2.54 mrnol, 88%). TLC (10:1 CHClrMeOH): Rf0.81; mp 75-76 °C; [a] 0 -54.0° (c 0.25, 
CHCh); 1H NMR (600 MHz, CDCh): 8 7.27 (d, 2 H, ArH), 6.90 (d, 2 H, ArH), 5.84 (m, 
1 H, CH=CH2), 5.56 (ct, 1 H, NH), 5.25 (dd, 1 H, CH=CH2), 5.18 (dd, 1 H, CH=CH2), 
5.11 (dd, 1 H, H-3\ 5.02 (t, 1 H, H-zl), 5.00 (t, 1 H, H-3 11), 4.96 (t, 1 H, H-41'), 4.72 (d, 1 
H, H-1 11, Im.Hz= 10.8 Hz), 4.58 (d, 1 H, ArCH2O), 4.46 (d, 1 H, ArCH2O), 4.44 (d, 1 H, 
H-1 1, Im.Hz= 7.8 Hz), 4.33 (m, 1 H, OCH2CH=CH2), 4.06 (m, 4 H, H-211 , H-6 11 , 
OCH2CH=CH2), 3.94 (dd, 1 H, H-61), 3.83 (m, 1 H, H-61), 3.82 (s, 3 H, OCH3), 3.69 (dd, 
1 H, H-5\ 3.55 (dt, 1 H, H-5 11), 3.04 (t, 1 H, H-41), 2.71 (t, 2 H, COCH2), 2.46 (t, 2 H, 
COCH2), 2.15 (s, 3 H, CH3CO), 2.07 (s, 3 H, CH3CO), 2.06 (s, 3 H, CH3CO), 2.05 (s, 3 
H, CH3CO), 2.02 (s, 3 H, CH3CO), 1.89 (s, 3 H, CH3CO); 13C NMR (75 MHz, CDCh): 8 
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206.55, 172.49, 171.59, 170.60, 170.12, 169.89, 169.58, 159.49, 133.78, 130.32, 129.80, 
117.41, 114.05, 99.86, 82.59, 75.91, 75.78, 74.41, 73.55, 72.65, 70.91, 69.78, 68.89, 
68.25, 62.80, 55.50, 52.62, 46.12, 37.90, 29.82, 28.23, 23.27, 21.15, 21.00, 20.89, 20.86: 
ESIMS (positive-ion mode): m/z 848.2 [M + Na]+, 864.2 [M +Kt.Anal. Calcd for 
C3sHs 1NO17S (825.29): C, 55.26; H, 6.22; N, 1.70. Found: C, 54.89; H, 6.10; N, 1.57. 
S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-0-levulinoyl-/J-D-glucopyranosyl)-( 1 ➔4 )-
2,3-di-O-acetyl-6-0-p-methoxybenzyl-4-thio-a,/J-D-glucopyranose (127). ( 1,5-
cyclooctadiene )bis(methyldiphenylphosphine )iridium(!) hexafluorophosphate (30 mg) 
was suspended in dry tetrahydrofuran (THF) (5.0 mL) and treated with H2 at r. t. for 15 
min until the solids had completely dissolved and the red color had completely changed 
to a pale tan color. Then the solution was evacuated, purged with N2, and added to a 50-
mL flask containing 64 (500 mg, 0.61 mmol) under N2. The reaction was stirred at r. t. 
for 3 days, after which time it was cooled down to O °C, and a solution of NaHCO3 (207 
mg, 2.46 mmol) in water (5 mL) and lz (500 g, 1.95 mmol) was added. The reaction was 
stirred at O °C for another 20 min, then it was diluted with water and CH2Ch. Solid 
sodium thiosulfate was added until the iodine color completely disappeared. The mixture 
was extracted with CH2Ch, and the combined organic phase was dried with anhyd 
Na2SO4 and then evaporated to dryness. The residue was submitted to coarse silica gel 
column chromatography (60:1 CH2ClrMeOH) to afford compound 127, with an a, /3 
anomeric ratio of 1:2, as a white amorphous solid (440 mg, 0.56 mmol, 92%). TLC (10:1 
CHCb-MeOH): Rr0.50; 1H NMR (600 MHz, CDCl3): 8 7.27 (d, 2 H, /3-ArH), 7.25 (d, 1 
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H, a-ArH), 6.91 (d, 2 H, ,8-ArH), 6.89 (d, 1 H, a-ArH), 5.73 (d, 0.5 H, a-NH), 5.55 (d, 1 
H, ,8-NH), 5.51 (dd, 0.5 H, a-H-31). 5.48 (t, 0.5 H, a-H-1 1, IHI, HZ= 3.0 Hz, IHI, oH = 3.6 
Hz), 5.15 (dd, lH, ,8-H-31), 5.05 (t, 1 H, a-H-3 11), 5.04 (t, 1 H, ,8-H-311), 5.02 (t, 0.5 H, a-
H-411), 4.97 (t, 1 H, ,8-H-41\ 4.92 (dd, 0.5 H, a-H-i), 4.84 (dd, 1 H, ,8-H-i), 4.80 (d, 0.5 
H, a-H-1 11, IHI, HZ= 10.8 Hz), 4.74 (d, 1 H, P.H-1 11 , IHi. HZ =10.2 Hz), 4.59 (dd, 1 H, ,8-H-
l 1, IHI, HZ= 8.4 Hz, IHI, oH = 8.4 Hz,), 4.57 (d, 1 H, ,8-ArCHzO), 4.55 (d, 0.5 H, a-
ArCHzO), 4.46 (d, 1 H, ,8-ArCHzO), 4.45 (d, 0.5 H, a-ArCHzO), 4.38 (m, 0.5 H, a-H-5 1), 
4.16-4.04 (m, 3 H, ,8-H-211, a-H-211, ,8-H-611, a-H-611), 3.97 (m, 1.5 H, ,8-H-61, a-H-61), 
3.82 (s, 4.5 H, a-CH30, ,8-CH3O), 3.81-3.71 (m, 2.5 H, ,8-H-61, a-H-61, ,8-H-51), 3.60 (m, 
1 H, ,8-H-511), 3.57 (m, 0.5 H, a-H-511), 3.08 (t, 1 H, ,8-H-41), 3.03 (t, 0.5 H, a-H-41), 2.71 
(t, 3 H, a-COCHz,,8-COCHz), 2.47 (m, 3 H, a-COCHz,,8-COCHz), 2.15 (s, 3 H, p. 
CH3CO), 2.10 (s, 3 H, ,8-CH3CO), 2.09 (s, 1.5 H, a-CH3CO), 2.08 (s, 3 H, a-CH3CO), 
2.07 (s, 7.5 H, ,8-CH3CO, a-CH3CO), 2.06 (s, 1.5 H, a-CH3CO), 2.03 (s, 3 H, ,8-CH3CO), 
1.91 (s, 1.5 H, a-CH3CO), 1.89 (s, 3 H, ,8-CH3CO); 13C NMR (75 MHz, CDCh): 8 
206.34, 172.21, 172.14, 171.34, 171.19, 170.70, 170.63, 170.43, 170.01, 169.63, 159.28, 
159.19, 129.87, 129.71, 129.56, 113.81, 113.74, 95.36, 90.08, 82.11, 81.91, 75.51, 75.40. 
74.38, 74.04, 73.34, 73.29, 72.41, 70.03, 69.81, 68.73, 68.62, 67.98, 67.90, 67.37, 62.39, 
62.31, 55.23, 52.30, 52.11, 45.72, 37.60, 29.52, 27.92, 22.93, 20.97, 20.84, 20.77, 20.67, 
20.60; ESIMS (positive-ion mode): mlz 808.0 [M + Na]+, 824.0 [M +Kt.Anal. Calcd 
for C3s~1N011S (785.26): C, 53.50; H, 6.03; N, 1.78. Found: C, 53.23; H, 5.96; N, 1.80. 
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S-(2-acetamido-4,6-di-0-acetyl-2-deoxy-3-0-levulinoy 1-/3-D-glucopyranosy I)-( 1 ➔4 )-
2,3-di-O-acetyl-6-0-p-methoxybenzy l-4-thio- a, /J-D-glucopyranosyl 
trichloroacetimidate (66). To a mixture of compound 127 (300 mg, 0.38 mmol) and 
trichloroacetonitrile (0.42 mL, 4.2 mmol) in dry CH2Cli (2 rnL) was added l ,5-
diazabicyclo[5.4.0]undec-5-ene (DBU) (2 drops). The reaction was stirred at r. t. for 40 
min, and then it was concentrated and submitted to coarse silica gel column 
chromatography (1:5 hexanes-EtOAc) to afford trichloroacetimidate 66, with an a, /3 
anomeric ratio of 8:1, as an unstable colorless foam (289 mg, 82%). TLC (10:1 
CHCh-MeOH): Re 0.69 (a anomer); [a] 0 +17.6° (c 0.5, CHC13, a anomer); mp 79-80 
°C; 1H NMR (600 MHz, CDCh, a anomer): 8 8.62 (s, 1 H, C=NH), 7.26 (d, 2 H, ArH), 
6.90 (d, 2 H, ArH), 6.60 (d, 1 H, H-1 1, IHI, ttz = 3.6 Hz), 5.66 (d, 1 H, NH), 5.54 (dd, 1 H, 
I I II II II H-3 ), 5.10 (dd, 1 H, H-2 ), 5.03 (t, 1 H, H-3 ), 4.99 (t, 1 H, H-4 ), 4.72 (d, 1 H, H-1 , lH1. 
I tt2 = 10.2 Hz), 4.54 (d, 1 H, ArCH2O), 4.46 (d, 1 H, ArCH2O), 4.30 (m, 1 H, H-5 ), 4.14 (t, 
1 H, H-i11), 4.10 (m, 1 H, H-61), 4.04 (m, 2 H, H-611), 3.81 (s, 3 H, OCH3), 3.67 (dd, 1 H, 
H-61), 3.50 (m, 1 H, H-51\ 3.24 (t, 1 H, H-41), 2.71 (t, 2 H, COCH2), 2.47 (t, 2 H, 
COCH2), 2.15 (s, 3 H, CH3CO), 2.08 (s, 3 H, CH3CO), 2.07 (s, 3 H, CH3CO), 2.00 (s, 3 
H, CH3CO), 1.98 (s, 3 H, CH3CO), 1.91 (s, 3 H, CH3CO); 13C NMR (75 l\.1Hz, CDCh, a 
anomer): 8 206.48, 172.51, 171.49, 170.53, 170.11, 170.04, 169.82, 161.01, 159.55, 
130.11, 129.84, 114.05, 94.34, 82.25, 75.74, 74.55, 73.75, 73.68, 71.34, 68.29, 68.12, 
67.22, 62.59, 55.50, 52.25, 45.26, 37.88, 29.81, 28.25, 23.25, 21.26, 20.88, 20.75; ESIMS 
(positive-ion mode): m/z 951.0 [M + Na]+, 967.0 [M +Kt.Anal. Calcd for 
C37& 7Cl3N2O17S (928.17): C, 47.77; H, 5.09; N, 3.01. Found: C, 47.99; H, 4.96: N, 3.04. 
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Ally I S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4 )-2,3-di-O-
acetyl-6-0-p-methoxybenzyl-4-thio-,B-D-glucopyranoside (67). To a solution of 
compound 64 (200 mg, 0.28 mmol) in acetic acid (0.5 mL) and pyridine (0.8 mL) was 
added hydrazine hydrate (0.1 mL) at O °C. The reaction was stirred for 10 min, after 
which time it was diluted with CH2Cl2, washed with satd NaHCO3, and extracted with 
CH2Ch. The organic phase was dried with anhyd Na2SO4 and then evaporated to dryness. 
The residue was submitted to coarse silica gel column chromatography (50: 1 
CH2Ch-MeOH) to afford compound 67 as a colorless foam (181 mg, 0.25 mmol, 89%). 
TLC (10:1 CHCl)-MeOH): Rr0.52; mp 86-87 °C; [a]o-80.4° (c 0.5, CHCl3); 1H NMR 
(600 MHz, CDCI)): 8 7.25 (d, 2 H, ArH), 6.88 (d, 2 H, ArH), 6.33 (d, 1 H, NH), 5.84 (m, 
1 H, CH=CH2), 5.22 (dd, 1 H, CH=CH2), 5.18 (dd, 1 H, CH=CH2), 5.18 (t, 1 H, H-31), 
5.05 (t, 1 H, H-i), 4.87 (m, 1 H, H-411). 4.65 (d, 1 H, H-1 11, ltt1, ttz = 9.0 Hz), 4.57 (d, 1 H, 
ArCH2O), 4.47 (d, 1 H, ArCH2O), 4.44 (d, 1 H, H-11, ltt1. tt2 = 7.8 Hz), 4.34 (dd, 1 H, 
OCH2CH=CH2), 4.12 (d, 1 H, H-61\ 4.07 (dd, 1 H, OCH2CH=CH2), 4.05 (m, 1 H, H-6 11 ), 
4.01 (m, 1 H, H-61), 3.84 (m, 1 H, H-61), 3.82 (s, 3 H, OCH3), 3.81 (m, 1 H, H-i), 3.74 
(dd, 1 H, H-51), 3.62 (t, 1 H, H-311), 3.54 (m, 1 H, H-5 11), 3.07 (t, 1 H, H-41), 2.13 (s, 3 H, 
CH3CO), 2.11 (s, 3 H, CH3CO), 2.07 (s, 3 H, CH3CO), 2.01 (s, 3 H, CH3CO), 2.00 (s, 3 
H, CH3CO); 13C NMR (75 MHz, CDCh): 8 172.79, 172.67, 170.57, 170.45, 169.48, 
159.47, 133.72, 130.29, 129.70, 117.43, 113.97, 99.83, 81.14, 77.00, 75.72, 75.68, 73.59, 
72.45, 71.40, 71.25, 69.76, 68.75, 63.15, 55.97, 55.51, 46.43, 22.98, 21.38, 21.12, 20.98, 
20.87; ESIMS (positive-ion mode): m/z 728.1 [M + Ht, 750.1 [M + Na]+, 766.0 [M + 
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Kt. Anal. Calcd for C33~sNO1sS (727.25): C, 54.46; H, 6.23; N, 1.92. Found: C, 54.27; 
H, 6.19; N, 1.83. 
Allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-0-levulinoyl-/J-D-glucopyranosyl)-
(1 ➔4 )-(2,3-di-0-acetyl-6-0-p-methoxybenzyl-4-thio-/J-D-glucopyranosyl)-( 1 ➔3)-S­
(2-acetamido-4,6-di-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4 )-2,3-di-0-acetyl-6-
0-p-methoxybenzyl-4-thio-P-D-glucopyranoside (128). To a solution of acceptor 67 
(300 mg, 0.41 mmol) in 1,2-dichloroethane (C2~Ch) was added TMSOTf (0.01 Min 
C2~C}z, 0.1 mL) at -15 °C under N2. The mixture was stirred for 10 min, and then a 
solution of trichloroacetimidate 66 (590 mg, 0.63 mmol, 1.53 equiv) in 1,2-
dichloroethane (C2~Clz) was added. The reaction was stirred at -15 °C under N ~ for 
another 2 h, after which time it was quenched with triethylamine (TEA), filtered. and 
then evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (50: 1 CH2Clz-MeOH) to afford compound 128 as a white amorphous 
solid (428 mg, 0.29 mmol, 69%). TLC (10:1 CHCb-MeOH): Rr0.50; [a] 0 +10.4° (c 0.5, 
CHC13); mp 122-123 °C; 1H NMR (600 MHz, CDCb): o 7.26 (d, 2H, ArH), 7.25 (d, 2H, 
ArH), 6.90 (d, 2 H, ArH), 6.89 (d, 2 H, ArH), 5.85 (m, 1 H, CH=CH2), 5.75 (d, 1 H, 
NH11), 5.61 (d, 1 H, NH1v), 5.25 (m, l H, CH=CH2), 5.18 (d, 1 H, CH=CH2), 5.10 (t, 1 H, 
H-3'), 5.08 (t, 1 H, H-3 1v), 5.05 (t, 2 H, H-3 111 , H-41v), 4.98 (t, 1 H, H-2'), 4.80 (t, 1 H, H-
411), 4.77 (d, 1 H, H-1 ,v, ltt1. HZ= 10.8 Hz), 4.74 (t, 1 H, H-2 11 '). 4.65 (d, 1 H. H-1 11 • JH I H::> 
= 10.2 Hz), 4.58 (d, 1 H, H-1 m, ltt1. Hz= 7.8 Hz), 4.55 (d, l H, ArCH2O), 4.50 (d, l H, 
ArCH2O), 4.45 (d, l H, ArCH2O), 4.44 (d, 1 H, H-1 1, ltt 1. ttz = 7.8 Hz), 4.42 (d, l H, 
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ArCH2O), 4.33 (dd, 1 H, OCH2CH=CH2), 4.20 (dd, 1 H, H-6rv), 4.12 (m, 2 H, H-6rv, H-
611), 4.04 (m, 3 H, OCH2CH=CH2, H-61\ H-2rv), 3.94 (m, 3 H, H-61, H-6m, H-i1\ 3.86 
(dd, H-6m), 3.82 (s, 6 H, OCH3), 3.81 (m, 2 H, H-61, H-3 11), 3.69 (m, 2 H, H-5m, H-51), 
3.59 (m, 1 H, H-5 11), 3.55 (m, 1 H, H-51v), 3.05 (t, 1 H, H-41), 3.01 (t, 1 H, H-411\ 2.72 (t, 
2 H, COCH2), 2.46 (t, 2 H, COCH2), 2.15 (s, 3 H, CH3CO), 2.09 (s, 3 H, CH3CO), 2.07 
(s, 3 H, CH3CO), 2.06 (s, 3 H, CH3CO), 2.05 (s, 3 H, CH3CO), 2.04 (s, 3 H, CH3CO), 
2.03 (s, 3 H, CH3CO), 2.02 (s, 3 H, CH3CO), 2.01 (s, 3 H, CH3CO), 1.95 (s, 6 H, 
CH3CO); 13C NMR (75 MHz, CDCh): 8 206.21, 172.12, 171.39, 171.15, 170.60, 170.29, 
169.92, 169.53, 169.49, 169.45, 169.16, 159.23, 158.97, 133.43, 130.09, 129.64, 129.46, 
129.38, 117.00, 113.76, 113.61, 100.05, 99.46, 81.93, 81.74, 78.71, 75.54, 75.29, 75.10, 
73.78, 73.10, 72.98, 72.52, 72.44, 70.62, 69.39, 68.85, 68.55, 68.45, 67.91, 62.83, 61.95, 
55.14, 53.42, 52.62, 45.45, 45.22, 37.54, 29.43, 27.84, 23.10, 22.90, 20.83, 20.68, 20.63, 
20.60, 20.52; ESTh1S (positive-ion mode): mlz 1495.3 [M + H]+, 1512.3 [M + ~t. 
1517.3 [M + Na]+, 1533.3 [M +Kt.Anal. Calcd for C6sH90N2O31S2(1495.57): C, 54.61; 
H, 6.07; N, 1.87. Found: C, 54.15; H, 6.24; N, 1.83. 
Allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-(2,3-di-O­
acetyl-6-0-p-methoxybenzyl-4-thio-/J-D-glucopyranosyl)-( 1 ➔3 )-S-(2-acetamido-4,6-
di-0-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4 )-2,3-di-0-acetyl-6-0-p-
methoxybenzyl-4-thio-,B-D-glucopyranoside (129). To a solution of tetrasaccharide 128 
(150 mg, 0.10 mmol) in acetic acid (0.3 mL) and pyridine (0.4 mL) was added hydrazine 
hydrate (0.2 mL) at O °C. The reaction was stirred for 10 min, after which time it was 
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diluted with CH2Clz, washed with a satd NaHCO3 solution, and extracted with CH~CI~. 
The organic phase was dried with anhyd Na2SO4 and then evaporated to dryness. The 
residue was submitted to coarse silica gel column chromatography (50: 1 CH2Clz-MeOH) 
to afford compound 129 as a colorless foam (123 mg, 0.088 mmol, 88%). TLC (10: 1 
CHCh-MeOH): Rr 0.37; mp 197-198 °C; [a]o-74.8° (c 0.1, CHCh); 1H NMR (600 
MHz, CDCh): 8 7.25 (d, 2H, ArH), 7.23 (d, 2H, ArH), 6.89 (d, 2 H, ArH), 6.88 (d, 2 H, 
ArH), 6.23 (d, 1 H, NHIY), 5.85 (m, 1 H, CH=CH2), 5.78 (d, 1 H, NH11), 5.25 (dd, 1 H, 
CH=CH2), 5.17 (dd, 1 H, CH=CH2), 5.14 (dd, 1 H, H-31), 5.10 (dd, 1 H, H-3 11\ 4.99 (t, 1 
H, H-211\ 4.94 (t, 1 H, H-4IV), 4.81 (t, 1 H, H-411), 4.80 (t, 1 H, H-2\ 4.71 (d, 1 H, H-iiv, 
IHI. HZ= 10.8 Hz), 4.66 (d, 1 H, H-1 n, ftt 1, HZ= 10.2 Hz), 4.61 (d, 1 H, H-1 1, IH1. H2 = 7.8 
Hz), 4.55 (d, 1 H, ArCH2O), 4.49 (d, 1 H, ArCH2O), 4.45 (d, 1 H, ArCH2O), 4.44 (d, 1 H, 
H-lm, Itti.H2 = 8.4 Hz), 4.42 (d, 1 H, ArCH2O), 4.33 (m, 1 H, OCH2CH=CH2), 4.21 (dd, 
1 H, H-6IV), 4.12 (m, 2 H, H-61v, H-611), 4.07 (m, 1 H, OCH2CH=CH2), 4.05 (m, 1 H, H-
611), 3.96 (m, 3 H, H-61, H-6m, H-i1), 3.88 (d, 1 H, H-6\ 3.82 (s, 3 H, OCH3), 3.81 (s, 3 
H, OCH3), 3.81 (m, 3 H, H-3 11, H-2IV, H-6m), 3.73 (m, 1 H, H-5\ 3.66 (m, 2 H, H-3 1v, H-
511\ 3.63 (m, 1 H, H-51\ 3.58 (m, 1 H, H-51v), 3.05 (t, 1 H, H-4111), 3.03 (t, 1 H, H-41), 
CH3CO), 2.06 (s, 3 H, CH3CO), 2.05 (s, 3 H, CH3CO), 2.02 (s, 3 H, CH3CO), 2.014 (s, 3 
H, CH3CO), 2.01 (s, 3 H, CH3CO), 1.94 (s, 6 H, CH3CO); 13C NMR (75 MHz, CDCIJ): 8 
172.28, 172.11, 171.63, 170.82, 170.37, 170.14, 169.67, 169.56, 169.54, 169.25, 159.29, 
159.05, 133.49, 130.14, 129.65, 129.46, 129.39, 117.07, 113.76, 113.67, 99.87, 99.50, 
81.66, 80.76, 78.50, 75.99, 75.66, 75.59, 75.11, 75.01, 73.19, 73.13, 72.56, 72.40, 71.10, 
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71.02, 70.67, 69.47, 68.91, 68.66, 68.54, 62.94, 62.51, 55.66, 55.22, 53.40, 45.68, 45.56, 
23.14, 22.77, 20.95, 20.90, 20.79, 20.74, 20.65, 20.58; ESIMS (positive-ion mode): m/z 
1397.4 [M + HJ+, 1414.4 [M + M-4t, 1419.3 [M + Na]+, 1435.3 [M +Kt.Anal. Calcd 
for C63Hs.iN2O29S2 (1396.46): C, 54.15; H, 6.06; N, 2.00. Found: C, 53.86; H, 6.20; N, 
1.93. 
Ally) S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-0-levulinoyl-/J-D-glucopyranosyl)-
(1 ➔4 )-(2,3-di-0-acetyl-6-0-p-methoxybenzyl-4-thio-/J-D-glucopyranosyl )-( 1 ➔ 3 )-S-
(2-acetamido-4,6-di-0-acety l-2-deoxy-/J-D-glucopyranosy l)-( 1 ➔4)-{2,3-di-0-acetyl-6-
0-p-methoxybenzyl-4-thio-/J-D-glucopyranosyl)-(1 ➔3)-S-(2-acetamido-4,6-di-O­
acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-2,3-di-0-acetyl-6-0-p-methoxybenzyl-4-
thio-/3-D-glucopyranoside (130). To a solution of acceptor 129 (68 mg, 0.048 mmol) in 
C2~Clz was added TMSOTf (0.01 Min C2~Cl2, 0.1 mL) at-15 °C under N2. The 
mixture was stirred for 10 min, and then a solution of trichloroacetimidate 66 (66.8 mg, 
0.072 mmol, 1.5 equiv) in C2~Clz was added. The reaction was stirred at -15 °C under 
N2 for 1 h, and then another 1.5 equiv of trichloroacetimiadte 66 (66.8 mg, 0.072 mmol) 
was added along with another catalytic amount of TMSOTf (0.01 Min C2~CI2, 0.1 mL). 
The reaction was then stirred at-15 °C under N2 for another 2 h, after which time it was 
quenched with triethylamine (TEA) and evaporated to dryness. The residue was 
submitted to coarse silica gel column chromatography (50: 1 CH2C}z-MeOH) to afford 
hexasaccharide 130 as a white amorphous solid ( 48.5 mg, 0.022 mmol, 46% ). TLC ( 10: 1 
CHClrMeOH): Rr0.38; [a]o-38.4° (c 0.5, CH2Clz); mp 133-134 °C; 1H NMR (600 
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MHz, CDCh): 8 7.25 (d, 4 H, ArH), 7.23 (d, 2 H, ArH), 6.91 (d, 2 H, ArH), 6.89 (d, 2 H, 
ArH), 6.88 (d, 2 H, ArH), 5.90 (d, 1 H, NH1v), 5.84 (m, 1 H, CH=CH2), 5.74 (d, 1 H, 
NH11), 5.57 (d, 1 H, NHv1), 5.25 (dd, 1 H, CH=CH2), 5.18 (dd, 1 H, CH=CH2), 5.10 (m. 4 
H, H-31, H-3m, H-3v, H-3v1), 5.05 (m, 2 H, H-2v, H-4v1), 4.99 (t, 1 H, H-2'), 4.87 (m, l H, 
H-41v), 4.80 (t, 1 H, H-411), 4.79 (d, 1 H, H-1 iv, Im, HZ= 9.0 Hz), 4.78 (d, 1 H, H-1 vi, IHI, 
H2 = 9.6 Hz), 4.77 (t, 1 H, H-2m), 4.69 (d, 1 H, H-1 11, IHI, HZ= 8.4 Hz), 4.64 (d, 1 H, H-1 v, 
Im,H2 = 8.4 Hz), 4.62 (d, 1 H, H-lm, Im.Hz= 7.2 Hz), 4.54 (d, 1 H, ArCH2O), 4.50 (d, 1 
H, ArCH2O), 4.46 (d, 1 H, ArCH2O), 4.45 (d, 1 H, ArCH2O), 4.43 (d, 1 H, H-1 1, lH1, H2 = 
7.8 Hz), 4.42 (d, 1 H, ArCH2O), 4.40 (d, 1 H, ArCH2O), 4.33 (m, 1 H, OCH2CH=CH2), 
4.24 (m, 1 H, H-6'), 4.21 (m, 1 H, H-6v1), 4.11 (dd, 2 H, H-6v1, H-61'), 4.04 (m, 3 H, 
OCH2CH=CH2, H-2v1, H-61'), 3.94 (m, 5 H, H-zlv, H-6m, H-6v, H-61v, H-2'1), 3.84 (m, 5 
H, H-6v, H-61v, H-6m, H-3 11 , H-31v), 3.83 (s, 3 H, OCH3), 3.82 (s, 3 H, OCH,). 3.81 (s. 3 
H, OCH3), 3.70 (m, 3 H, H-5 1, H-5 111 , H-5v), 3.66 (m, l H, H-5 1v), 3.59 (m, l H, H-5 11 ), 
3.56 (m, 1 H, H-5v1), 3.04 (t, 1 H, H-4'), 3.03 (t, 1 H, H-411'), 3.00 (t, 1 H, H-4v), 2.72 (t, 
2 H, COCH2), 2.46 (t, 2 H, COCH2), 2.16 (s, 3 H, CH3CO), 2.09 (s, 6 H, CH3CO), 2.07 
(s, 6 H, CH3CO), 2.06 (s, 6 H, CH3CO), 2.05 (s, 3 H, CH3CO), 2.04 (s, 3 H, CH3CO), 
2.03 (s, 3 H, CH3CO), 2.01 (s, 3 H, CH3CO), 2.00 (s, 3 H, CH3CO), 1.95 (s, 3 H, 
CH3CO), 1.94 (s, 3 H, CH3CO), 1.90 (s, 3 H, CH3CO); 13C NMR (75 MHz, CDCh): 8 
206.28, 172.24, 171.57, 171.46, 171.26, 171.06, 170.74, 170.39, 170.00, 169.71, 169.59, 
169.54, 169.26, 159.34, 159.19, 159.10, 133.54, 130.20, 129.83, 129.73, 129.50, 117.09, 
113.86, 113.79, 113.70, 99.91, 99.57, 82.04, 81.81, 81.24, 78.70, 78.53, 77.21. 75.66. 
75.41, 75.22, 73.93, 73.20, 73.13, 72.60, 70.65, 70.49, 69.48, 68.89, 68.66, 68.00, 62.97, 
139 
62.54, 62.03, 55.25, 53.42, 52.69, 45.59, 45.34, 45.24, 37.65, 29.65, 29.53, 27.97, 25.45, 
23.22, 23.14, 23.01, 20.85, 20.63; ESIMS (positive-ion mode): m/z 2164.7 [M + H]+, 
2186.6 [M + Na]+, 2202.6 [M + K]\ MALDIMS (positive-ion mode): m/z 2186.4339 [M 
+Nat.Anal. Calcd for C9sH129N3O45S3 (2163.71): C, 54.36; H, 6.01; N, 1.94. Found: C, 
54.01; H, 6.17; N, 1.92. 
Allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-/J-D-glucopyranosyl)-
(1 ➔4 )-(2,3-di-O-acetyl-4-thio-/J-D-glucopyranosyl)-(1 ➔3)-S-(2-acetamido-4,6-di-O­
acetyl-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-(2,3-di-O-acety 1-4-thio-/J-D-
glucopyranosyl)-(1 ➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-/J-D­
glucopyranosyl)-(1 ➔4)-2,3-di-O-acetyl-4-thio-/J-D-glucopyranoside (131). To a 
solution of hexasaccharide 130 (43 mg, 0.02 mmol) in CH2Ch (5 mL) and H2O (0.3 mL) 
was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (27 mg, 0.12 mmol, 6 
equiv). After stirring for 1.5 h, the mixture was poured into a satd NaHCO3 solution and 
extracted with CH2Cl2. The organic phase was dried with anhyd Na2SO4 and then 
evaporated to dryness. The residue was submitted to coarse silica gel column 
chromatography (20:1 CH2C}z-MeOH) to afford compound 131 as a white amorphous 
solid (30 mg, 0.017 mmol, 83%). TLC (10: 1 CHCh-MeOH): Rr 0.32; [a] 0 -54.2° (c 0.5, 
CH2Ch); mp 255-256 °C; 1H NMR (600 MHz, 5: 1 CDClrCD3OD): 8 5.84 (m, 1 H, 
CH=CH2), 5.26 (d, 1 H, CH=CH2), 5.20 (d, 1 H, CH=CH2), 5.17 (t, 1 H, H-3vI), 5.06 (m, 
I III V VI I IV II H H lVI J 4 H, H-3, H-3 , H-3 , H-4 ), 4.91 (m, 3 H, H-2, H-4 , H-4 ), 4.82 (d, 1 , - , HI. 
H2 = 10.2 Hz), 4.72 (m, 2 H, H-i111 , H-2v), 4.63 (m, 4 H, H-1 11 , H-1 Iv, H-1 111 , H-1 v, JH1. H2 
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= 7.2 Hz, 7.8 Hz, 10.8 Hz), 4.51 (d, 1 H, H-1 1, JH 1, H2 = 7.8 Hz), 4.33 (dd, 1 H, 
OCH2CH=CH2), 4.22 (m, 2 H, H-6v 1), 4.15 (m, 4 H, H-6 11 , H-6 1v), 4.10 (dd, I H, 
H H 6v H 6III) 3 70 ( 3 H H 511 H 5IY H 5Y') 3 54 ( 3 51 H 5111 v , - , - , . m, , - , - , - , . m, H, H- , - , H-5 ), 3.00 
(t, 1 H, H-41), 2.87 (dt, 2 H, H-4111 , H-4v), 2.74 (t, 2 H, COCH2), 2.47 (t, 2 H, COCH2), 
2.17 (s, 3 H, CH3CO), 2.12 (s, 12 H, CH3CO), 2.09 (s, 3 H, CH3CO), 22.07 (s, 3 H, 
H, CH3CO), 2.028 (s, 3 H, CH3CO), 2.00 (s, 3 H, CH3CO), 1.98 (s, 3 H, CH3CO), 1.92 (s, 
3 H, CH3CO); 13C NMR (75 MHz, 5:1CDCh-CD30D):6207.02, 172.17, 171.18, 
170.97, 170.84, 170.10, 169.95, 169.77, 133.12, 117.16, 99.31, 99.17, 83.95, 83.34, 78.56, 
75.30, 75.10, 74.95, 73.48, 72.57, 71.37, 71.16, 70.92, 69.72, 68.32, 67.84, 62.54, 62.04, 
61.71, 61.27, 60.97, 53.46, 52.69, 45.92, 45.74, 37.38, 29.43, 29.22, 27.67, 22.56, 22.35, 
20.39, 20.24; MALDIMS (positive-ion mode): 1825.9617 [M + Na]+, 1841.9717 [M + 
Kt. Anal. Calcd for C1Jl1osN3O42S3 (1804.82): C, 49.25; H, 5.86; N, 2.33. Found: C, 
48.91; H, 6.05; N, 2.29. 
Ally I S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-(1 ➔4)-( 4-thio-/J-D-
glucopyranosyluronic acid )-(1 ➔3 )-S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-
(1 ➔4 )-( 4-thio-/J-D-glucopyranosyluronic acid )-(1 ➔3)-S-(2-acetamido-2-deoxy-/J-D­
glucopyranosyl)-(1 ➔4 )-4-thio-/J-D-glucopyranosiduronic acid (133). To a solution of 
compound 131 (40 mg, 0.022 mmol) in dry DMF (2 mL) was added pyridinium 
dichromate (PDC) (249 mg, 0.066 mmol, 30 equiv). The reaction was allowed to stir at r. 
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t. for 2 days, after which time it was evaporated to dryness and the residue was submitted 
to coarse silica gel column chromatography (10:1:1 CH2Clz-MeOH-AcOH) to afford 
compound 132 as a white amorphous solid (28 mg, 0.015 mmol, 69%). The resulting 
solid was redissolved in 1:2 THF and water (3 mL) and treated with lithium hydroxide 
monohydride (16.5 mg, 0.39 mmol, 26 equiv) at r. t. for 10 h. After which time the 
reaction mixture was neutralized with Dowex-50 x 2 (Ir form), filtered, and evaporated 
to dryness. The residue was purified by Sephadex G-10 size-exclusion column 
chromatography (20 cm) using water as solvent to give compound 133 as a white 
amorphous solid (15 mg, 0.012 mmol, 80%). 1H NMR (600 MHz, D20): 8 5.92 (m, 1 H, 
II IV CH=CH2), 5.35 (d, 1 H, CH=CH2), 5.25 (d, 1 H, CH=CH2), 4.59 (m, 3 H, H-1 , H-1 , 
H-lv1), 4.49 (m, 3 H, H-1 1, H-1 111, H-lv),4.33 (d, 1 H, OCH2CH=CH2), 4.18 (m, 1 H, 
OCH2CH=CH2), 4.01 (d, 1 H, H-31), 3.96 (d, 2 H, H-3 111, H-3v), 3.89 (d, 3 H, H-611 , H-61v, 
H-6v'), 3.85 (m, 1 H, H-2v'), 3.71 (m, 8 H, H-611, H-61v, H-6v1, H-2 11, H-21v, H-3 11 , H-3 1v, 
H-3v1), 3.52 (t, 3 H, H-411, H-4IV, H-4v1), 3.44 (m, 6 H, H-51, H-5 11, H-5 111, H-5IV, H-5v, H-
5v,) I III V I Ill V 0 ( 3 H 3.34 (m, 3 H, H-2 , H-2 , H-2 ), 2.97 (t, 3 H, H-4 , H-4 , H-4 ), 2. 1 s, , 
CH3CO), 1.98 (s, 6 H, CH3CO); MALDIMS (negative-ion mode): 1242.3100 [M - Hr, 
1264.2767 [M - 2H + Na]", 1280.2525 [M - 2H + Kr, 1286.2227 [M - 3H + 2Nar, 
1297.2186 [M- 3H + N~ + KL MALDIMS (positive-ion mode): 1266.4201 [M + Na]+, 
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APPENDIX I. CRYSTAL DATA FOR COMPOUND S0A 
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Table 1. Crystal data and structure refinement for compound 80a. 
Tmin - 0.9570, Tmax - 0.9947 




a= 5.8241(5) A 
b = 28.617(2) A 
c = 16.6076(14) A 
/3= 96.207(2)0 
V = 2751.7(4) A3 
Z=2 
Dx = 1.214 Mg/m3 
Mo Ka radiation 
Cell parameters from 5069 reflections 
0 = 1.88 to 26.41 ° 
µ = 0.106 mm-1 
T= 295(2) K 
Plate, colorless 
3 0.42 x 0.35 x 0.05 mm 
Data collection 
Bruker SMART/CCD diffractometer 
w and If/ scans 
Absorption correction: Semi-empirical 
from equivalents 
11 0 16 independent reflections 
6091 reflections with I> 2a(J) 
Rint = 0.0475 
Bmax = 26.41 ° 
h =-7-7 
k=-35-35 
l = -20- 20 
Refinement 
Refinement on F2 
R1 = 0.0449 
wR2 = 0.0964 
S = 0.983 
11016 reflections 
666 parameters 
R1 = .E IIFal - IFcll/ LlFol 
wR2 = ( L[w(F}- F/)2]IL[wF})2J112 
(Af O")max = 0.006 
0 -3 
liPmax = 0.208 e.A 
0 -3 
li,Dmin = 0.140 e.A 
Absolute structure parameter= -0.06 (14) 
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (A 2 x 103) for compound 80a. 
X y z U(eqt 
Si(l) 3152(1) 5063(1) 8264(1) 47(1) 
0(4) 1287(3) 5123(1) 7447(1) 49(1) 
0(5) -2482(4) 4993(1) 2547(1) 55(1) 
0(8) -690(4) 6192(1) 3809(1) 52(1) 
0(3) -865(4) 4717(1) 5084(1) 52(1) 
0(1) 3024(4) 4254(1) 6760(1) 53(1) 
0(7) 1446(4) 5977(1) 2425(2) 67(1) 
C(l 1) 1433(5) 5036(1) 6613(2) 43(1) 
0(6) -621(4) 5201(1) 1467(1) 62(1) 
C(12) -506(5) 5306(1) 6126(2) 47(1) 
0(2) 2639(5) 3708(1) 5706(2) 78(1) 
C(23) -2520(5) 5431(1) 3782(2) 44(1) 
C(22) -2523(5) 5466(1) 4707(2) 46(1) 
C(l0) 1139(5) 4523(1) 6387(2) 46(1) 
C(27) -530(5) 5724(1) 3513(2) 46(1) 
C(24) -2381(5) 4941(1) 3413(2) 46(1) 
C(9) 1037(6) 4465(1) 5477(2) 52(1) 
C(l3) -592(6) 5209(1) 5215(2) 44(1) 
C(26) -546(6) 5727(1) 2593(2) 50(1) 
C(51) -229(6) 4751(1) 1174(2) 50(1) 
0(9) -4746(4) 5324(1) 4919(2) 62( l) 
0(13) -3681(4) 4172(1) 3250(2) 83(1) 
C(25) -525(6) 5222(1) 2320(2) 51(1) 
C(28) -4296(6) 4611(1) 3565(2) 58(1) 
C(l) 4749(7) 3506(1) 6973(3) 65(1) 
C(53) 2170(6) 4097(1) 985(2) 62(1) 
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Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (A2 x 103) for compound 80a (cont'd). 
X y z U(eq/ 
C(54) 408(7) 3887(1) 498(2) 60( I) 
C(7) 2725(6) 3774(1) 6547(2) 61(1) 
0(11) 526(5) 3457(1) 135(2) 87( 1) 
C(37) 1437(6) 6386(1) 4157(3) 69( 1) 
C(38) 1042(7) 6829(1) 4587(2) 66( l) 
C(8) 770(7) 3952(1) 5278(2) 74(1) 
C(30) -4603(7) 3412(1) 2773(3) 67(1) 
C(29) -5297(7) 3816(1) 3257(3) 75(1) 
C(34) -2142(8) 3069(2) 1862(3) 83(1) 
C(56) -2002(6) 4546(1) 686(2) 64(1) 
C(5) 7813(8) 2947(2) 6991(4) 94(2) 
C(44) 1325(8) 6199(2) 1643(3) 84(1) 
C(52) 1842(6) 4535(1) 1311(2) 61(1) 
C(48) -4231(10) 7183(2) 1142(4) 103(2) 
C(45) -648(8) 6543(1) 1477(3) 73(1) 
C(32) -5240(9) 2628(2) 2277(3) 94(2) 
0(12) -2989(8) 2275(1) 1381 (3) 122(1) 
C(55) -1679(7) 4112(1) 348(2) 69(1) 
C(46) -1830(10) 6584(2) 714(3) 94(2) 
C(49) -3082(10) 7147(2) 1906(4) 94(2) 
C(39) -940(9) 7078(2) 4469(3) 93(1) 
C(35) -2748(7) 3434(1) 2328(3) 77(1) 
C(33) -3411(9) 2660(2) 1834(3) 86(1) 
C(41) 579(18) 7664(2) 5387(5) 135(3) 
C(2) 5363(9) 3572(2) 7778(3) 106(2) 
C(57) 2694(9) 3246(2) 123(4) 113(2) 
155 
Table 2. Atomic coordinates (x 104) and equivalent isotropic displacement 
parameters (A 2 x 103) for compound 80a (cont'd). 
X y z U(eqt 
C(43) 2774(10) 7005(2) 5109(4) 132(2) 
C(6) 5979(7) 3189(2) 6573(3) 82(1) 
C(4) 8401(8) 3020(2) 7788(4) 93(1) 
C(50) -1336(9) 6835(2) 2068(3) 87(1) 
C(40) -1145(13) 7503(2) 4894(4) 121(2) 
C(31) -5837(8) 2995(2) 2731(3) 86(1) 
C(47) -3568(11) 6907(2) 549(4) 116(2) 
C(36) -1153(12) 2303(2) 870(5) 142(2) 
C(3) 7203(10) 3337(2) 8180(3) 113(2) 
C(42) 2511(16) 7425(3) 5512(5) 178(4) 
0(10) -4128(7) 5935(1) 6272(2) 93(1) 
N(l) -296(6) 5803(1) 6313(2) 66(1) 
C(19) 3102(5) 5632(1) 8832(2) 57(1) 
C(15) 2131(6) 4581(1) 8871(2) 68(1) 
C(16) 4405(7) 5583(2) 9688(2) 84(1) 
C(14) 6079(5) 4941(1) 7988(2) 68(1) 
C(20) -2124(11) 6079(2) 6417(2) 78(1) 
C(18) 4196(7) 6024(1) 8364(3) 78(1) 
C(17) 589(6) 5774(2) 8914(3) 95(2) 
C(21) -1556(12) 6562(2) 6715(3) 131(2) 
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Table 3. Bond lengths [A] and angles [0 ] for com~ound 80a.b 
Si(l)-O(4) 1.653(2) Si(l)-C(l5) 1.843(4) 
Si(l)-C(14) 1.845(3) Si(l)-C(19) 1.885(4) 
O(4)-C(l 1) 1.419(3) O(5)-C(25) 1.402(4) 
O(5)-C(24) 1.440(3) O(8)-C(37) 1.422(4) 
O(8)-C(27) 1.434(4) O(3)-C(9) 1.421(4) 
O(3)-C(13) 1.430(4) O(1)-C(7) 1.424( 4) 
O(1)-C(lO) 1.427(3) O(7)-C(26) 1.416(4) 
O(7)-C(44) 1.441(5) C(ll)-C(l0) 1.520(4) 
C(l 1)-C(12) 1.527(4) O(6)-C(51) 1.402(4) 
O(6)-C(25) 1.413(4) C(12)-N(l) 1.458(4) 
C(12)-C(13) 1.533(4) O(2)-C(7) 1.405(4) 
O(2)-C(8) 1.418(4) C(23)-C(22) 1.539(4) 
C(23 )-C(24) 1.537(4) C(23)-C(27) 1.535(4) 
C(22)-O(9) 1.437(3) C(22)-C(13) 1.522(4) 
C(10)-C(9) 1.514(4) C(27)-C(26) 1.527(4) 
C(24 )-C(28) 1.502(4) C(9)-C(8) 1.508(5) 
C(26)-C(25) 1.515(4) C(5 l)-C(52) 1.353(5) 
C(51)-C(56) 1.375(5) O(13)-C(29) 1.389(4) 
O(13)-C(28) 1.423(4) C(l)-C(2) 1.358(6) 
C(l)-C(6) 1.370(5) C(l)-C(7) 1.516(5) 
C(53)-C(54) 1.375(5) C(53)-C(52) 1.386(5) 
C(54)-C(55) 1.375(5) C(54)-O(11) 1.375(4) 
O(11)-C(57) 1.401(5) C(37)-C(38) 1.485(5) 
C(38)-C(39) 1.353(6) C(38)-C(43) 1.355(6) 
C(30)-C(35) 1.374(5) C(30)-C(31) 1.391(5) 
C(30)-C(29) 1.486(5) C(34)-C(35) 1.368(6) 
C(34)-C(33) 1.382(6) C(56)-C(55) 1.382(5) 
C(5)-C(4) 1.348(6) C(5)-C(6) 1.395(6) 
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Table 3. Bond lengths [A] and angles [0 ] for com~ound 80a (cont'd).b 
C( 44 )-C( 45) 1.516(6) C(48)-C(47) 1.351(8) 
C(48)-C(49) 1.374(7) C(45)-C(50) 1.380(6) 
C( 45)-C( 46) 1.379(6) C(32)-C(33) 1.360(7) 
C(32)-C(31) 1.359(6) O(12)-C(33) 1.371(6) 
O(12)-C(36) 1.437(7) C(46)-C(47) 1.376(7) 
C(49)-C(50) 1.359(6) C(39)-C( 40) 1.420(7) 
C(41)-C(40) 1.309(8) C(41)-C(42) 1.315(9) 
C(2)-C(3) 1.377(6) C(43)-C(42) 1.391(9) 
C(4)-C(3) 1.353(6) O(10)-C(20) 1.237(5) 
N(l)-C(20) 1.351(6) C(19)-C(16) 1.543(5) 
C(l 9)-C(l 7) 1.539(5) C(19)-C(18) 1.542(5) 
C(20)-C(21) 1.493(6) O(4)-Si( 1)-C( 14) 111.04(14) 
0( 4 )-Si( 1 )-C( 15) 107.78(15) 0(4 )-Si(l )-C(l 9) 106.06(14) 
C(15)-Si(l)-C(14) 110.86(18) C(14 )-Si(l)-C(l 9) 110.61(16) 
C(15)-Si(l)-C(19) 110.35(17) C(25)-O( 5)-C(24) 111.8(2) 
C(l 1)-O(4)-Si(l) 132.80(17) C(9)-O(3)-C(13) 111.2(2) 
C(37)-O(8)-C(27) 114.7(2) C(26)-O(7)-C( 44) 116.1(3) 
C(7)-O( 1)-C(10) 110.2(2) O(4)-C(l 1)-C(12) 108.0(2) 
O(4)-C(l 1)-C(lO) 113.2(2) C( 51 )-0( 6)-C(25) 113.4(2) 
C(10)-C(l 1)-C(12) 107.6(2) N(l)-C(12)-C(13) 112.4(3) 
N(l)-C(12)-C(l 1) 110.0(3) C(7)-O(2)-C(8) 112.0(3) 
C(l 1)-C(12)-C(13) 111.9(2) C(22)-C(23 )-C(27) 109.7(3) 
C(22)-C(23)-C(24) 117.7(3) O(9)-C(22)-C( 13) 111.0(3) 
C(24 )-C(23 )-C(27) 107.9(2) C( 13 )-C(22)-C(23) 116.2(3) 
O(9)-C(22)-C(23) 108.9(2) O(l)-C(10)-C(9) 108.6(2) 
O(1)-C(l0)-C(l 1) 110.7(2) O(8)-C(27)-C(26) 110.0(2) 
C(l 1)-C(10)-C(9) 110.1(2) C(26)-C(27)-C(23) 111.8(3) 
O(8)-C(27)-C(23) 109.3(2) O(5)-C(24 )-C(23) 107.9(2) 
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Table 3. Bond lengths [A] and angles [0 ] for compound 80a (cont'd).h 
O(5)-C(24 )-C(28) 106.4(2) O(3)-C(9)-C(8) 109.7(3) 
C(28)-C(24 )-C(23) 115.7(3) C(8)-C(9)-C( 10) 108.5(3) 
O(3)-C(9)-C(10) 110.3(3) 0(3 )-C(l 3 )-C(l 2) 108.7(2) 
O(3)-C(13)-C(22) 109.2(3) O(7)-C(26)-C(25) 112.9(3) 
C(22)-C(13)-C(l2) 113.7(3) C(25 )-C(26 )-C(27) 107.1(3) 
O(7)-C(26)-C(27) 106.5(3) C(52)-C(5 l)-O(6) 122.5(3) 
C(52)-C(51)-C(56) 120.1(3) C(29)-O( 13 )-C(28) 116.6(3) 
C(56)-C(51)-O(6) 117.2(3) O(5)-C(25)-C(26) 109.5(3) 
O(5)-C(25)-O(6) 107.7(2) O(13)-C(28)-C(24) 105.7(3) 
0( 6)-C(25)-C(26) 109.9(3) C(2)-C( 1 )-C(7) 119.8(4) 
C(2)-C(l)-C(6) 118.3(4) C(54)-C(53)-C(52) 120.0(3) 
C( 6)-C( 1 )-C(7) 121.9(4) C(55)-C(54)-C(53) 119.3(3) 
C(55)-C(54)-O(11) 115.2(3) O(2)-C(7)-O(1) 111.5(3) 
O(11)-C(54)-C(53) 125.4(3) 0( 1 )-C(7)-C( 1) 107.7(3) 
O(2)-C(7)-C( 1) 109.8(3) O(8)-C(37)-C(38) 110.8(3) 
C(54)-O(1 l)-C(57) 118.6(3) C(39)-C(38)-C(37) 123.6(4) 
C(39)-C(38)-C(43) 117.5(5) O(2)-C(8)-C(9) 108.3(3) 
C(43)-C(38)-C(37) 118.9(4) C(35)-C(30)-C(29) 122.1(3) 
C(35)-C(30)-C(3 l) 116.2(4) O(13)-C(29)-C(30) 110.0(3) 
C(31)-C(30)-C(29) 121.6(4) C(5 l )-C(56)-C(55) 119.8(3) 
C(35)-C(34 )-C(33) 119.7(4) O(7)-C( 44 )-C( 45) 114.4(3) 
C(4)-C(5)-C(6) 120.7(4) C( 4 7)-C( 48)-C( 49) 118.7(6) 
C(51 )-C(52)-C(53) 120.4(3) C(50)-C( 45)-C( 44) 122.3(4) 
C(50)-C( 45)-C( 46) 116.7(5) C(33)-C(32)-C(31) 120.7(4) 
C( 46)-C( 45)-C( 44) 121.0(4) C(54)-C(55)-C(56) 120.3(4) 
C(33)-O(12)-C(36) 118.0(4) C(50)-C(49)-C(48) 120.8(5) 
C( 4 7)-C( 46)-C( 45) 121.5(5) C(34 )-C(35)-C(30) 122.4(4) 
C(38)-C(39)-C( 40) 119.7(5) C(32)-C(33 )-C(34) 119.0(5) 
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Table 3. Bond lengths [A] and angles [0 ] for compound 80a (cont'd).b 
C(32)-C(33)-O(12) 116.1(4) C(40)-C(41)-C(42) 120.0(7) 
O(12)-C(33)-C(34) 124.8(5) C(38)-C(43)-C(42) 121.1(6) 
C(l)-C(2)-C(3) 121.2(4) C(3)-C(4)-C(5) 119.2(4) 
C(l)-C(6)-C(5) 120.0(4) C( 41 )-C( 40)-C(39) 120.9(6) 
C( 49)-C(50)-C( 45) 121.7(5) C( 48)-C( 4 7)-C( 46) 120.7(6) 
C(32)-C(3 l)-C(30) 121.9(4) C( 41 )-C( 42)-C( 43) 120.8(7) 
C(4)-C(3)-C(2) 120.6(5) C(l6)-C(19)-C(l 7) 108.7(3) 
C(20)-N(l)-C(12) 123.3(4) C(l 7)-C(l 9)-C(l 8) 107.5(3) 
C(l6)-C(19)-C(18) 109.9(3) C( 17)-C( 19)-Si( 1) 109.8(2) 
C(16)-C(l9)-Si(l) 110.6(3) O(10)-C(20)-N(l) 121.3(4) 
C( 18)-C( 19)-Si( 1) 110.3(2) N(l)-C(20)-C(21) 115.7(5) 
0( 10)-C(20)-C(21) 123.0(5) 
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Table 4. Anisotropic dis~lacement parameters (A 2 x 103) for compound 80a.c 
II 2 33 23 13 12 u u u u u u 
Si(l) 38(1) 62(1) 43(1) -1(1) 7(1) 3(1) 
0(4) 45(1) 66(1) 37(1) 0(1) 7(1) 10(1) 
0(5) 64(1) 60(2) 39(1) 2(1) 5(1) -7(1) 
0(8) 55(1) 50(1) 49(1) -1(1) 5(1) -2(1) 
0(3) 59(1) 49(1) 47(1) -2(1) -1 (l) 1 (1) 
0(1) 58(1) 46(1) 54(1) 1 (1) 1 (1) 9(1) 
0(7) 77(2) 70(2) 60(2) 3(1) 28(1) -14(1) 
C(ll) 45(2) 52(2) 34(2) -2(2) 12(1) 2(2) 
0(6) 87(2) 59(2) 40(1) 4(1) 12(1) 6(1) 
C(12) 57(2) 42(2) 42(2) -1(2) 8(2) 1(2) 
0(2) 108(2) 55(2) 65(2) -9(1) -8(2) 21(1) 
C(23) 43(2) 50(2) 40(2) 4(2) 7(2) 3(2) 
C(22) 45(2) 49(2) 45(2) 1(2) 10(2) 5(1) 
C(lO) 47(2) 47(2) 44(2) 6(2) 8(2) 2(2) 
C(27) 48(2) 48(2) 43(2) 3(2) 8(2) 1(1) 
C(24) 50(2) 54(2) 35(2) 1(2) 4(1) -4(2) 
C(9) 58(2) 48(2) 49(2) -2(2) 2(2) 6(2) 
C(13) 46(2) 46(2) 41(2) 3(2) 10(2) -2(1) 
C(26) 54(2) 49(2) 48(2) 2(2) 13(2) -3(2) 
C(51) 62(2) 54(2) 37(2) 1(2) 12(2) -1(2) 
0(9) 42(1) 84(2) 62(2) 7(1) 20(1) 4(1) 
0(13) 83(2) 64(2) 106(2) -20(2) 29(2) -25(1) 
C(25) 57(2) 61(2) 37(2) 3(2) 10(2) 0(2) 
C(28) 53(2) 64(2) 58(2) -3(2) 9(2) -11(2) 
C(l) 82(3) 47(2) 65(3) 2(2) 4(2) 7(2) 
C(53) 63(2) 74(3) 49(2) 0(2) 4(2) 13(2) 
C(54) 71(2) 50(2) 59(2) -3(2) 10(2) -2(2) 
161 
Table 4. Anisotropic displacement parameters (A 2 x 103) for compound 80a 
(cont'd)/ 
u u u33 u u u 
C(7) 73(2) 45(2) 62(3) 1(2) 0(2) 8(2) 
0(11) 98(2) 60(2) 102(2) -22(2) 10(2) 0(2) 
C(37) 61(2) 68(3) 77(3) -14(2) 2(2) -5(2) 
C(38) 80(3) 58(2) 58(3) -1(2) 3(2) -9(2) 
C(8) 100(3) 56(2) 61(3) -5(2) -14(2) 14(2) 
C(30) 73(2) 54(2) 72(3) 8(2) -3(2) -11(2) 
C(29) 70(2) 68(3) 87(3) 13(2) 14(2) -21(2) 
C(34) 89(3) 61(3) 99(4) -11(2) 12(3) -17(2) 
C(56) 55(2) 76(3) 61(2) 7(2) 3(2) 8(2) 
C(5) 88(3) 83(3) 112(4) -10(3) 15(3) 32(3) 
C(44) 118(3) 76(3) 67(3) 7(2) 47(3) -14(3) 
C(52) 57(2) 77(3) 50(2) -12(2) 5(2) - l (2) 
C(48) 123(4) 78(4) 109(5) 10(3) 13(4) -9(3) 
C(45) 115(3) 51(2) 58(3) 8(2) 31(3) -18(2) 
C(32) 126(4) 56(3) 98(4) 4(3) 8(3) -34(3) 
0(12) 171(4) 63(2) 134(3) -26(2) 28(3) -30(2) 
C(55) 65(2) 65(3) 76(3) -14(2) -1(2) -7(2) 
C(46) 124(4) 99(4) 62(3) -8(3) 23(3) -20(3) 
C(49) 140(4) 53(3) 92(4) 0(3) 19(4) -4(3) 
C(39) 113(3) 72(3) 91(4) -9(3) -6(3) 16(3) 
C(35) 79(3) 54(2) 101(3) -5(2) 17(3) -21(2) 
C(33) 110(3) 57(3) 89(3) 3(3) 1(3) -14(3) 
C(41) 215(9) 72(4) 120(5) -31(4) 25(6) -20(5) 
C(2) 150(4) 93(3) 71(3) -4(3) -7(3) 71 (3) 
C(57) 122(4) 74(3) 147(5) -25(3) 29(4) 14(3) 
C(43) 109(4) 127(5) 152(6) -71(4) -21(4) -2(3) 
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Table 4. Anisotropic displacement parameters (A 2 x 103) for compound 80a 
(cont'd).c 
u u u33 u u u 
C(6) 88(3) 73(3) 83(3) -15(2) 3(2) 16(2) 
C(4) 100(3) 73(3) 103(4) 6(3) -6(3) 27(3) 
C(50) 138(4) 62(3) 62(3) 0(2) 14(3) 0(3) 
C(40) 166(6) 82(4) 117(5) -3(4) 27(5) 31(4) 
C(31) 95(3) 75(3) 87(3) 18(3) 5(3) -32(2) 
C(47) 128(5) 125(5) 89(4) 9(4) -11(4) -11(4) 
C(36) 157(5) 95(4) 177(7) -46(4) 34(5) -5(4) 
C(3) 153(5) 96(4) 82(4) -6(3) -18(3) 56(4) 
C(42) 187(8) 144(7) 190(8) -102(6) -40(6) -17(6) 
0(10) 121(3) 96(2) 65(2) 1(2) 23(2) 52(2) 
N(l) 96(2) 47(2) 52(2) -1(2) 3(2) 8(2) 
C(19) 43(2) 71(2) 58(2) -15(2) 11(2) -2(2) 
C(15) 64(2) 85(3) 55(2) 16(2) 6(2) 2(2) 
C(16) 78(3) 112(4) 61(3) -18(2) 4(2) -15(2) 
C(14) 48(2) 88(3) 69(2) -16(2) 11(2) 5(2) 
C(20) 132(4) 56(3) 46(2) 2(2) 6(3) 24(3) 
C(18) 71(2) 67(3) 96(3) -10(2) 6(2) -2(2) 
C(17) 51(2) 111(4) 125(4) -59(3) 18(2) 2(2) 
C(21) 238(7) 63(3) 90(4) -12(3) 7(4) 46(4) 
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Table S. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A 2 
x 103) for com~ound 80a. 
X y z U(eq) 
H(ll) 2927 5146 6468 52 
H(12) -1969 5198 6301 56 
H(22) -2351 5798 4846 55 
H(lO) -302 4407 6568 55 
H(27) 933 5588 3751 56 
H(24) -900 4799 3615 56 
H(9) 2474 4581 5292 63 
H(26) -1939 5884 2342 60 
H(9A) -4988 5448 5347 93 
H(25) 878 5067 2566 62 
H(28A) -4433 4588 4140 70 
H(28B) -5757 4719 3292 70 
H(53) 3583 3946 1095 75 
H(7) 1288 3659 6733 73 
H(37A) 2427 6445 3735 83 
H(37B) 2214 6164 4535 83 
H(8A) -683 3837 5436 89 
H(8B) 774 3904 4700 89 
H(29A) -6801 3928 3031 90 
H(29B) -5410 3717 3810 90 
H(34) -883 3096 1566 99 
H(56) -3415 4697 584 77 
H(5) 8640 2732 6717 113 
H(44A) 1172 5960 1228 101 
H(44B) 2767 6362 1601 101 
H(52) 3052 4680 1627 73 
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Table 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A 2 
x 103) for com~ound 80a (cont'd). 
X y z U(eq) 
H(48) -5441 7394 1034 124 
H(32) -6090 2353 2268 112 
H(55) -2878 3973 17 83 
H(46) -1444 6388 302 113 
H(49) -3504 7339 2318 113 
H(39) -2165 6970 4111 112 
H(35) -1873 3706 2345 93 
H(41) 437 7948 5650 162 
H(2) 4525 3781 8061 128 
H(57A) 3693 3452 -134 170 
H(57B) 2523 2958 -173 170 
H(57C) 3350 3185 668 170 
H(43) 4161 6843 5200 158 
H(6) 5590 3136 6023 98 
H(4) 9616 2855 8066 112 
H(50) -586 6817 2591 104 
H(40) -2522 7670 4821 145 
H(31) -7107 2966 3022 103 
H(47) -4294 6935 25 139 
H(36A) -1392 2569 519 213 
H(36B) -1139 2024 550 213 
H(36C) 297 2334 1200 213 
H(3) 7627 3396 8727 135 
H(42) 3716 7537 5873 214 
H(l) 1058 5927 6360 79 
H(l5A) 898 
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Table S. Hydrogen coordinates ( x 104) and isotropic displacement parameters (A 2 
x 103) for com~ound 80a (cont'd). 
X y z U(eq) 
H(15B) 3381 4473 9249 102 
H(15C) 1582 4330 8520 102 
H(l6A) 4352 5875 9971 126 
H(16B) 5984 5500 9645 126 
H(16C) 3690 5344 9981 126 
H(14A) 6066 4653 7691 102 
H(14B) 7136 4915 8472 102 
H(14C) 6558 5191 7659 102 
H(18A) 3367 6054 7835 117 
H(18B) 5780 5948 8314 117 
H(18C) 4124 6313 8653 117 
H(17A) -158 5531 9186 143 
H(17B) -218 5822 8385 143 
H(17C) 574 6058 9220 143 
H(21A) -2423 6785 6372 197 
H(21B) 66 6619 6705 197 
H(21C) -1945 6594 7259 197 
H(13) 870(50) 5295(10) 5025(17) 42(8) 
H(23) -4040(50) 5583(10) 3555(17) 41(8) 
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Table 6. Torsion angles [0 ] for compound SOa.b 
C(15)-Si(l)-O(4)-C(l 1) 
C(14)-Si(l)-O(4)-C(l 1) 
C( 19)-Si( 1 )-0( 4 )-C( 11) 






C(24 )-C(23 )-C(22)-O(9) 
C(27)-C(23)-C(22)-O(9) 
C(24 )-C(23 )-C(22)-C( 13) 
C(27)-C(23 )-C(22)-C( 13) 
C(7)-O(1)-C(10)-C(l 1) 








C(24 )-C(23 )-C(27)-O(8) 
C(22)-C(23 )-C(27)-C(26) 

































Table 6. Torsion angles [0 ] for compound 80a (cont'd).b 
C(27)-C(23)-C(24)-O(5) -57.2(3) 
C(22)-C(23 )-C(24 )-C(28) 59.2(4) 
C(27)-C(23 )-C(24 )-C(28) -176.1(3) 
C(13)-O(3)-C(9)-C(8) -176.1(3) 
C(13)-O(3)-C(9)-C(10) 64.4(3) 
0(1 )-C( 10)-C(9)-O(3) 178.3(2) 
C(l 1)-C(10)-C(9)-O(3) -60.4(3) 
0(1 )-C( 10)-C(9)-C(8) 58.1(3) 
C(l 1)-C(10)-C(9)-C(8) 179.4(3) 
C(9)-O(3)-C(13)-C(22) 173.6(2) 
C(9)-O(3 )-C( 13 )-C( 12) -61.7(3) 
O(9)-C(22)-C( 13 )-0(3) 59.5(3) 
C(23 )-C(22)-C( 13 )-0(3) -65.6(3) 
O(9)-C(22)-C( 13 )-C( 12) -62.1(4) 
C(23)-C(22)-C(13)-C(12) 172.8(3) 
N(l)-C(12)-C(13)-O(3) -178.3(3) 
C( 11 )-C( 12)-C( 13 )-0(3) 57.3(3) 
N(l)-C(12)-C(13)-C(22) -56.4(4) 
C(l 1)-C(12)-C(13)-C(22) 179.2(3) 
C( 44 )-O(7)-C(26)-C(25) 88.7(4) 





C(25)-O(6)-C(51 )-C(52) -67.1(4) 
C(25)-O(6)-C(51)-C(56) 117.2(3) 
C(24 )-O(5)-C(25)-O( 6) 172.2(2) 
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Table 6. Torsion angles [0 ] for compound 80a (cont'd).h 
C(24)-O(5)-C(25)-C(26) -68.3(3) 
C(51)-O(6)-C(25)-O(5) -70.7(3) 
C(51 )-O(6)-C(25)-C(26) 170.1(3) 
O(7)-C(26)-C(25)-O(5) 176.7(2) 
C(27)-C(26)-C(25 )-0( 5) 59.8(3) 
O(7)-C(26)-C(25)-O( 6) -65.2(3) 
C(27)-C(26)-C(25)-O(6) 177.9(2) 
C(29)-O( 13 )-C(28)-C(24) -174.6(3) 
O(5)-C(24)-C(28)-O(13) 66.5(3) 
C(23 )-C(24 )-C(28)-O( 13) -173.8(3) 
C(52)-C(53)-C(54 )-C(55) -0.7(6) 
C(52)-C(53)-C(54 )-0(11) 179.4(3) 
C(8)-O(2)-C(7)-O( 1) -60.7(4) 
C(8)-O(2)-C(7)-C( 1) -180.0(3) 
C(10)-O(l)-C(7)-O(2) 60.6(4) 
C( 10)-0( 1 )-C(7)-C( 1) -178.9(3) 
C(2)-C( 1 )-C(7)-O(2) 170.6(4) 
C( 6)-C( 1 )-C(7)-O(2) -10.4(5) 
C(2)-C( 1 )-C(7)-O( 1) 49.0(5) 
C( 6)-C( 1 )-C(7)-O( 1) -132.0(4) 









Table 6. Torsion angles [0 ] for compound 80a (cont'd).h 
C(28)-O(13)-C(29)-C(30) 169.4(3) 
C(35)-C(30)-C(29)-O(13) -6.4(6) 
C(31 )-C(30)-C(29)-O( 13) 175.2(4) 
C(52)-C(51 )-C(56)-C(55) 1.2(5) 
O(6)-C(51)-C(56)-C(55) 176.9(3) 
C(26)-O(7)-C( 44 )-C( 45) 57.5(4) 
C(56)-C(51)-C(52)-C(53) -2.2(5) 
O(6)-C(51)-C(52)-C(53) -177.7(3) 
C(54 )-C(53)-C(52)-C(51) 1.9(5) 
O(7)-C( 44 )-C( 45)-C(50) 38.0(5) 
O(7)-C( 44 )-C( 45)-C( 46) -142.9(4) 
O(1 l)-C(54)-C(55)-C(56) 179.6(3) 
C(53)-C(54)-C(55)-C(56) -0.3(6) 
C(51 )-C(56)-C(55)-C(54) 0.1(6) 
C(50)-C( 45)-C( 46)-C( 4 7) 1.6(7) 
C( 44 )-C( 45)-C( 46)-C( 4 7) -177.6(4) 
C(47)-C(48)-C(49)-C(50) -1.0(8) 
C( 43 )-C(3 8)-C(39)-C( 40) -0.7(8) 
C(37)-C(38)-C(39)-C( 40) -178.6(4) 
C(33)-C(34 )-C(35)-C(30) -0.5(7) 
C(31 )-C(30)-C(35)-C(34) 0.5(6) 
C(29 )-C(30 )-C(3 5 )-C(34) -177.9(4) 
C(31)-C(32)-C(33)-O(12) -178.4(4) 
C(31 )-C(32)-C(33 )-C(34) 0.9(7) 
C(36)-O(12)-C(33)-C(32) 176.6(5) 
C(36)-O(12)-C(33)-C(34) -2.6(8) 
C(35)-C(34 )-C(33 )-C(32) -0.3(7) 
C(35)-C(34 )-C(33 )-0( 12) 179.0(4) 
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Table 6. Torsion angles [0 ] for compound 80a (cont'd).b 
C(6)-C(l)-C(2)-C(3) 1.4(8) 
C(7)-C( 1 )-C(2 )-C(3) -179.5(5) 





C( 6)-C( 5)-C( 4 )-C(3) -0.7(8) 
C( 48)-C( 49)-C(50)-C( 45) 0.1(7) 
C( 46)-C( 45)-C(50)-C( 49) -0.4(6) 
C(44)-C(45)-C(50)-C(49) 178.8(4) 
C( 42)-C( 41 )-C( 40)-C(39) -1.9(12) 
C(38)-C(39)-C( 40)-C( 41) 1.4(9) 
C(33)-C(32)-C(3 l )-C(30) -0.9(8) 
C(35)-C(30)-C(3 l )-C(32) 0.1(6) 
C(29)-C(30)-C(3 l )-C(32) 178.6(4) 
C( 49)-C( 48)-C( 4 7)-C( 46) 2.2(8) 
C( 45)-C( 46)-C( 4 7)-C( 48) -2.6(8) 
C(5)-C( 4 )-C(3 )-C(2) 1.8(9) 
C( 1 )-C(2)-C(3 )-C( 4) -2.3(9) 
C( 40)-C( 41 )-C( 42)-C( 43) 1.6(14) 
C(38)-C(43)-C(42)-C(41) -0.8(13) 
C(l l)-C(l2)-N(l)-C(20) -138.6(3) 
C(l3)-C(l2)-N(l)-C(20) 96.0(4) 
0( 4 )-Si(l )-C( 19)-C( 16) 168.7(2) 
C( 15)-Si( 1 )-C( 19)-C( 16) 52.2(3) 
C(l4 )-Si(l )-C(l 9)-C( 16) -70.8(3) 
0( 4 )-Si( 1 )-C( 19)-C( 17) 48.7(3) 
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Table 6. Torsion angles [0 ] for compound 80a (cont'd).b 
C(15)-Si(l)-C(19)-C(l 7) -67.7(3) 
C(14)-Si(l)-C(19)-C(l 7) 169.2(3) 
O(4)-Si(l)-C(19)-C(l 8) -69.5(3) 
C(15)-Si(l)-C(19)-C(l 8) 174.0(2) 
C(14 )-Si( 1)-C( 19)-C(l 8) 51.0(3) 
C(12)-N(l)-C(20)-O(10) -7.9(6) 
C(12)-N(l)-C(20)-C(21) 172.0(4) 
a U (eq) is defined as one third of the trace of the orthogonalized U11 tensor. 
b Symmetry transformations used to generate equivalent atoms. 
c The anisotropic displacement factor exponent takes the form: -21t2[h2 a*2U 11 + ... + 2 h 
k a* b* U12 ]. 
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gCOSY spectrum (600 MHz, CDCh) of p-methoxyphenyl C-(2-acetamido-4,6-O-benzylidene-3-O-tert-butyldimethylsilyl-2-
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gCOSY spectrum (600 MHz, CDCh) of p-methoxyphenyl C-(2-acetamido-4,6-O-benzylidene-3-O-tert-butyldimethylsilyl-2-
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gCOSY spectrum (600 MHz, CDCh) of p-methoxyphenyl C-(2-acetamido-4,6-O-benzylidene-3-O-tert-butyldimethylsilyl-2-
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1H NMR spectrum (600 MHz, CDCh) of p-methoxyphenyl C-(2-acetamido-4,6-0-benzylidene-3-0-tert-butyldimethylsilyl-2-
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gCOSY spectrum (600 MHz, CDCh) of p-methoxyphenyl C-(2-acetamido-4,6-O-benzylidene-2-deoxy-P-D-glucopyranosyl)-
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13C NMR spectrum (62.5 MHz, CDCIJ) of allyl 2,3-di-0-acetyl-4,6-0-p-methoxybenzylidene-P.D-galactopyranoside (101). 
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13C NMR and DEPT spectra (62.5 MHz, CDCIJ) of allyl S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-fi-D-glucopyranosyl)-
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HSQC spectrum (1H: 600 MHz, 13C: 150 MHz, CDCh) of S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-,B-o-glucopyranosyl)-
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gCOSY spectrum (600 MHz, CDCh) of allyl S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-p-o-glucopyranosyl)-(1 ➔4)-(2,3-di­
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... _J F2 
. ____ _s -=--"") (ppm) 




--· ~ --~ 
_) 
c' __ J 
-~ -; .. 
_,..l 









: ... _ 
I I I I I I I I 
130 120 
OAc . 
( PMBO Ptr--'\-g---~-- 0 <OPMB 
Ac;o-y-\..--O\ -· .:::\,.o o ,~-- ..... , s--·y-.\.--q 
AcO-~--A~O ~------0--~-sno -~-- OAII 
AcHN AcO AcHN BnO 
• ... 
' . . . 




I·, ·r··r··r·T···r·r·r·1--·•T"·r·T·rT··1 I rT··i-r ·,-·1 f I I I , J I I I I ,. I 'I I , .. r··T·"·T r .. .,., I 
110 100 90 80 70 60 50 40 30 
Fl (ppm) 
HSQC spectrum (1H: 600 MHz, 13C: 150 MHz, CDCh) of allyl S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-P-D-
glucopyranosyl )-( I ➔4 )-(2,3-di-O-acetyl-6-O-p-methox ybenzyl-4-thio-/J-D-glucopyranos yl )-( I ➔ 3 )-S-(2-acetamido-4,6-O-




~ HO c Ph~O-.. O CO2H A O ---~-L-0 0 ~l-- S 0 
~co A~o~O~n~-OAII 
AcHN AcO AcHN BnO 
- A ~_JJ li1 ~~J~ ltM~~ L '
I 
Vt 
---·•····✓·', \,!\. .l 
, , , I r - , , -, .. r .. , -- -r - , - , 1 , , , , ... I ---- ,-- -, --- ... ,---- ,- ---- ·1 ·r·· -- , - , .. , -- I , , , , 1 , , , , I , 
7 6 5 4 3 2 1 ppn 
1H NMR spectrum (600 MHz, CDCIJ/CD10D = 5: 1) of allyl S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-p-o-glucopyranosyl)-
(1➔4)-(2,3-di-O-acetyl-4-thio-/J-D-glucopyranosyluronic acid)-(1➔3)-S-(2-acetamido-4,6-O-benzylidene-2-deoxy-/3-D­





C Ph"l.'O, C02H A O:-\:--~q H_9f.~ .. A~ o--\.__\_.q s .--L-o 
~cO-~--J..~o-~-o-~Bn~OAII 
AcHN AcO AcHN BnO 
~JL~~/1 . . : ill 
I'' 11 1111··1··rrT·T·-,··1·1T···1T .. , I I,,--,' J,, I' 11 Ii I I I I, ,--r·,..-, ,. .. .,, ... , .. :.r·-,,--·,1r·1·r···1--,···r·······rr·r·1 i 111 I' I I I -1 I I f , r I 1··1 
160 HO 120 100 80 60 40 ppm 
13C NMR spectrum (75 MHz, CDCh/CD30D = 5: 1) of allyl S-(2-acetamido-3,4,6-tri-0-acetyl-2-deoxy-,8-D-glucopyranosyl)-
(1➔4)-(2,3-di-O-acetyl-4-thio-,8-D-glucopyranosyluronic acid)-(1➔3)-S-(2-acetamido-4,6-0-benzylidene-2-deoxy-,8-D­




) ....... _: : •·2 
) (ppm) 

















'1 5. 6 







h,;:i! U1 (bjl 
" !.~;~ 
":' r] ,: ,. {6:·~\f'tNCl'} 
Q ('/' gilW 
- . . •S:-j_.; . 
i1? ~, • .. _ m 
r ~-IJ 
ilj "i;\l'' 
I.~ ~lj(' r:J''' ,i•• ., Cl ~· . . ,... Ul:{0 
···• .ti .. •' El \)ti 
l~ ~ITJ m 
, , l{ir.1l~O ' 
I~ ,.1-JrJ.fu 





,,,,;11,11111illjllll,llllll1iljillllll;·11; 1·;•.,,,,, 1.11:jll•llllll!•il•jlli•jl'lllitlljillijilllllliljllllj<lli(lll1JIIIIII• 
5.6 5.4 5.2 5.0 4.8 4.1, 4.4 4.2 4.0 3.8 3.6 3.4 3.2 
t'l (ppm} 
)> 
~~~ Z, 0 
O"l: 
), 









gCOSY spectrum (600 MHz, CDCh/CD3OD = 5: 1) of allyl S-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-
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glucopyranosyl)-(1 ➔4)-2,3-di-O-benzyl-4-thio-~D-glucopyranosiduronic acid (110). 
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gCOSY spectrum (600 MHz, D20) of n-propyl S-(2-acetamido-2-deoxy-,8-D-glucopyranosyl)-(1➔4)-(4-thio-,B-D­
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HSQC spectrum ciH: 600 MHz, 13C: 150 MHz, D20) of n-propyl S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-(1➔4)-(4-
thio-/J-D-glucopyranosyluronic acid)-(1➔3)-S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-(1➔4)-4-thio-/J-D­
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gCOSY spectrum (600 MHz, CDC'3) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-,8-D-glucopyranosyl)-
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HSQC spectrum (1H: 600 MHz, 13C: 150 MHz, CDCl3) of ally! S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-,B-o-
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gCOSY spectrum (600 MHz. CDCl3) of S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-P-D-glucopyranosyl)-(1➔4)-
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HSQC spectrum (1H: 600 MHz, 13C: 150 MHz, CDCh) of S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-,B-D-
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HSQC spectrum ('H: 600 MHz, 13C: 150 MHz, CDC1 3) of allyl S-(2-acetamido--l.6-di-O-acetyl-2-deoxy-p-o-glucopyranosyl)-
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1H NMR spectrum (600 MHz, CDCh) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-P-D-glucopyranosyl)-
( 1 ➔4 )-(2,3-di-O-acetyl-6-O-p-methoxybenzyl-4-thio-P-D-glucopyranos yl )-( 1 ➔ 3 )-S-(2-acetamido-4,6-di-O-acetyl-2-deox y-/3-
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13C NMR spectrum (75 MHz, CDCh) of ally] S-(2-acetamido-4,6-di-0-acetyl-2-deoxy-3-0-levulinoyl-/J-D-glucopyranosyl)-
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gCOSY spectrum (600 MHz, CDCI:,) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-,B-D-glucopyranosyl)-
( 1 ➔4 )-(2,3-di-O-acetyl-6-O-p-methox ybenz yl-4-thio-P-D-glucopyranosyl )-( 1 ➔ 3 )-S-(2-acetamido-4,6-di-O-acetyl-2-deox y-,8-
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TOCSY spectrum (600 MHz, CDC'3) of allyl S-(2-acetamido-4.6-d1-O-acetyl-2-deoxy-3-O-levulinoyl-,B-o-glucopyranosyl)-
( I ➔4 )-(2,3-di-O-acetyl-6-O-p-methox ybenzyl-4-thio-/J-D-gl ucopyranosyl )-( l ➔3 )-S-(2-acetamido-4,6-di-O-acet yl-2-Jeox y-/3-
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HSQC spectrum ( 1H: 600 MHz, 13C: 150 MHz, CDCh) of allyl S-(2-acetamido-4,6-di-0-acetyl-2-deoxy-3-O-levulinoyl-P-o-
glucopyranosyl)-( I ➔4 )-(2,3-di-O-acetyl-6-0-p-methoxybenzyl-4-thio-P-D-glucopyranosyl)-( l ➔3)-S-(2-acetamido-4,6-di-O­
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acet yl-6-O-p-methox ybenzyl-4-thio-/J-D-glucopyranos yl )-( 1 ➔ 3 )-S-(2-acetamido-4 ,6-di-O-acetyl-2-deox y-P-D-




,OAc /OPMB (OAc ,OPMD 
A(·<·) ... ~\ __ Q \ () Ac·o··~-\--O - \ O . - ' <·-----,-,.---,~ __ · , c---\---•--·'-', 
HU - •-- -·AcO-~---··?""-.\..--- 0 -- 1 _,_ ··:K(;o--~--OAII 
Acl IN AcO Ad It~ AcO 
~,111~/illl~l/lt;~IA~1 ~~p,i~••,-.tllil~'11~~wm~~rlfflMIIH!t1•~tJ111~.~wi 
, , I 1 , 1 , t r I r , I 1 1 1 ·, 1 , , 1 I 1 • 1 , , 1 , • t 1· 1 1 , ·1 1 ·1··1 ··• ,. J , I ,· 1 r 1 • 1 • J , r 1 1 t , , , I 1 • 1 , I 1 , ·1 t ( I ,, .. ,,,"r·1··1-·1··1··1 I 1 • 1 I I 
<10 2 0 1111111 lhO I 6 0 I •H I 2 0 100 II D (i 0 
13C NMR spectrum (75 MHz, CDCh) of ally) S-(2-acetamido-4,6-di-0-acetyl-2-deoxy-,8-D-glucopyranosyl)-(1➔4)-(2,3-di-O­
acetyl-6-0-p-methoxybenzyl-4-thio-,B-D-glucopyranosyl)-(1➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-p-o­
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gCOSY spectrum (600 MHz, CDCI,) of ally! S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-/J-D-glucopyranosyl)-(1➔4)-(2,3-di-O­
acetyl-6-0-p-methoxybenzyl-4-thi<l-/l-D-glucopyranosyl)-(1➔3)-S-(2-acetamido-4,6-di-<)-acetyl-2-deoxy-/J-D­
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TOCSY spectrum (600 MHz, CDCh) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-,6-D-glucopyranosyl )-(1 ➔4 )-(2,3-di-O-
acetyl-6-O-p-methox ybenzyl-4-thio-/J-D-gl ucopyranos yl )-(I ➔ 3 )-S-(2-acetamido-4,6-di-O-acet yl-2-deox y-,6-D-
gl ucopyranos yl )-( 1 ➔4 )-2,3-di-O-acet yl-6-O-p-methox ybenz yl-4-thio-P-D-gl ucopyranoside (129). 
N 
00 ...... 
-J =J.-2 (ppm) 
I 3. o 








' 5.0 ' l 5.5 
:) 6.0 
I 6. '.) 
l 7.0 
.. OAc: /OJ'lv113 /0/\c .. OPMB 
A 0 .--·~\ 0 \ · A1·CJ·····y··\ .. -O ( 0 C - . . - S - \" _\ --- U . . . '.\._ - S -- ,-~--- '-', 
110- ·-··AcO-.\....-r--\.,·-0-- -AcO-~OAII 
AcHN AcO AcHN AcO 
•\ . . 
. . .. 
~ 
. ... . 
.. 
I 7. s ·, 1 1 1 ·1 1 r·1, 1 , 1 , l I I I I I I I I I ' i I I ,· ·1 I -r-· I ,-, I I I I I 1 · I I I I I I ' 




HSQC spectrum (1H: 600 MHz, 13C: 150 MHz, CDCl 3) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-p-o-glucopyranosyl)-
( l ➔4)-(2,3-di-O-acetyl-6-O-p-methoxybenzyl-4-thio-P-o-glucopyranosyl)-(l➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-/J­
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1H NMR spectrum (600 MHz, CDCh) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-/J-D-glucopyranosyl)-
( 1 ➔4 )-(2,3-di-O-acetyl-6-O-p-methoxybenzyl-4-thio-P-D-glucopyranosyl)-( 1 ➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-/J­
D-gl ucopyranos yl )-( l ➔4 )-(2,3-di-O-acetyl-6-O-p-methox ybenz yl-4-thio-/J-D-glucopyranosyl)-( 1 ➔ 3 )-S-(2-acetamido-4,6-di-
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13C NMR spectrum (75 MHz, CDCl3) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-0-levulinoyl-,8-D-glucopyranosyl)-
( I ➔4 )-(2,3-di-0-acetyl-6-0-p-methoxybenzyl-4-th10-,8-D-glucopyranosyl)-( I ➔3)-S-(2-acetamido-4,6-di-0-acetyl-2-deoxy-~ 
D-gl ucopyranosyl)-( 1 ➔4 )-(2,3-di-O-acet yl-6-0-p-mcthox ybenzyl-4-thio-,B-D-glucopyranosyl)-( I ➔ 3 )-S-( 2-acetamido-4,6-di-
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gCOSY spectrum (600 MHz, CDC13) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-/J-D-glucopyranosyl)-
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TOCSY spectrum (600 MHz, CDCb) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-P-D-glucopyranosyl)-
( I ➔4 )-(2,3-di-O-acetyl-6-O-p-methoxybenzyl-4-thio-P-D-glucopyranosyl )-( I ➔3 )-S-(2-acetamido-4,6-di-O-acetyl-2-deox y-/3-
D-gl ucopyranos yl )-( I ➔4 )-(2,3-di-O-acetyl-6-O-p-methox ybenzyl-4-thio-/3-D-glucopyranosyl)-( 1 ➔ 3 )-S-(2-acetamido-4,6-di-
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1H NMR spectrum (600 MHz, CDCh/CD30D = 5: 1) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-P-D-
glucopyranosyl)-( I ➔4 )-(2,3-di-O-acetyl-4-thio-/J-D-glucopyranosyl)-( 1 ➔3 )-S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-fi-D-
gl ucopyranos yl )-( I ➔4 )-(2,3-di-O-acetyl-4-th i o-/J-D-glucopyranosyl )-( 1 ➔ 3 )-S-(2-acetamido-4 ,6-di-O-acetyl-2-deox y-/J-D-
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13C NMR spectrum (75 MHz, CDCh/CD3OD = 5: 1) of ally! S-(2-acetamido-4,6-di-0-acetyl-2-deoxy-3-0-levulinoyl-,B-D-
glucopyranosyl )-( l ➔4 )-(2,3-di-O-acetyl-4-thio-,8--D-glucopyranosyl )-( l ➔3 )-S-(2-acetamido-4,6-di-0-acetyl-2-deox y-,8-D-
glucopyranos yl )-( l ➔4 )-(2,3-di-0-acetyl-4-thio-,B--D-glucopyranos yl H l ➔3 )-S-(2-acetamido-4,6-di-0-acetyl-2-deox y-,8--D-
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gCOSY spectrum (600 MHz, CDCl]ICD3OD = 5: 1) of allyl S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-levulinoyl-JJ-o-
glucopyranosyl)-(l➔4)-(2,3-di-O-acetyl-4-thio-JJ-o-glucopyranosyl)-(l➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-JJ-o­
glucopyranosyl)-(1 ➔4)-(2,3-di-O-acetyl-4-thio-,B-D-glucopyranosyl)-(1➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-JJ-D­
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HSQC spectrum (1H: 600 MHz, 13C: 150 MHz, CDCl:i/CD30D = 5: 1) of ally! S-(2-acetamido-4,6-di-O-acetyl-2-deoxy-3-O-
levulinoyl-/J-D-glucopyranosyl)-(l➔4)-(2,3-di-O-acetyl-4-thio-p-o-glucopyranosyl)-(1➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-
deox y-fi-D-glucopyranosyl )-( l ➔4 )-(2,3-di-O-acet yl-4-thio-fi-D-glucopyranosyl)-( l ➔3)-S-(2-acetamido-4,6-di-O-acetyl-2-
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1H NMR spectrum (600 MHz, D20) of ally) S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-(1➔4)-(4-thio-/J-D­
glucopyranosyluronic acid)-(1 ➔3)-S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-( I ➔4)-(4-thio-/J-o-glucopyranosyluronic 
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gCOSY spectrum (600 MHz, D20) of allyl S-(2-acetamido-2-deoxy-,B-o-glucopyranosyl)-( l ➔4)-(4-thio-fi-D­
glucopyranosyluronic acid)-( 1 ➔3 )-S-(2-acetamido-2-deoxy-,8-D-glucopyranosyl)-( l ➔4 )-( 4-thio-fi-D-glucopyranosyluronic 
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TOCSY spectrum (600 MHz, D20) of allyl S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-(1➔4)-(4-thio-/J-D­
glucopyranosyluronic acid)-(1➔3)-S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-(1➔4)-(4-thio-/J-D-glucopyranosyluronic 
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HSQC spectrum (1H: 600 MHz, 13C: 150 MHz, D2O) of allyl S-(2-acetamido-2-deoxy-,B-o-glucopyranosyl)-(1➔4)-(4-thio-,B­
D-glucopyranosyluronic acid)-(1➔3)-S-(2-acetamido-2-deoxy-,B-D-glucopyranosyl)-(1➔4)-(4-thio-/J-D-glucopyranosyluronic 
acid)-( I ➔3)-S-(2-acetamido-2-deoxy-/J-D-glucopyranosyl)-( l ➔4)-4-thio-,B-o-glucopyranosiduronic acid ( 133). 
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